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		Currently,	 in	vitro	cell	culture	models	for	the	study	of	hepatotropic	viruses	rely	on	the	use	 of	 primary	 human	 hepatocytes	 and	 hepatoma	 cell	 lines,	 which	 both	 have	conceivable	 limitations.	 Alternative	 sources	 of	 human	 hepatocytes	 are	 human	embryonic	 (hESCs)	 and	 induced	 pluripotent	 stem	 cell	 (iPSC)-derived	 hepatocyte-like	cells.	 These	 pluripotent	 stem	 cells	 (PSCs)	 have	 numerous	 advantages	 compared	 to	primary	cells,	 including	the	fact	that	they	can	theoretically	self-renew	indefinitely,	can	differentiate	 into	 any	 cell	 type	 of	 the	 human	 body	 and	 can	 relatively	 easily	 be	genetically	modified.		Previous	 studies	 from	 the	 Verfaillie	 lab	 demonstrated	 that	 stem	 cell-derived	hepatocytes	 can	 be	 infected	with	 the	 hepatitis	 C	 virus	 (HCV).	 Another	more	 recently	described	 virus	 that	 causes	 hepatitis	 is	 the	 hepatitis	 E	 virus	 (HEV).	 Every	 year	 20	million	people	become	infected	with	HEV	causing	over	3	million	cases	of	acute	hepatitis.	Although	hepatitis	E	 is	usually	an	acute	self-limiting	 form	of	hepatitis,	 severe	cases	of	fulminant	 hepatitis	 and	 chronic	 infections	 have	 been	 reported,	 causing	 an	 estimated	56.000	deaths	per	year.	HEV	research	is	severely	hampered	by	the	lack	of	efficient	cell	culture	models	 that	 support	HEV	 replication.	 In	 this	 thesis	 I	 differentiated	hESCs	 and	hiPSCs	 toward	 hepatocytes	 and	 subsequently	 infected	 the	 hepatic	 progeny	 cells	with	HEV.	 I	 demonstrated	 that	 stem	 cell-derived	 hepatocytes	 support	 the	 complete	replication	 of	 the	 HEV.	 In	 addition,	 I	 found	 that	 pluripotent	 stem	 cells	 differentiated	toward	 mesoderm	 or	 neural	 progenitor	 cells	 did	 not	 support	 HEV	 replication	confirming	the	specific	hepatocyte	tropism	of	HEV.	However,	I	demonstrated	that	both	mesodermal	 cells	 and	 neuroprogenitors	 can	 support	 replication	when	 the	 viral	 entry	step	was	circumvented.			The	hepatocyte	differentiation	protocol	that	was	used	to	demonstrate	the	susceptibility	of	 stem	 cell-derived	 hepatocytes	 to	 HEV	 consisted	 of	 a	 mixed	 population	 of	 cells.	Therefore,	I	performed	studies	to	improve	hepatocyte	differentiation	from	PSCs	by	the	addition	 of	 dimethyl	 sulfoxide	 (DMSO).	 I	 demonstrated	 that	 addition	 of	DMSO	during	hepatocyte	differentiation	induced	a	more	homogenous	population	of	PSC	progeny.	The	improved	 PSC	 progeny	 homogeneity	 also	 enhanced	 HEV	 infection.	 Moreover,	 the	expression	of	Natrium-taurocholate	cotransporting	polypeptide	(NTCP),	a	key	receptor	
	for	HBV,	was	tremendously	increased	by	the	addition	of	DMSO.	Because	of	the	abundant	NTCP	 expression,	 the	 DMSO	 differentiated	 hepatocyte	 progeny	 cells	 were	 also	supporting	infection	with	HBV,	even	if	these	studies	will	need	further	confirmation.		Finally,	 I	 examined	whether	 PSC-derived	 hepatocytes	 could	 be	 infected	with	 the	 zika	virus	 (ZIKV).	Recently,	ZIKV	gained	attention	because	of	birth	defects	associated	with	ZIKV	 infection	 in	South	America.	However,	 ZIKV	mouse	models	 suggest	not	only	high	viral	RNA	 titers	 in	 the	brain	but	 also	 in	 the	 liver.	As	 a	 case	 report	 published	 in	1954	described	 the	 occurrence	 of	 liver	 damage	 and	 jaundice	 in	 two	 patients	with	 elevated	ZIKV	 viral	 antibodies,	 and	 ZIKV	belongs	 to	 the	Flaviviridae	 family,	 also	 encompassing	Dengue	 virus	 and	 Yellow	 Fever	 virus,	 we	 tested	 if	 ZIKV	 can	 infect	 human	 PSC-hepatocytes.	 I	demonstrated	that	hPSC-HLCs	support	the	complete	replication	cycle	of	ZIKV,	 including	 entry,	 replication	 and	 production	 of	 infectious	 virions.	 I	 also	demonstrated	 that	 treatment	 with	 7-deaza-2’-C-methyladenosine	 (7DMA),	 a	 known	(+)ssRNA	virus	inhibitor,	inhibits	ZIKV	infection	in	a	dose-dependent	manner.	Although	clinical	data	about	ZIKV	infection	are	limited,	these	studies	suggest	that	the	liver	might	be	 a	 potential	 target	 for	 ZIKV	 and	 that	 certain	 strains	 could	 cause	 hepatitis	 and	 liver	damage.				In	conclusion,	the	studies	in	this	thesis	demonstrate	that	pluripotent	stem	cell-derived	hepatocytes	are	a	promising	model	to	study	infection	with	various	hepatotropic	viruses	and,	can	be	considered	a	novel	test	system	for	antiviral	drugs.						
		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
	
	
	
	
	
Samenvatting	
		
Momenteel	worden	primaire	humane	hepatocyten	en	hepatoma	cellijnen	gebruikt	voor	de	 in	vitro	 studie	van	hepatocyt	specifieke	virussen.	Het	gebruik	van	deze	systemen	is	echter	 gelimiteerd.	 Alternatieve	 bronnen	 van	 humane	 hepatocyten	 zijn	 humane	embryonale	 (hESCs)	 en	 geïnduceerde	 pluripotente	 (hiPSCs)	 stamcel	 afgeleide	hepatocyten.	hESCs	en	hiPSCs	hebben	vele	voordelen	vergeleken	met	primaire	humane	hepatocyten	zoals	de	capaciteit	om	zichzelf	oneindig	te	hernieuwen,	de	potentie	om	te	differentiëren	in	elk	mogelijk	cel	type	en	de	mogelijkheid	om	genetisch	gemanipuleerd	te	worden.			Voorgaande	studies	hebben	aangetoond	dat	stamcel	afgeleide	hepatocyten	geïnfecteerd	kunnen	worden	met	het	hepatitis	C	(HCV)	en	hepatitis	B	virus	(HBV).	Een	ander,	meer	recent	 beschreven,	 virus	 dat	 hepatitis	 veroorzaakt,	 is	 het	 hepatitis	 E	 virus	 (HEV).	 Elk	jaar	worden	20	miljoen	mensen	geïnfecteerd	met	het	hepatitis	E	virus	wat	resulteert	in	meer	dan	3	miljoen	gevallen	van	acute	hepatitis.	Hoewel	Hepatitis	E	voornamelijk	acute	hepatitis	 veroorzaakt,	 zijn	 er	 ook	 gevallen	 van	 fulminante	 en	 chronische	 hepatitis	gerapporteerd	 resulterend	 in	 ongeveer	 56.000	doden	per	 jaar.	HEV	onderzoek	wordt	belemmerd	 door	 het	 gebrek	 aan	 efficiënte	 celcultuur	 systemen	 die	 HEV	 replicatie	ondersteunen.	 	 In	 deze	 thesis,	 differentieerde	 ik	 hESCs	 en	 hiPSCs	 tot	 hepatocyten	 en	infecteerde	deze	met	HEV.	Ik	toonde	aan	dat	stamcel	afgeleide	hepatocyten	de	volledige	replicatie	 cyclus	 van	 HEV	 ondersteunen.	 Bovendien	 vonden	we	 dat	 stamcel	 afgeleide	mesodermale	 cellen	 en	 neuroprogenitors	 HEV	 replicatie	 niet	 ondersteunen	 en	 HEV	replicatie	 dus	 specifiek	 lijkt	 te	 zijn	 voor	 hepatocyten.	 Nochtans	 konden	 deze	 twee	celtypes	 wel	 de	 replicatie	 van	 HEV	 ondersteunen	 wanneer	 de	 binnenkomst	 van	 het	virus	omzeild	was.			Het	hepatocyt	differentiatie	protocol	dat	gebruikt	werd	om	de	infectie	met	HEV	aan	te	tonen	 resulteerde	 in	 een	 gemengde	 cel	 populatie.	 Ik	 streefde	 daarom	 ernaar	 het	hepatocyt	 differentiatie	 protocol	 te	 verbeteren	 door	 het	 toevoegen	 van	 dimethyl	sulfoxide	(DMSO).	Het	toevoegen	van	DMSO	zorgde	voor	een	meer	homogene	populatie	van	stamcel	afgeleide	hepatocyten	en	een	betere	infectiviteit	met	HEV.	Bovendien	was	de	 expressie	 van	 natrium-taurocholaat	 cotransporting	 polypeptide	 (NTCP)	 enorm	verhoogd	door	de	toevoeging	van	DMSO.	Aangezien	NTCP	een	cruciale	HBV	receptor	is,	was	de	stamcel	afgeleide	hepatocyt	populatie	nu	ook	susceptibel	voor	HBV.		
		
Tot	 slot	 onderzocht	 ik	 of	 stamcel	 afgeleide	 hepatocyten	 ook	 geïnfecteerd	 konden	worden	met	het	zika	virus	(ZIKV).	ZIKV	werd	recent	in	de	media	gebracht	vanwege	de	mogelijke	link	met	geboortedefecten.	Nochtans	tonen	muis	modellen	aan	dat	ZIKV	niet	alleen	gevonden	kan	worden	 in	de	hersenen	maar	ook	 in	de	 lever.	Verder	werd	er	 in	1954	een	case	rapport	gepubliceerd	waarbij	er	een	mogelijke	link	zou	zijn	tussen	ZIKV	en	 geelzucht.	 Ik	 toonde	 aan	 dat	 stamcel	 afgeleide	 hepatocyten	 ook	 de	 volledige	replicatie	 cyclus	 van	 ZIKV	 ondersteunen.	 Bovendien	 toonde	 ik	 aan	 dat	 ZIKV	 infectie	geïnhibeerd	kon	worden	met	7-deaza-2’-C-methyladenosine	(7DMA);	een	gekende	RNA	virus	 inhibitor.	Wij	suggereren	dus	dat	ZIKV	mogelijks	 infectieus	 is	voor	de	 lever	al	 is	bijkomend	klinisch	onderzoek	nodig	om	dit	te	bevestigen.			Samengevat	tonen	onze	studies	aan	dat	pluripotente	stamcel	afgeleide	hepatocyten	een	veelbelovend	model	zijn	voor	de	studie	van	verschillende	hepatocyt	specifieke	virussen	en	gebruikt	kunnen	worden	voor	het	evalueren	van	antivirale	geneesmiddelen.			
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	 	 Abbreviations	
	
(+)ssRNA	 	 	 	 positive	strand	RNA	(-)ssRNA	 	 	 	 negative	strand	RNA	αSMA	 	 	 	 	 alpha	smooth	muscle	actin	AAT	 	 	 	 	 alpha	1-antitrypsin	AFP	 	 	 	 	 alpha	fetoprotein	ALB	 	 	 	 	 albumin	ALT	 	 	 	 	 alanine	aminotransferase	ATF5	 	 	 	 	 activating	transcription	factor	5	BAL	 	 	 	 	 bio-artificial	liver		BIO	 	 	 	 	 6-bromoindirubin-3′-oxime	BLBP	 	 	 	 	 brain	lipid-binding	protein	BMP4	 	 	 	 	 bone	morphogenetic	protein	4	cccDNA	 	 	 	 covalently	closed	circular	DNA	COL1A1	 	 	 	 collagen	type	1	alpha	1	CYP450	 	 	 	 cytochrome	P450	DLX2	 	 	 	 	 distal-less	homeobox	2	DE	 	 	 	 	 definitive	endoderm	DEX	 	 	 	 	 dexamethason	DMEM		 	 	 	 dulbecco’s	modified	Eagle’s	medium	DMSO	 	 	 	 	 dimethyl	sulfoxide			EIF2AK2	 Eukaryotic	 Translation	 Initiation	 Factor	 2	 Alpha				Kinase	2	FBS	 	 	 	 	 fetal	bovine	serum	FGF	 	 	 	 	 fibroblast	growth	factor	FISH	 	 	 	 	 fluorescence	in	situ	hybridization	FOXA1	 	 	 	 Forkhead	Box	A1	G6PD	 	 	 	 	 Glucose-6-phosphate	dehydrogenase	GAPDH	 	 	 	 glyceraldehyde-3-phosphate	dehydrogenase		GSK3β		 	 	 	 Glycogen	synthase	kinase	3	beta	HBV	 	 	 	 	 hepatitis	B	virus	HBeAg		 	 	 	 hepatitis	B	e	antigen	HBsAg		 	 	 	 hepatitis	B	surface	antigen	HCC	 	 	 	 	 hepatocellular	carcinoma	
	 	 Abbreviations	
	
hESC	 	 	 	 	 human	embryonic	stem	cells	HEV	 	 	 	 	 hepatitis	E	virus	HGF	 	 	 	 	 hepatocyte	growth	factor	hiPSC	 	 	 	 	 human	induced	pluripotent	stem	cells	HBx	 	 	 	 	 hepatitis	B	X	protein	HLC	 	 	 	 	 hepatocyte-like	cell	HNF4α	 	 	 	 hepatocyte	nuclear	factor	4	IFN	 	 	 	 	 interferon	alpha	iHEP	 	 	 	 	 induced	hepatocytes	iMEF	 	 	 	 	 inactivated	mouse	embryonic	mouse	fibroblasts		ISG	 	 	 	 	 interferon	stimulated	genes	JAK	 	 	 	 	 janus	kinase	LSEC		 	 	 	 	 liver	sinusoidal	endothelial	cells	LOX1	 	 	 	 	 leech	homeobox	1	NIM	 	 	 	 	 neural	induction	medium	NMM	 	 	 	 	 neural	maintenance	medium	NTCP	 	 	 	 	 natrium-taurocholate	cotransporting	polypeptide	MyrB	 	 	 	 	 myrcludex	B	OD	 	 	 	 	 optical	density	OSM	 	 	 	 	 oncostatin	M	ORF	 	 	 	 	 open	reading	frame	PAX6	 	 	 	 	 Paired	box	protein	Pax-6	PDGFRβ	 	 	 	 beta-type	platelet-derived	growth	factor	receptor		PHH	 	 	 	 	 primary	human	hepatocytes	PPAR	 	 	 	 	 peroxisome	proliferator-	activated	receptor	PROX1	 	 	 	 Prospero	Homeobox	1	PSC	 	 	 	 	 pluripotent	stem	cells	PXR	 	 	 	 	 pregnane	X	receptor	RBV	 	 	 	 	 ribavirin	rcDNA		 	 	 	 relaxed	circular	DNA	RdRp	 	 	 	 	 RNA-dependent	RNA	polymerase	RIG1	 	 	 	 	 retinoic	acid-inducible	gene	1	ROS	 	 	 	 	 reactive	oxygen	species	
	 	 Abbreviations	
	
qRT-PCR	 quantitative	reverse-transcription	polymerase	chain	reaction	SCID	 severe	combined	immunodeficiency	SEM	 	 	 	 	 standard	error	of	the	mean	SSEAA		 	 	 	 stage-specific	embryonic	antigen-4	STAT	 	 	 	 	 signal	transducer	and	activator	of	transcription	STM	 	 	 	 	 septum	transversum	TGFb	 	 	 	 	 transforming	growth	factor	beta	TNFα	 	 	 	 	 tumor	necrosis	factor	alpha	TLR	 	 	 	 	 toll-like	receptor	uPA	 	 	 	 	 urokinase	plasminogen	activator	UTR	 	 	 	 	 untranslated	region	VLP	 	 	 	 	 virus	like	particle		ZIKV	 	 	 	 	 ZIKA	virus	
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1.1	Human	hepatocytes:	general	introduction		
1.1.1	Organization	of	the	liver		The	 liver	 is	 the	 largest	 internal	 organ	 and	 is	 responsible	 for	 the	 major	 metabolic	functions	of	the	human	body,	including	detoxification,	metabolism	of	drugs	and	dietary	nutrients,	protein	synthesis,	production	of	albumin	and	bile	and	glycogen	storage.	All	of	these	 functions	 are	 executed	 by	 hepatocytes,	 the	 main	 liver	 cell	 type	 accounting	 for	approximately	 70%	 of	 the	 total	 liver	 mass	 (1,	 2).	 Blood	 and	 nutrients	 enter	 the	sinusoidal	space	of	 the	 liver	via	 the	portal	vein	and	the	hepatic	artery	and	re-enter	 in	the	 circulation	 through	 the	 central	 vein.	 The	 liver	 is	 zonated	 and	 the	 function	 of	hepatocytes	 differs	 according	 to	 their	 location	 along	 the	 porto-central	 axis,	 which	 is	associated	 with	 a	 decrease	 in	 oxygen	 level	 (Figure	 1).	 Periportal	 hepatocytes	 are	responsible	 for	 urea	 synthesis,	 gluconeogenesis	 and	 oxidative	 phosphorylation	 while	perivenous	hepatocytes	manage	glutamine	synthesis	and	glycolysis.	Other	functions	of	the	 liver	 such	 as	 albumin	 secretion	 are	 however	 not	 subjected	 to	 zonation	 (3).	 In	addition,	hepatocytes	are	polarized	cells	with	a	basolateral	and	apical	membrane	 that	are	 distinct	 by	 their	 expression	 of	 various	 (drug)	 transporters.	 The	 apical	membrane	faces	the	bile	canaliculi	while	 the	basolateral	membrane	 is	 facing	the	sinusoidal	space	(2).			 The	 other	 liver	 cell	 types;	 stellate	 cells	 and	 liver	 sinusoidal	 endothelial	 cells	(LSECs),	are	derived	from	the	embryonic	mesoderm	while	kupffer	cells	originate	from	the	 yolk	 sac	 (4).	 The	 hepatocytes	 are	 organized	 in	 single	 cell	 layers	 and	 lined	 by	 the	LSECs.	Hepatic	stellate	cells	reside	in	the	space	of	Disse,	which	is	the	space	between	the	hepatocytes	and	the	LSECs	(Figure	1)	(2).	Hepatic	stellate	cells	represent	approximately	8%	of	the	liver	tissue	and	remain	quiescent	in	healthy	liver.	Upon	liver	damage,	stellate	cells	become	activated,	secrete	collagen	and	form	a	fibrotic	scar	that	can	eventually	lead	to	irreversible	liver	damage	and	cirrhosis	(5).	The	liver	sinusoidal	endothelial	cells	are	characterized	by	pores	or	fenestrae,	which	is	specific	for	endothelial	cells	residing	in	the	liver.	 The	 fenestrae	 function	 as	 a	 sieve	 to	 filter	 the	 blood	 that	 arrives	 in	 the	 sinusoid	through	 the	 portal	 vein	 before	 it	 is	 passed	 through	 the	 hepatocytes	 (6).	 	 In	 addition,	LSECs	function	as	scavengers	of	macromolecules	and	contribute	to	the	maintenance	of	the	liver	homeostasis	by	the	release	of	soluble	mediators	such	as	nitric	oxide	and	pro-
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inflammatory	mediators	(7,	8).	 	Kupffer	cells	are	present	on	the	endothelial	 lining	and	function	 as	 the	macrophages	 of	 the	 liver,	 playing	 important	 roles	 in	 inflammation	 by	producing	pro-inflammatory	cytokines	such	as	tumor	necrosis	factor	alpha	(TNFa)	(9).			
	
Figure	 1.	 Organization	 of	 the	 liver.	 Hepatocytes	 are	 lined	 by	 the	 liver	 sinusoidal	
endothelial	 cells	with	 in	 between	 the	 hepatic	 stellate	 cells	 in	 the	 space	 of	Disse.	 Kupffer	
cells	 are	 present	 in	 the	 sinusoids	 adjacent	 to	 the	 endothelial	 cells.	 Blood	 flows	 from	 the	
portal	 vein	and	hepatic	arteriole	 to	 the	 central	 vein	 together	with	a	decrease	 in	oxygen	
concentration.		
1.1.2	Hepatocytes	and	the	need	for	renewable	sources		The	liver	is	prone	to	many	diseases	caused	by	e.g.	hepatitis	viruses,	drug	intake,	alcohol	abuse	 or	 inheritable	 and	 auto-immune	 disorders	 such	 as	 alpha-1-antitrypsinedeficiency.	 In	 healthy	 liver,	 hepatocytes	 remain	 in	 a	 quiescent	 state	 but	upon	 liver	 injury,	 hepatocytes	 are	 triggered	 to	 proliferate	 in	 order	 to	 restore	 and	regenerate	the	damaged	tissue	(10).	When	liver	damage	proceeds	stellate	cells	become	activated	 and	 form	 a	 fibrotic	 scar,	 which	 evolves	 into	 cirrhosis.	 Both	 cirrhosis	 and	uncontrolled	 hepatocyte	 proliferation	 can	 lead	 to	 hepatocellular	 carcinoma,	 the	 third	leading	 cause	 of	 cancer	 deaths	 (11).	 The	 process	 of	 hepatocyte	 activation	 is	 still	 not	completely	understood.	Expression	of	several	 liver-enriched	transcription	factors	such	as	 Hepatocyte	 Nuclear	 Factor	 4	 alpha	 (HNF4a)	 and	 the	 Wnt/b-catenin	 pathway	 are	
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thought	to	be	involved	in	the	control	of	hepatocyte	proliferation	and	liver	regeneration	(10,	12).	Because	mature	hepatocytes	are	characterized	by	a	tremendous	regeneration	potential,	 the	 existence	 and	 role	 of	 liver	 stem	 cells	 or	 progenitor	 cells	 is	 still	 under	debate.	 During	 recent	 years,	 studies	 were	 published	 both	 in	 favor	 or	 against	 the	presence	of	resident	stem	cells	in	the	liver	(13-16).	For	instance,	Lu	et	al.	demonstrated	the	activation	and	regeneration	capability	of	a	hepatic	progenitor	cell	population	when	senescence	 of	 hepatocytes	 was	 induced	 in	 an	 inducible	MdM2-mouse	model	 (17).	 In	contrast,	Shaub	et	al.	and	others	failed	to	detect	liver	stem	cells	and	demonstrated	that	newly	 formed	 hepatocytes	 all	 originated	 from	 pre-existing,	 proliferating	 hepatocytes	(18).		Although	the	liver	is	capable	of	regeneration,	liver	failure	remains	inevitable	upon	excessive	 tissue	 damage.	 The	 only	 curative	 therapy	 for	 liver	 failure	 is	 liver	transplantation	which	is	indicated	mainly	for	alcoholic	liver	disease	and	hepatocellular	carcinoma.	However,	 the	major	 limitation	 is	 the	 shortage	 of	 donors.	Moreover,	 organ	transplantation	requires	 life-long	 immunosuppression	(19).	Alternatively,	bio-artificial	liver	devices	(BAL)	that	take	over	the	primary	functions	of	the	hepatocytes	are	used	to	support	patients	on	the	liver	transplant	waiting	list	or	to	support	the	injured	liver.	The	BAL	have	however	a	limited	efficacy	and	their	use	is	 	also	impaired	due	to	the	limited	number	and	the	quality	of	available	donor	cells	(20).	Besides	the	urge	for	a	renewable	source	 of	 hepatocytes	 in	 regenerative	 medicine,	 the	 need	 for	 hepatocytes	 in	 drug	development	 increases.	Hepatocytes	contain	the	main	drug	metabolizing	enzymes	and	hepatotoxicity	 is	one	of	 the	main	 reasons	why	drugs	 fail	during	 clinical	 trials	 and	are	withdrawn	 from	 the	 pharmaceutical	 market.	 Currently,	 the	 pharmaceutical	 industry	relies	on	the	use	of	animals,	chiefly	rodents,	to	test	the	efficiency	and	toxicity	of	drugs.	Translation	 to	 humans	 is	 not	 straightforward	 and	 drug	 metabolization	 differences	between	 human	 and	 animal	 models	 remain	 a	 concern.	 Pharmaceutical	 industry	 is	therefore	 continuously	 searching	 for	 assays	 that	 more	 closely	 mimic	 the	 human	condition	to	predict	more	reliably	the	efficacy	and	toxicity	of	drugs.			
1.1.3	Alternatives	for	primary	human	hepatocytes		Currently,	 primary	 human	 hepatocytes	 (PHH)	 are	 the	 gold	 standard	 for	 in	vitro	 drug	metabolization	 studies.	 However,	 the	 use	 of	 PHH	 is	 associated	 with	 some	 major	drawbacks:	 (i)	 shortage	and	 inter-donor	variability,	 (ii)	 inability	of	 in	vitro	 expansion,	
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(iii)	 rapid	 in	 vitro	 dedifferentiation	 causing	 a	 loss	 of	 human	 specific	 drug	transporters/enzymes	 and	 a	 loss	 of	 phenotypical	 characteristics	 such	 as	 polarization	(21).	 Over	 the	 years,	 several	 attempts	 have	 been	 made	 to	 prevent	 the	 process	 of	dedifferentiation.	 Micropatterning	 of	 PHH	 with	 supporting	 fibroblasts,	 3D	 spheroid	cultures	and	overlay	cultures	of	PHH	with	two	layers	of	extracellular	matrix	are	some	of	the	strategies	used	to	retain	the	phenotype	of	isolated	hepatocytes.	Recently,	Godoy	et	
al.,	demonstrated	that	the	gene	regulatory	networks	of	cultivated	PHH	resemble	that	of	inflamed	livers	(22).		This	should	be	considered	when	cultivated	PHH	are	used	for	drug	toxicity	testing.	Although	several	approaches	could	to	some	degree	maintain	the	human	liver	metabolism,	the	limited	availability	of	donors	remains	another	major	hurdle	(23-25).			
	
Figure	2.	Advantages	and	disadvantages	of	primary	human	hepatocytes	and	alternatives.		Alternatives	 for	PHH	are	human	hepatoma	cell	 lines	and	immortalized	hepatocyte	cell	lines.	 Hepatoma	 cell	 lines	 such	 as	 HepG2	 and	 Huh7	 cells	 resemble	 some	 of	 the	 drug	metabolizing	 enzymes	 but	most	 of	 the	 phase	 I	 cytochrome	 P450	 (CYP)	 enzymes	 and	phase	II	metabolizing	enzymes	are	only	poorly	expressed.	Considering	these	limitations,	their	 availability,	 unlimited	 growth,	 stability	 and	 cost	 are	 advantages	 for	 some	 drug	metabolism	and	toxicity	studies	(26).	More	recently,	 the	HepaRG	cell	 line	was	derived	from	 a	 hepatocellular	 carcinoma.	 HepaRG	 cells	 are	 bipotential	 proliferating	 cells	 that	can	differentiate	to	both	biliary	and	hepatocyte-like	cells	upon	the	addition	of	dimethyl	sulfoxide	 (DMSO).	 In	 contrast	 to	 other	 hepatoma	 cell	 lines,	 HepaRG	 cells	 express	 a	higher	 level	 of	 certain	 CYP	 enzymes	 such	 as	 CYP3A4	 and	 other	 drug-metabolizing	enzymes.	 Nevertheless,	 HepaRG	 cells	 are	 derived	 from	 a	 single	 patient	 and	 remain	
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transformed	 cells	 that	 do	 not	 completely	 mimic	 the	 physiology	 of	 primary	 human	hepatocytes	(27).		Differentiated	 human	 stem	 cells	 are	 another	 alternative	 and	 promising	renewable	 source	 of	 hepatocytes.	 Numerous	 protocols	 have	 been	 described	 for	 the	differentiation	 of	 human	 pluripotent	 stem	 cells	 toward	 the	 hepatic	 lineage.	Alternatively,	 certain	 adult	 stem	 cells	 have	 the	 potential	 to	 differentiate	 into	hepatocytes.	However,	comparison	of	the	different	hepatocyte	differentiation	protocols	and	microarray	analysis	demonstrated	that	human	stem-cell	derived	hepatocytes	mimic	better	 fetal	 than	 mature	 hepatocytes	 and	 still	 lack	 the	 expression	 of	 mature	 (drug-metabolizing)	 liver	 markers.	 Nevertheless,	 methods	 of	 hepatocyte	 differentiation	 are	progressively	 improving	 holding	 great	 promise	 for	 the	 use	 of	 stem	 cell-derived	hepatocytes	in	the	future.			
1.2	From	stem	cell	to	hepatocyte		
1.2.1	Liver	embryogenesis		Embryogenesis	 is	 a	well-orchestrated	 stepwise	process	whereby	 totipotent	 stem	cells	are	 fated	 to	 either	 the	 trophectoderm	 or	 to	 the	 inner	 cell	mass.	 The	 trophoectoderm	differentiates	 into	 the	 extra-embryonic	 trophoblast	 that	 supports	 the	 developing	embryo,	 while	 the	 cells	 within	 the	 inner	 cell	 mass	 differentiate	 to	 the	 primitive	endoderm	 or	 to	 the	 epiblast.	 The	 primitive	 endoderm	 contributes	 together	 with	 the	trophoblast	to	the	extra-embryonic	tissues.	In	contrast,	the	epiblast	cells	are	pluripotent	and	give	rise	to	three	germ	layers	of	the	embryo	-the	endoderm,	the	mesoderm	and	the	ectoderm-	 whereby	 the	 liver	 originates	 from	 the	 endoderm	 (28,	 29).	 	 During	gastrulation	 the	 epiblast	 cells	 generate	 the	 primitive	 streak	 (PS).	 The	 epiblast	 cells	migrate	 through	 the	PS	 to	 form	 the	mesendoderm	 that	 further	 differentiates	 into	 the	mesoderm	 and	 definitive	 endoderm	 (DE).	 Consensus	 of	 different	 studies	 indicate	 an	essential	 role	 for	 two	 members	 of	 the	 Transformation	 Growth	 Factor	 Beta	 (TFGβ)	superfamily,	Activin-A	and	Nodal.	Both	factors	are	known	to	be	involved	in	the	earliest	cell	 fate	 decisions,	 the	 maintenance	 of	 pluripotency	 and	 the	 formation	 of	 the	PS/mesoderm.	Besides	the	Nodal/Activin-A	pathway,	gastrulation	and	generation	of	the	
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PS	 is	also	regulated	by	other	signal	cascades	such	as	canonical	Wnt	signaling	(30-32).	Throughout	 gastrulation,	 the	 DE	 is	 turned	 into	 the	 primitive	 gut	 tube	 that	 is	 further	patterned	 into	 foregut,	 midgut	 and	 hindgut	 domains.	 From	 the	 ventral	 part	 of	 the	foregut	a	hepatic	diverticulum	or	foregut	epithelium	is	formed	which	is	adjacent	to	the	developing	heart.	The	 liver	diverticulum	 is	 lined	by	 endoderm	cells,	 the	hepatoblasts,	which	 invade	 the	 septum	 transversum	 (STM)	 of	 the	 heart	 to	 form	 the	 liver	 bud.	 The	close	 proximity	 of	 hepatic	 endoderm	 and	 cardiac	mesoderm	 is	 important	 for	 hepatic	specification	whereby	 the	 STM	mesenchyme	 and	 the	 cardiac	mesoderm	 secrete	Bone	Morphogenetic	Proteins	 (BMPs)	 and	Fibroblast	Growth	Factors	 (FGFs),	 both	essential	for	 liver	 formation	 (4,	 33).	 Hepatoblasts	 are	 bipotential	 cells	 that	 differentiate	 into	hepatocytes	 or	 cholangiocytes.	 The	 hepatoblasts	 continue	 to	 proliferate	 under	 the	control	 of	 several	 growth	 factors,	 such	 as	 Hepatocyte	 Growth	 Factor	 (HGF),	which	 is	expressed	by	 the	STM,	 endothelial	 cells	 and	 the	hepatoblasts.	Hepatoblasts	 in	 contact	with	the	portal	vein	form	the	cholangiocytes	whereas	hepatoblasts,	not	in	contact	with	the	portal	vein,	differentiate	into	mature	hepatocytes	(4).			
1.2.2	Stem	cells:	a	renewable	source	for	hepatocyte	generation		As	briefly	discussed	above,	stem	cells	hold	great	promise	as	a	renewable	source	for	the	generation	of	hepatocytes.	Both	pluripotent	as	well	as	adult	stem	cells	were	shown	to	differentiate	into	functional	hepatocytes	in	vitro.		Mouse	and	human	embryonic	stem	cells	(ESCs)	were	first	isolated	from	the	inner	cell	mass	 of	 the	 blastocyst	 in	 1981	 and	 1998,	 respectively	 (34,	 35).	 Embryonic	 stem	cells	 are	 pluripotent	 cells	 capable	 of	 differentiation	 into	 the	 three	 germ	 layers	(endoderm,	mesoderm	and	ectoderm)	and	are	characterized	by	extensive	self-renewal	without	senescence	and	reconstitution	of	an	entire	organism	from	single	cells	following	blastocyst	 injection.	 The	 unique	 property	 of	 differentiation	 into	 specific	 cell	 lineages	holds	great	potential	for	regenerative	medicine,	drug	development	and	gene	therapies.	Mouse	and	human	ESCs	express	a	number	of	similar	markers	such	as	OCT4,	SOX2	and	
NANOG	 that	 control	 pluripotency	 and	 self-renewal.	 However,	mouse	 ESC	 express	 cell	surface	marker	stage-specific	embryonic	antigen	1	(SSEA1)	while	human	ESCs	express	
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SSEA3	and	SSEA4.	These	differences	between	mouse	and	human	ESCs	suggest	that	their	downstream	signaling	pathways	may	differ	(36,	37).		In	 2006,	 Takahashi	 et	 al	 demonstrated	 that	 retroviral	 transfection	 of	 four	transcription	 factors,	 OCT4,	 SOX2,	 KLF4	 and	 c-MYC,	 can	 reprogram	 mouse	 adult	fibroblasts	 towards	 cells	 with	 ESC	 characteristics.	 They	 named	 these	 reprogrammed	cells	“induced	pluripotent	stem	cells	(iPSCs)”	(38).	A	year	later,	several	groups	reported	the	 successful	 generation	 of	 iPSCs	 from	 human	 somatic	 cells,	 such	 as	 human	 adult	fibroblasts	(39,	40).		Although	ESCs	and	iPSCs	are	highly	similar,	differences	still	exist	at	the	molecular	level.	It	has	been	recently	shown	that	iPSCs	retain	an	epigenetic	memory	of	 their	 somatic	 cells	 or	 origin.	 This	 implies	 that	 differentiation	 capacities	 and	 gene	expression	 could	 be	 different.	 However,	 the	 epigenetic	 memory	 can	 be	 erased	 by	addition	 of	 small	 molecules	 like	 valproic	 acid	 or	 longer-term	 passaging.	 By	 contrast,	retaining	the	epigenetic	memory	might	enhance	the	differentiation	capacity	of	iPSC	into	the	desired	cell	lineage	of	origin	(41,	42).	The	ability	to	generate	pluripotent	stem	cells	from	patients	with	genetic	disorders	is	promising	for	in	vitro	disease	modeling,	disease-specific	 treatment	 testing	 and	 cell	 replacement	 therapy.	Moreover,	 use	 of	 autologous	iPSCs	 might	 circumvent	 the	 need	 for	 immunosuppression	 and	 the	 ethical	 concerns	related	to	ESCs	as	they	can	be	derived	in	a	non-invasive	way	from	the	patient	itself (43).  	 Alternatively,	diverse	adult	stem	cells	can	be	isolated	from	the	human	body	and	differentiated	into	hepatocytes.	Adult	stem	cells	are	undifferentiated	cells	that	reside	in	differentiated	 tissues	 such	 as	 the	 bone	 marrow,	 brain	 and	 gut.	 Adult	 stem	 cells	 are	multipotent	 and	 can	 differentiate	 into	 the	 tissue	 of	 origin	 or	 transdifferentiate	 into	some	 cell	 types	 of	 other	 lineages.	 Human	mesenchymal	 stem	 cells	 isolated	 from	 the	bone	 marrow,	 umbilical	 cord	 blood	 or	 adipose	 tissue	 were	 previously	 shown	 to	differentiate	into	hepatocytes	(44,	45).	Adult	stem	cells	are	characterized	by	extensive	proliferation	but	do	not	grow	 indefinite	 such	as	pluripotent	 stem	cells.	They	could	be	obtained	 from	 the	 patient	 and	hence	 applied	 in	 an	 autologous	manner	 and	 obviously	avoid	 the	sacrifice	of	 the	embryo.	However,	 the	hepatocyte	differentiation	potential	 is	more	restricted	and	less	efficient	compared	to	hESCs	and	hiPSCs	(46-48).				
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1.2.3	Differentiation	of	stem	cells	to	hepatocyte-like	cells			Numerous	 protocols	 have	 been	 described	 to	 differentiate	 pluripotent	 stem	 cells	towards	 hepatocytes.	 Pluripotent	 stem	 cells	 can	 be	 spontaneously	 differentiated	 in	three-dimensional	(3D)	aggregates	or	embryoid	bodies.	Under	defined	conditions,	these	embryoid	 bodies	 spontaneously	 form	 hepatocytes	 (49,	 50).	 A	 major	 drawback	 of	spontaneous	differentiation	 is	 the	 formation	of	other	cell	 types,	 limiting	 the	efficiency	and	yield	of	this	differentiation	approach.	Alternatively,	directed,	two	dimensional	(2D),	stem	cell	differentiation,	under	control	of	specific	growth	factors	has	proven	to	provide	more	 homogeneous	 populations	 of	 cells	 with	 hepatocyte	 characteristics.	 In	 this	approach,	 pluripotent	 stem	 cells	 are	 differentiated	 to	 the	 hepatic	 lineage	 by	recapitulating	 embryonic	 development	 through	 the	 sequential	 addition	 of	 different	signaling	 factors.	 In	 general,	 pluripotent	 stem	 cells	 are	 first	 differentiated	 into	endodermal	 cells	 by	 the	 addition	 of	 Activin-A	 either	 alone	 or	 together	 with	 Wnt3A.	Endodermal	 cells	 are	 further	 differentiated	 into	 hepatoblasts	 by	 bone	morphogenetic	protein	 4	 or	 2	 (BMP4	 or	 2)	 and	 fibroblast	 growth	 factor	 1	 or	 4	 (FGF1	 or	 4).	 Finally,	hepatocyte	maturation	is	induced	by	exposure	to	hepatic	growth	factor	(HGF)	often	in	combination	with	Oncostatin	M	(OSM)	and	dexamethasone	(51-54).		
	
Figure	 3.	 Hepatocyte	 differentiation	 protocol.	 Consensus	 of	 different	 differentiation	
protocols.	Pluripotent	stem	cells	are	differentiated	to	endodermal	cells	by	Activin-A	alone	
or	together	with	Wnt3A.	Endodermal	cells	are	further	differentiated	into	hepatoblasts	and	
hepatocytes	 by	 BMPs/FGFs	 and	 HGF/Dexamethasone	 (DEX)/Oncostatin	 M	 (OSM),	
respectively.			
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It	is	essential	to	review	the	efficiency	of	hepatocyte	differentiation	by	a	combination	of	morphological,	 phenotypical	 and	 functional	 assays.	 Microscopically,	 hepatocytes	 are	cuboidal	cells	with	large	nuclei	and	abundant	microvilli.	In	general,	RT-qPCR	is	used	for	gene	 expression	 analysis	 to	 determine	 the	 commitment	 of	 stem	 cells	 to	 the	 specified	lineage.	 	Gene	expression	results	should	be	confirmed	by	protein	immunofluorescence	and	western	blot.	Hepatocytes	are	responsible	for	numerous	metabolic	and	detoxifying	functions	 and	 characterization	 of	 hepatocyte	 functionality	 is	 therefore	 a	 prerequisite	(55).	 Extensive	 characterization	 of	 the	 hepatic	 progeny	 allows	 to	 compare	 various	protocols	and	to	review	the	maturity	of	the	differentiated	hepatocytes.	Table	1	outlines	some	 examples	 of	 genes,	 proteins	 and	 functionality	 assays	 that	 are	 generally	 used	 to	define	the	several	stages	of	hepatocyte	differentiation.				
	
Table	 1:	 Genes,	 proteins	 and	 functionality	 assays	 used	 to	 review	 the	 differentiation	 of	
stem	cells	to	hepatocytes.		The	 question	 arises:	How	 closely	 do	 stem	 cell-derived	 hepatocytes	 resemble	 primary	human	adult	hepatocytes?	Recently,	Hanley	et	al.	demonstrated	 that	stem	cell-derived	hepatocytes	mimic	fetal	rather	than	adult	hepatocytes	and	are	therefore	often	referred	to	as	hepatocyte-like	cells.	The	research	group	compared	the	proteome	of	differentiated	hepatocytes	 to	 freshly	 isolated	 fetal	 and	 adult	 hepatocytes.	 Several	 markers	 such	 as	albumin	 and	 alpha-1-antitrypsin	 (AAT)	 approximated	 the	 expression	 levels	 of	 adult	hepatocytes.	 However,	 the	 expression	 of	 alpha-fetoprotein	 (AFP),	 a	 marker	 for	 fetal	hepatocytes,	was	 still	 abundant	 in	 stem	 cell-derived	 hepatocytes.	 In	 addition,	 several	mature	markers	such	as	CYP3A4	were	only	expressed	at	low	levels	in	the	differentiated	hepatic	 progeny	 cells	 (56).	 Another	 study	 compared	 the	 gene	 regulatory	 networks	 of	
Gene/Protein	
expression
Pluripotency:	OCT4, Nanog, SSEA4, TRA1-60Endoderm:	MIXL1,	CXCR4,	EOMES,	SOX17Fetal	hepatocytes:	AFP,	AAT,	Albumin,	HNF4!Mature	hepatocytes:	Albumin,	AAT,	HNF4!,	NTCP,	CYP3A4,	CYP2D6,	MRP2,		UGT1A1
Functionality Synthetic function:	Albumin/AAT/AFP	secretion	(ELISA)Energy	metabolism:	Urea	production,	glycogen	production	(Periodic	Acid-Shiff staining),	LDL	uptakeDetoxification	function:	Phase	I	(CYP3A4,	CYP2D6,	CYP1A2)	and	Phase	II	enzymes	(UGT,	 																		GST)
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three	 independent	 hepatocyte	 differentiation	 populations	 to	 those	 of	 freshly	 isolated	primary	 adult	 hepatocytes	 and	 cultivated	 hepatocytes.	 All	 the	 three	 differentiation	protocols	resulted	in	a	mixed	population	of	cells	with	features	of	not	only	liver	but	also	of	colon,	stem	cells	and/or	fibroblasts.	The	study	identified	unfavorable	gene	regulatory	networks	with	clusters	of	hepatic	genes	that	are	poorly	expressed	in	the	differentiated	progeny	cells,	clusters	of	highly	expressed	proliferation	associated	genes	and	clusters	of	genes	 that	 are	 linked	 to	 epithelial-to-mesenchymal	 transition	 and	dedifferentiation	of	cultivated	primary	human	hepatocytes	in	vitro.	Moreover,	this	study	demonstrated	that	genes	 that	 are	 only	 at	 low	 levels	 expressed	 in	 differentiated	 hepatocytes,	 such	 as	 the	main	 drug	metabolizing	 enzyme	CYP3A4,	 overlap	with	 genes	 that	 are	 downregulated	during	the	dedifferentiation	of	cultured	primary	human	hepatocytes.	This	observation	is	in	line	with	the	notion	that	the	in	vitro	cultivation	methods	are	currently	suboptimal	to	induce	or	maintain	a	mature	hepatocyte	phenotype	(57).		
	
1.2.4	Recent	advances	in	hepatocyte	differentiation		The	 fetal	 phenotype	 and	 lack	 of	 key	 metabolizing/mature	 hepatocyte	 markers	 are	currently	 the	 major	 limitations	 of	 stem	 cell-derived	 hepatocytes.	 Genome-wide	characterization	 of	 the	 differentiated	 hepatic	 progeny	 cells	 demonstrated	 the	 lack	 of	certain	 transcription	 factors	 such	 as	 pregnane	 X	 receptor	 (PXR),	 while	 other	unfavorable	 transcription	 factors	 such	 as	 TWIST1	 were	 abundantly	 expressed	 (57).	Overexpression	 of	 key	 transcription	 factors	 is	 one	 approach	 to	 enhance	 hepatocyte	maturation.	Previous	studies	demonstrated	that	overexpression	of	hepatic	transcription	factors	such	as	HNF4a,	CCAAT/enhancer	binding	protein	alpha	(c/EBPa)		and	forkhead	box	 A1	 protein	 (FOXA1)	 resulted	 in	 trans-differentiation	 of	 fibroblasts	 into	 induced	hepatocytes	 (iHEPs)	 (58).	 In	 addition,	 Nakamori	 et	 al.,	 transduced	 differentiated	hepatocyte-like	 cells	 with	 activating	 transcription	 factor	 5	 (ATF5),	 c/EBPa	 and	prospero	 homeobox	 Protein	 1	 (PROX1)	 and	 observed	 a	 slight	 improvement	 of	 some	hepatocyte	 markers.	 The	 expression	 of	 CYP3A4	 expression	 remained	 however	unchanged	 (59).	 Alternatively,	 newly	 developed	 gene	 editing	 techniques	 such	 as	CRISPR/CAS9	 will	 allow	 to	 relatively	 easily	 knock-down	 and/or	 knock-out	 specific	unfavorable	transcription	factors	to	study	the	effect	on	hepatocyte	maturation.		
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Most	 of	 the	 published	 protocols	 differentiate	 pluripotent	 stem	 cells	 toward	hepatocytes	 through	 the	 addition	 of	 various	 growth	 factors	 that	 mimic	 embryonic	development	(Figure	3).	Small	molecules	are	an	attractive	cost-effective	alternative	 to	growth	 factors.	 For	 instance,	 bromo-indirubin-3’-oxime	 (BIO),	 a	 glycogen	 synthase	kinase	 3	 beta	 (GSK3b)	 –	 inhibitor	 that	 prevents	 the	 degradation	 of	 b-catenin,	 was	previously	 used	 to	 replace	Wnt3A	 during	 endoderm	 differentiation	 (60).	 In	 addition,	small	molecules	can	be	added	to	induce	further	maturation	of	the	differentiated	hepatic	progeny	 cells.	 In	2013	Shan	et	al.	 screened	12480	 small	molecules	 and	 identified	 two	classes	 of	molecules	 that	 either	 induced	 proliferation	 of	 primary	 human	 hepatocytes	and/or	 improved	 differentiation	 of	 stem	 cell-derived	 hepatocytes.	 Two	 hits	 were	identified	 that	 increased	 albumin	 secretion	 and	 CYP3A4	 activity,	while	 AFP	 secretion	was	decreased	(61).	Based	on	the	structural	properties	of	the	identified	small	molecules	gene	regulatory	networks	might	be	unraveled	to	obtain	more	insight	 in	the	process	of	hepatocyte	proliferation	and/or	maturation.			 Cell-cell	 junctions	 are	 critical	 for	 hepatocyte	maturation	 but	 are	 limited	 in	 2D	cultures.	Therefore,	 several	groups	have	cultured	stem	cell-derived	hepatocytes	 in	3D	spheroids	 to	 better	 mimic	 the	 in	 vivo	 microenvironment.	 3D	 cultures	 show	 some	improvement	of	 the	hepatocyte	 functions	and	 induce	hepatocyte	polarization	and	bile	canaliculi	formation	(62-65).	Nevertheless,	complete	hepatocyte	maturation	was,	to	the	best	of	our	knowledge,	not	yet	demonstrated.	Moreover,	hepatocytes	reside	in	the	liver	in	 close	 contact	with	 other	 liver	 cell	 types.	 Attempts	 have	 been	made	 to	mimic	 these	heterotypic	 cell-cell	 interactions	 in	 vitro	 either	 in	 2D	 or	 in	 3D	 culture	 systems.	Heterotypic	 cell-cell	 interactions	 are	 also	 crucial	 during	 liver	 development.	 To	recapitulate	the	in	vivo	liver	embryogenesis,	Takebe	et	al.	first	differentiated	pluripotent	stem	 cells	 to	 hepatic	 endoderm.	 The	 differentiated	 hepatic	 endoderm	 was	 then	 co-cultured	with	 human	 umbilical	 cord	 endothelial	 cells	 and	 human	mesenchymal	 stem	cells.	Interestingly,	the	cells	self-organized	into	3D	cell	aggregates	that	were	ectopically	transplanted	 into	 immunocompromised	 mice.	 Upon	 transplantation,	 the	 liver	 buds	became	vascularized	and	improved	the	survival	of	mice	with	liver	injury.	Although	the	liver	 buds	 were	 promising,	 complete	 hepatocyte	 maturation	 was	 unfortunately	 not	identified	 (66).	 Bioreactors	 and	 microfluidic	 devices	 are	 another	 promising	 tool	 to	culture	2D	or	3D	differentiated	hepatocytes	cultures.	 In	 these	systems	oxygen	tension	
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and	 the	 flow	of	nutrients,	growth	 factors	and	compounds	 is	dynamic	and	controllable	which	recapitulates	better	the	in	vivo	liver	environment	(67,	68).			 During	the	last	15	years	enormous	progress	has	been	made	in	understanding	the	processes	 underlying	 hepatocyte	 differentiation	 and	 maturation.	 Despite	 these	tremendous	improvements,	the	generation	of	completely	mature	hepatocytes	remains	a	major	 hurdle	 as	 the	 differentiated	 hepatocytes	 are	 still	more	 closely	 resembling	 fetal	hepatocytes.	 Nevertheless,	 stem	 cell-derived	 hepatocytes	 are	 a	 promising,	 more	physiological,	 valuable	 alternative	 to	 hepatoma	 and	 immortalized	 cell	 lines	 to	 study	drug-induced	 hepatotoxicity,	 the	 virology	 of	 hepatotropic	 viruses	 and	 liver	regeneration.			
1.3	Virology	of	hepatocyte	pathogenic	viruses			
1.3.1	Hepatitis	E	virus	
	
1.3.1.1	Genome	structure	and	genetic	characteristics			The	hepatitis	E	virus	belongs	to	the	family	of	the	Hepeviridae	and	is	classified	as	the	sole	member	 of	 the	 Hepevirus	 genus	 (69).	 Four	 major	 genotypes	 of	 HEV	 are	 recognized.	Genotype	1	and	2	are	pathogenic	for	humans,	while	genotype	3	and	4	are	zoonotic	with	reservoirs	both	 in	humans	and	animals	 including	pigs	 (70).	Recently,	 also	genotype	5	and	6	were	identified	in	wild	boars	and	genotype	7	in	camels	(71).		HEV	is	a	7.2kb	positive-sense	single	stranded	RNA	virus	containing	a	capped	5’	UTR	and	3’	UTR	followed	by	a	polyA-tail	5	(Figure	4).	The	RNA	genome	contains	three	partially	 overlapping	 open	 reading	 frames	 (ORF1,	 2	 and	 3).	 ORF1	 encodes	 the	 non-structural	 proteins,	 including	 the	methyltransferase,	 protease,	 helicase	 and	 and	 RNA-dependent	RNA	polymerase	(72).	Various	aspects	of	 the	HEV	replication	remain	to	be	elucidated	due	to	the	lack	of	efficient	and	physiological	relevant	cell	culture	systems	and	
in	 vivo	 animal	 models.	 Until	 now	 it	 remains	 unclear	 if	 ORF1	 functions	 as	 a	 large	polyprotein	 or	 is	 cleaved	 into	 its	 functional	 proteins	 (69).	 ORF2	 and	 ORF3	 partially	overlap	and	the	ORF-encoded	proteins	 interact	during	replication.	Their	 interaction	 is	believed	 to	 be	 important	 for	 viral	 infectivity	 (73).	ORF2	 encodes	 the	 viral	 capsid	 and	
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contains	 three	 glycosylation	 sites	 known	 to	 be	 involved	 in	 the	 infectivity	 of	 the	 viral	particles	 and	 the	 binding	 to	 susceptible	 cells	 (74,	 75).	 A	 small	 phosphoprotein	 is	encoded	by	ORF3	but	the	function	of	this	phosphoprotein	is	still	under	debate.	Recent	findings	 demonstrated	 that	ORF3	 is	 involved	 in	 viral	 egress,	HEV	 budding	 and	 virion	morphogenesis	(76-78).			
	
Figure	 4.	 HEV	 genome	 containing	 a	 capped	 5’	 UTR	 and	 polyA-tail	 at	 the	 3’UTR.	 Non-
structural	 proteins	 (Mtase;	 methyltransferase,	 Y;	 Y-domain;	 PCP;	 papain-like	 cysteine	
protease,	 HVR;	 hypervariable	 regionX;	 macrodomain,	 RdRp;	 RNA-dependent	 RNA	
polymerase)	 are	 translated	 from	 ORF1.	 ORF2	 and	 ORF3	 are	 partially	 overlapping	 and	
encode	the	capsid	and	a	small	phosprotein,	respectively.		
1.3.1.2	HEV	replication	cycle		The	life	cycle	of	the	hepatitis	E	virus	is	not	well	understood	due	to	the	unavailability	of	efficient	 in	vitro	 and	 in	vivo	models.	 The	 hepatitis	 E	 replication	 cycle	 seems	 however	typical	for	a	positive	single-stranded	RNA	virus	(Figure	5).	The	hepatitis	E	virus	mainly	replicates	 in	hepatocytes	 (79,	80).	Extrahepatic	 sites	 such	as	 colon,	 spleen	and	 lymph	nodes	are	however	also	being	described.	Initially,	 the	virus	binds	to	the	cells	via	a	yet	unknown	receptor.	Recently	several	groups,	determined	the	3D	crystal	structure	of	HEV	virus-like	 particles	 (VLPs).	 VLPs	 are	 empty	 viral	 particles	 containing	 the	 N-terminal	capsid	 protein	 expressed	 by	ORF2	 in	Baculovirus	 expression	 system	 (81).	Mutational	analysis	 and	 attachment	 studies	 with	 these	 VLPs	 will	 aid	 in	 understanding	 the	mechanism	of	HEV	cell	entry.	Upon	entry,	the	viral	single-stranded	RNA	is	released	into	the	 cytoplasm.	 Through	 cap-mediated	 translation	 the	 non-structural	 proteins	 are	produced.	 The	 RNA-dependent	 RNA	 polymerase	 produces	 a	 negative-strand	 RNA	replication	intermediate	from	the	positive-sense	strand	HEV	RNA.	The	negative-strand	
Chapter	I	 	 Introduction	
	 14	
RNA	 is	 the	 template	 for	 the	 production	 of	 the	 full-length	 positive-sense	RNA	 and	 the	subgenomic	 RNA	 that	 is	 translated	 into	 the	 structural	 proteins	 of	 ORF2	 and	 ORF3.	Replication	 probably	 occurs	 in	 close	 proximity	 with	 the	 membranes	 of	 the	endoplasmatic	reticulum.	ORF2	is	translated	into	the	capsid	and	encapsulates	the	newly	produced	viral	RNA	while	 the	structural	proteins	encoded	by	ORF3	are	 thought	 to	be	involved	in	viral	egress	and	HEV	budding	(82).		
	
Figure	5.	HEV	replication	cycle.	Upon	HEV	entry,	the	viral	RNA	is	released	and	translated	
into	 the	 non-structural	 proteins	 in	 the	 cytoplasm.	 The	 RNA-dependent	 RNA	 polymerase	
creates	the	negative-strand	intermediate	(green)	that	is	the	template	for	the	production	of	
more	 full-length	 and	 subgenomic	 positive-strand	 RNA	 (red).	 The	 subgenomic	 positive-
strand	RNA	 is	 translated	 into	 the	 structural	proteins	 to	assemble	and	produce	new	HEV	
viral	particles	that	are	released	from	the	cell.		
1.3.1.3	Epidemiology		Worldwide	20	million	people	are	annually	infected	with	the	hepatitis	E	virus	resulting	in	3.5	million	cases	of	acute	liver	injury	and	approximately	56000	deaths	(83).	Hepatitis	
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E	is	an	enterically	transmitted	virus	with	the	highest	prevalence	in	Asia	and	Africa	(84,	85).	 However,	 the	 incidence	 of	 hepatitis	 E	 in	 the	Western	world	 is	 increasing	with	 a	seroprevalence	 ranging	between	5%	and	50%	(86-88)	 .	Genotype	1	and	2	only	 infect	humans	and	usually	cause	infections	in	developing	countries	through	contamination	of	drinking	water.	Genotype	3	and	4	have	their	main	reservoir	in	domestic	pigs	and	are	the	main	source	of	hepatitis	E	infection	in	industrialized	countries	due	to	the	consumption	of	 undercooked	 pig	 meat	 (69,	 89).	 Interestingly,	 certain	 cases	 of	 fulminant	 hepatitis	have	 been	 reported	 in	 pregnant	 women	 with	 mortality	 rates	 up	 to	 30%	 in	 certain	countries	 such	 as	 India,	 Iran	 and	 Ethiopia	 (90).	 The	 altered	 cellular	 immunity	 and	hormonal	 balance	 are	 probably	 related	 to	 the	 higher	 incidence	 of	 fulminant	 hepatitis	during	pregnancy	(91).			
1.3.1.4	Pathogenesis		Hepatitis	 E	 was	 believed	 to	 be	 mainly	 transmitted	 via	 the	 fecal-oral	 route	 through	drinking	 of	 contaminated	 water	 or	 consumption	 of	 undercooked	meat	 in	 developing	and	 industrialized	 countries,	 respectively	 (69,	 89).	 However,	 several	 countries	(including	Canada,	Japan,	Germany,	…)		now	documented	that	hepatitis	E	can	as	well	be	transmitted	via	blood	transfusions	(92-94).	Usually	hepatitis	E	is	linked	with	acute	self-limiting	asymptomatic	hepatitis.	However	symptomatic	cases	of	acute	hepatitis	E	have	been	described	and	are	marked	by	flu-like	symptoms	such	as	myalgia,	abdominal	pain,	vomiting	and	in	some	cases	by	clinical	symptoms	of	acute	hepatitis	including	jaundice,	itching	and	 increased	 levels	of	alanine	aminotransferase	(ALT).	The	 incubation	period	of	symptomatic	hepatitis	E	is	approximately	40	days	(95).	Although	hepatitis	E	is	mainly	a	causative	agent	of	acute	hepatitis,	infection	with	hepatitis	E	might	evolve	in	chronicity	in	 immunocompromised	 patients.	 Solid-organ	 transplant	 patients	 as	 well	 as	 HIV	patients	 have	 an	 impaired	 T-cell	 response	which	might	 lead	 to	 chronic	 hepatitis	 and	eventually	liver	cirrhosis	when	left	untreated.	Beside	chronic	events,	cases	of	fulminant	hepatitis	are	known	to	occur	in	patients	with	underlying	liver	disease	and	interestingly	in	pregnant	women	(91,	96-99).	As	aforementioned,	 the	reason	why	pregnant	women	are	more	prone	to	fulminant	hepatitis	is	still	unclear	but	might	be	related	altered	T-cell	immunity.	 Next	 to	 hepatic	 manifestations,	 there	 is	 clear	 evidence	 that	 hepatitis	 E	 is	linked	 to	 neurologic	 disorders	 such	 as	 Guillain-Barré	 syndrome	 and	 neuralgic	
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amyotrophy	but	 it	 remains	 to	be	resolved	 if	 this	 is	a	primary	or	a	 secondary	effect	of	hepatitis	E	virus	infection	(100,	101).			
1.3.1.5	Host	response	and	factors	related	to	HEV	
	Hepatitis	 E	 is	 usually	 causing	 self-limiting	 or	 acute	 hepatitis.	 However,	 chronic	infections	 are	 reported	 in	 immunocompromised	 patients	 with	 weakened	 T-cell	responses.	Also	pregnant	women	have	a	higher	incidence	of	fulminant	hepatitis	which	might	be	related	with	reduced	immunity	during	pregnancy.	Studies	about	the	immune	responses	 to	HEV	are	 limited	due	 to	 inefficient	 cell	 culture	 systems,	 the	 lack	of	 small	animal	models	and	difficulties	 to	obtain	 liver	biopsies.	An	 interesting	study	published	by	Prabhu	et	al.	 found	an	 increase	of	CD8+	and	CD4+	cells	 in	 liver	biopsies	of	deceased	patients	 who	 underwent	 acute	 HEV	 infection	 compared	 to	 healthy	 liver	 biopsies	providing	evidence	of	the	induction	of	a	cellular	T-cell	response	upon	HEV	infection.		Hepatitis	 E	 virus	 also	 induces	 a	 cellular	 innate	 interferon	 response.	 The	 virus	replicates	 via	 a	 double-stranded	 RNA	 intermediate	 that	 is	 recognized	 by	 Toll	 Like	Receptors	 (TLR)	and	Retinoic	acid-Inducible	Gene	 I	 (RIG-I)	 like	receptors	upon	which	IFNa/b	 is	produced.	The	binding	of	IFNa/b	to	the	IFN	receptor	induces	the	JAK/STAT	signaling	 cascade	 that	 results	 in	 the	 production	 of	 interferon	 stimulated	 genes	 (ISG)	such	 as	 MX1	 and	 Eukaryotic	 translation	 initiation	 factor	 2	 alpha	 kinase	 (EIF2KA2).	Interferon	 stimulated	genes	 can	prevent	viral	 entry,	 assembly,	 egress,	 translation	and	induce	 an	 inflammatory	 immune	 response.	 Nevertheless,	 it	 was	 demonstrated	 that	ORF3	 inhibits	 the	 phosphorylation	 of	 STAT1,	 thereby	 suppressing	 the	 induction	 of	interferon	stimulated	genes	and	escaping	the	type	I	IFN	response	(102).	Little	is	known	about	 the	 interaction	 of	 host	 factors	 with	 the	 hepatitis	 E	 virus.	 Proteomic	 studies	 to	identify	host	factors	are	usually	carried	out	on	HEV	infected	swine	livers.	The	identified	proteins	were	mostly	 involved	 in	 lipid	 and	 cholesterol	metabolism	 and	 inflammatory	and	immune	responses.	However,	these	data	still	need	to	be	confirmed	in	human	(103,	104).	In	addition,	Chandra	et	al.,	demonstrated	that	ORF3	phosphorylates	liver-enriched	transcription	 factor	 HNF4a	 which	 resulted	 in	 the	 downregulation	 of	 several	 HNF4a	target	genes	(105).	Interestingly,	albumin	and	transthyretin	levels,		both	HNF4a	target	genes,	were	lower	in		the	plasma	of	HEV	infected	patients	compared	to	healthy	controls	(106).	 Due	 to	 the	 difficulty	 of	 HEV	 replication	 in	 cells/cell	 lines	 in	 vitro,	 most	 host	
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factors	 and	 pathways	 studies	 rely	 on	 in	vitro	 replicon	 and	 overexpression	 systems	 in	carcinoma	 cell	 lines	 to	 understand	 their	 role	 during	 natural	 human	 HEV	 infection.	However,	these	studies	have	to	be	critically	reviewed	as	carcinoma	cell	lines	often	have	impaired	 host	 responses	 and	 overexpression	 systems	 express	 viral	 proteins	 at	 non-physiological	levels.			
1.3.1.6	Treatment	and	antiviral	HEV	therapy		Hepatitis	 E	 usually	 causes	 asymptomatic	 or	 self-limiting	 acute	 hepatitis	 in	 healthy	individuals	that	does	not	require	antiviral	treatment.	However,	treatment	is	necessary	for	 chronic	 hepatitis	 in	 immune	 suppressed	 transplant	 patients	 and	immunocompromised	patients.	Initially,	immunosuppressive	therapy	will	be	reduced	in	transplant	patients	to	reduce	the	viral	load.	When	reduction	of	therapy	is	not	sufficient,	antiviral	 therapy	 with	 ribavirin	 is	 the	 standard	 method	 of	 choice.	 Alternatively,	pegylated	 interferon-a-2a	 can	 be	 administrated	 but	 causes	 severe	 side-effects	 and	might	 lead	 to	graft	 rejection.	Both	ribavirin	and	pegylated	 interferon-a-2a	are	contra-indicated	 in	pregnant	women,	 leaving	no	 treatment	 for	 this	 group	of	HEV	susceptible	patients.	Additionally,	personal	hygiene,	quality	of	water	supplies	and	adequate	cooking	of	meat	 are	 important	prophylactic	measurements	 in	 the	prevention	of	HEV	 infection	(89,	107).	Vaccination	 is	 another	effective	 strategy	 to	prevent	HEV	 infection.	 In	2011,	Hecolinâ	was	approved	by	the	China’s	State	Food	and	Drug	Administration.	Hecolinâ	is	composed	of	the	recombinant	truncated	capsid	protein	and	produces	viral-like	particles	(VLP)	 that	 preserves	 the	 viral	 epitopes.	 The	 vaccine	 could	 be	 a	 potential	measure	 to	prevent	 outbreaks	 in	 endemic	 areas	 and	 as	prophylactic	 agent	 in	 risk	 groups	 such	 as	immunocompromised	patients	and	pregnant	women	(108).			
1.3.1.7	Culture	systems	and	animal	models			
In	 vitro	 studies	 with	 HEV	 have	 long	 been	 hampered	 due	 to	 the	 lack	 of	 efficient	 cell	culture	systems.	A	breakthrough	was	in	2007	when	Tanaka	and	co-workers	isolated	the	JE03-1760F	strain	of	genotype	3	from	a	fecal	specimen	of	a	Japanese	patient	with	acute	hepatitis	 E	 (109).	 The	 JE03-1760F	 strain	 was	 propagated	 efficiently	 in	 a	 human	hepatocellular	carcinoma	cell	line	(PLC/PRF/5)	and	a	lung	cancer	cell	line	(A549)	(109).	
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In	 2009,	 the	 same	 group	 isolated	 the	 HE-JF5/15F	 strain	 of	 genotype	 4	 from	 another	fecal	 specimen	of	a	patient	with	 fulminant	hepatitis	E.	This	 strain	was	as	well	 able	 to	efficiently	replicate	in	the	two	aforementioned	cell	lines	(110).	Another	strain	(Kernow	C1)	of	genotype	3	was	isolated	from	the	feces	of	a	chronically	infected	HEV	patient	by	Shukla	et	al.	and	was	shown	to	efficiently	replicate	in	HepG2/C3A	cells	(hepatoma	cell	line)	(111).	After	various	cell	culture	passaging	the	Kernow	C1	strain	acquired	next	to	point	 mutations	 a	 ribosomal	 protein	 that	 probably	 enhances	 the	 processing	 and	translation	 of	 the	 RNA	 (112).	 To	 further	 elucidate	 the	 aspects	 of	 HEV	 replication,	infectious	cDNA	clones	of	genotype	3	(JE03-1760F	and	Kernow	C1	strain)	and	genotype	1	(Sar55	strain)	were	constructed	(112-114).	Mutational	analysis	and	cloning	of	these	cDNA	 clones	 allowed	 gaining	 insight	 in	 the	 function	 of	 the	 different	 ORFs,	 the	processing	of	HEV	RNA	and	the	production	of	HEV	reporter	constructs	(112,	115).		Another	 limitation	 in	 the	 study	 of	 HEV	 replication,	 molecular	 biology	 and	pathogenesis	is	the	lack	of	a	small	animal	model.	Macaques	and	chimpanzees	are	animal	models	susceptible	to	all	HEV	genotypes,	while	pigs	are	a	reservoir	for	genotypes	3	and	4	 human	 HEV.	 The	 use	 of	 both	 animal	 models	 however	 pose	 ethical,	 financial	 and	practical	 concerns.	 In	 2016,	 two	 groups	 successfully	 infected	 a	 human	 hepatocyte	reconstituted	 immunodeficient	 transgenic	mouse	model	with	 HEV	 (116,	 117).	 In	 this	mouse	 model	 urokinase-type	 plasminogen	 activator	 (uPA)	 is	 under	 control	 of	 the	mouse	albumin	promoter.	The	overexpression	of	uPA	induces	liver	toxicity	upon	which	the	mouse	 liver	can	be	repopulated	by	transplantation	of	human	primary	hepatocytes	creating	 a	 humanized	 mouse	 liver.	 This	 mouse	 model	 was	 previously	 shown	 to	 be	permissive	 for	 hepatitis	 B	 and	 hepatitis	 C	 and	 more	 recently	 as	 well	 for	 hepatitis	 E	infection.	 The	 small	 animal	model	 could	 now	 be	 used	 for	 drug	 screening.	 The	major	drawback	is,	however,	the	lack	of	an	adaptive	immune	system,	which	makes	the	animal	model	 not	 useful	 for	 vaccine	 development	 and	 the	 study	 of	 the	 immune	 response	induced	by	the	viral	infection	(116,	118).							
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1.3.2	Hepatitis	B	virus		
1.3.2.1	Classification	and	virion	structure		The	hepatitis	B	virus	belongs	to	the	virus	family	of	the	Hepadnaviridae	and	is	classified	into	 several	 genotypes	 designed	 from	 A-J	 (119).	 The	 infectious	 ‘Dane’	 particle	 has	 a	diameter	of	42nm	and	comprises	 the	3.2kb	partially	double-stranded	 relaxed	 circular	DNA	(rcDNA)	within	an	inner	nucleocapsid	or	core	that	 is	surrounded	by	an	envelope	that	 contains	 the	 HBV	 surface	 proteins.	 HBV	 is	 a	 retrovirus	 containing	 a	 reverse-transcriptase	DNA	polymerase	that	is	linked	to	the	5’	end	of	the	minus	strand	DNA.	The	HBV	 DNA	 encodes	 four	 partially	 overlapping	 open	 reading	 frames	 that	 encode	 the	surface	 proteins,	 the	 viral	 DNA	polymerase,	 the	HBV	 (pre)-core	 and	 protein	 X	 (HBx).	The	surface	proteins	are	transcribed	from	the	same	ORF	by	using	three	different	start	codons.	 The	 precore	 protein	 is	 processed	 into	 the	 e	 antigen	 (HBeAg)	 that	 has	 no	function	in	the	viral	life	cycle	but	is	a	marker	for	the	viremia	in	patients	(120)	(Figure	6).	The	function	of	the	X	protein	remains	to	be	resolved	but	there	is	growing	evidence	that	 the	X	protein	 is	 implicated	 in	oncogenesis	 (121,	122)	 .	Besides	 the	Dane	particle,	two	other	types	of	particles	are	produced	during	HBV	replication,	which	are	filaments	and	 spheres.	 Both	 these	particles	 are	not	 infectious	 as	 they	do	not	 contain	 viral	DNA	(123,	124).					
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Figure	 6.	 HBV	 viral	 genome.	 The	HBV	 genome	 is	 a	 relaxed-circular	DNA	 that	 contains	
four	partially	overlapping	open	reading	frames.	ORF	core	(ORF-C)	encodes	the	capsid,	ORF	
S	encodes	the	surface	proteins,	ORF	P	encodes	the	viral	polymerase	and	ORF	X	encodes	the	
HBV	X	protein.	Figure	is	adapted	from	(125)	.		
1.3.2.2	HBV	replication	cycle		HBV	 infection	 is	 specific	 for	 humans,	 chimpanzees	 and	 treeshrew	and	 is	 restricted	 to	hepatocytes.	Both	the	small	and	large	envelope	proteins	are	essential	for	binding	to	the	host	 cells.	 A	 major	 breakthrough	 in	 the	 study	 of	 HBV	 was	 in	 2012	 when	 Yan	 et	 al.	demonstrated	the	binding	of	the	preS1-domain	of	the	large	envelope	protein	to	the	bile	acid	 transporter	NTCP.	NTCP	appeared	 to	be	an	essential	 receptor	 for	HBV	entry	and	overexpression	 of	 NTCP	 in	 non-susceptible	 cell	 lines	 such	 as	 HepG2	 rendered	 them	permissive	for	HBV	infection	(126).	Upon	entry,	the	capsid	is	released	in	the	cytoplasm	and	 the	 rcDNA	 translocates	 to	 the	 nucleus.	 The	 rcDNA	 is	 repaired	 by	 cellular	 DNA	enzymes	to	form	the	covalently	closed	circular	DNA	(cccDNA).	The	cccDNA	acts	as	the	template	for	transcription	and	is	a	stable	mini-chromosome	that	is	extremely	difficult	to	eradicate.	Additionally,	HBV	DNA	might	integrate	into	the	host	genomic	DNA,	which	is	believed	 to	 be	 related	 to	 the	 development	 of	 hepatocellular	 carcinoma	 (HCC).	 The	cccDNA	 is	 transcribed	 into	 four	 transcripts:	 the	pre-core	mRNA,	 the	pregenomic	RNA,	the	 envelope	 protein	 mRNA	 and	 the	 mRNA	 for	 the	 X	 protein.	 The	 pregenomic	 RNA	together	 with	 the	 viral	 polymerase	 are	 encapsidated	 within	 the	 core	 protein.	 The	
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polymerase	reverse	transcribes	the	pregonmic	RNA	into	the	rcDNA.	After	completion	of	the	HBV	rcDNA,	new	viral	particles	bud	into	the	endoplasmatic	reticulum	and	the	golgi	apparatus	upon	which	they	are	secreted	from	the	cell	(Figure	7)	(120).			
		
Figure	 7.	 HBV	 viral	 life	 cycle.	 Upon	 binding	 to	 NTCP,	 HBV	 enters	 the	 hepatocyte	 and	
releases	 the	 rcDNA	 into	 the	 cytoplasm.	 The	 rcDNA	 is	 translocated	 to	 the	 nucleus	 and	
repaired	 to	 form	 the	 cccDNA.	The	 cccDNA	 is	 transcribed	 into	 the	pregenomic	 viral	RNA	
and	other	 viral	 proteins	 to	 produce	new	 viral	 particles	 that	 are	 secreted	upon	budding.	Figure	adapted	from	(127).		
1.3.2.3	Epidemiology	and	pathogenesis		About	 one	 third	 of	 the	world	 population	 has	 been	 infected	with	 the	 hepatitis	 B	 virus	with	 over	more	 than	 350	million	 chronic	 carriers	 and	 approximately	 800.000	 deaths	
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yearly	due	to	liver	cirrhosis	and	hepatocellular	carcinoma	making	hepatitis	B	virus	still	a	global	health	care	burden	(128).	Transmission	of	HBV	occurs	via	contaminated	blood	or	semen.	In	high	endemic	regions	such	as	Asia,	Africa	and	Pacific	islands,	HBV	is	mainly	transmitted	 perinatally	 from	 mother	 to	 child,	 which	 often	 leads	 to	 chronic	 HBV	infection.	 In	 areas	 with	 intermediate	 endemicity	 (Asia,	 central	 and	 southern	 Europe,	Russia,	South	and	Central	America)	HBV	 is	 transmitted	both	horizontally	and	through	contact	with	 infected	blood	or	 semen	via	 sexual	 contact,	 drug	 abuse	or	 contaminated	needles.	 In	 low	 endemic	 areas	 (Northern	 America,	 western	 Europe,	 Australia,	 Japan)	sexual	transmission	is	the	main	route	of	infection.	Prevention	of	HBV	infection,	through	blood	 screening	 and	 a	 vaccination	 program	 tremendously	 decreased	 the	 incidence	 of	HBV	 infection	 and	 hepatocellular	 carcinoma	 but	 the	 prevalence	 of	 chronic	 HBV	infections	and	related	HCC	remains	a	global	health	concern	(129).			
1.3.2.4	Pathogenesis		HBV	 is	 not	 cytopathic	 and	 induces	 only	 a	weak	 innate	 immune	 response.	 Damage	 to	hepatocytes	is	therefore	mainly	mediated	through	the	activation	of	cytotoxic	T-cells	in	response	 to	 several	 viral	 antigens.	 Infections	 that	 are	 acquired	 during	 adulthood	 are	mostly	transient	and	90%	of	infected	adults	are	able	to	clear	the	virus	without	therapy.	In	contrast	 to	adults,	neonates	and	young	children	are	at	high	risk	 to	develop	chronic	infection	due	 to	a	weaker	adaptive	 immune	response	(120,	129).	Four	disease	phases	can	 be	 distinguished	 during	 chronic	 HBV	 infection.	 During	 the	 first	 immune	 tolerant	phase,	 HBeAg	 is	 present	 with	 high	 levels	 of	 serum	 HBV	 DNA	 and	 normal	 levels	 of	alanine	 aminotransferase	 (ALT).	 The	 immune	 tolerant	 phase	 can	 progress	 into	 the	immune	 clearance	 phase	 with	 increased	 ALT	 levels	 and	 decreased	 serum	 HBV	 DNA.	During	this	phase	HBeAg	seroconversion	occurs	in	10-20%	of	the	patients	and	leads	to	a	decrease	in	HBV	DNA	and	a	normalization	of	ALT	levels	in	the	inactive	phase.	Patients	in	the	inactive	phase	have	generally	a	good	prognosis.	20-30%	of	patients	in	the	inactive	phase	will	have	reactivation	of	HBV	infection	with	elevated	HBV	DNA	and	ALT	levels	in	the	 absence	 of	 HBeAg	 due	 to	mutations	 in	 the	 (pre)-core.	 These	 patients	 are	 usually	older	and	at	high	risk	of	liver	cirrhosis	and	cancer	(129,	130).			
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1.3.2.5	Host	response	and	factors	related	to	HBV		Hepatitis	B	is	a	non-cytopathic	virus	and	not	the	virus	itself	but	the	immune	response	is	the	cause	of	liver	damage.	Both	the	innate	and	adaptive	immune	response	are	important	for	 the	 disease	 progression	 during	 HBV	 infection.	 The	 role	 of	 the	 immune	 system	 is	mainly	studied	in	HBV	infected	chimpanzees	and	transgenic	mouse	models	that	express	HBV	 antigens	 and	 HBV	 viral	 genomes.	 Upon	 infection,	 CD4+	 helper	 T	 cells	 produce	antibodies	 against	 the	 viral	 surface	 proteins	 while	 CD8+	 cytotoxic	 T	 cells	 clear	 the	infected	 cells	 and	 produce	 IFNg	 and	 tumor	 necrosis	 factor	 alpha	 (TNFa)	 that	 will	eliminate	the	virus	without	killing	of	the	cell.	The	cytotoxic	T	cell	response	is	crucial	to	eradicate	the	virus	and	impaired	cytotoxic	T	cell	responses	lead	to	viral	persistence	and	chronic	 HBV	 infection	 (131,	 132).	 Initially,	 it	 was	 thought	 that	 the	 innate	 immune	response	was	negligible	as	studies	failed	to	detect	a	type	I	interferon	response	in	animal	models.	However,	this	seems	to	be	the	consequence	of	the	immune	evasion	strategies	of	the	virus	(131).	Both,	the	HBV	viral	polymerase	and	HBx	protein	are	known	to	interfere	with	 the	 interferon	response	and	abolish	 IFNb	production	 (133,	134).	Moreover,	HBV	replicated	 more	 efficiently	 in	 IFNa/b	 receptor	 knock-out	 mice	 compared	 to	 control	mice	and	in	humans	HBV	infection	can	be	treated	by	interferon	alpha	therapy	(135).		 Replication	of	HBV	is	tightly	controlled	by	several	cellular	host	factors.	The	HBV	viral	genome	contains	four	promotor	and	two	enhancer	regions	and	its	transcription	is	regulated	 by	 cellular	 transcription	 factors	 such	 as	 HNF4a,	 CCAAT/enhancer	 binding	protein	 (C/EBP)	 and	 forkhead	 box	 O1	 (FOXO1)	 (Figure	 6).	 Most	 of	 the	 transcription	factors	that	interact	with	the	HBV	genome	are	related	to	liver	metabolism.	Hence,	 it	 is	not	surprising	that	HBV	alters	the	glucose	and	lipid	metabolism	of	the	liver	(136).	For	instance,	 the	 HBx	 protein	 upregulates	 peroxisome	 proliferator	 associated	 receptor	gamma	(PPARg)	which	promotes	fatty	acid	accumulation	and	steatosis	and	in	turn	also	enhances	the	transcription	of	HBV	itself	(137).	Cellular	host	factors	are	also	important	for	 the	 formation	 of	 the	 cccDNA.	 In	 addition,	 cccDNA	 transcription	 is	 regulated	 by	epigenetic	 modifications	 and	 is	 suppressed	 by	 DNA	 hypermethylation.	 Both,	 the	formation	 and	 transcription	 of	 the	 cccDNA	 are	 potential	 drug	 targets	 that	 would	completely	eradicate	the	hepatitis	B	virus	and	clear	the	infection	(138).			
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1.3.2.6	Prevention	and	antiviral	treatment		Recombinant	HBsAg	vaccines	are	present	since	the	early	1980s	and	have	an	efficiency	of	about	95%	when	administered	to	infants	and	children.	Although	advised	by	the	WHO,	HBV	vaccination	is	not	yet	globally	integrated.	Other	preventive	measurements	can	be	taken	to	reduce	the	risk	of	HBV	infection	such	as	testing	of	blood	and	organ	donors,	use	of	 condoms,	 prevention	 of	 drug	 abuse	 and	 the	 use	 of	 sterile	 needles	 (139).	 The	treatment	of	chronic	hepatitis	B	depends	on	the	serum	HBV	DNA	levels,	the	ALT	levels,	liver	damage	and	other	 factors	such	as	 family	history	and	age.	Two	treatment	options	are	 available	 i.e.	 (pegylated-)	 interferon	 alpha	 treatment	 and	 nucleo(s)tide	 analogues	(e.g.	 lamivudine,	 adefovir,	 tenofovir,	 entecavir,	 telbivudine).	 In	 general,	 treatment	 is	recommended	when	HBV	DNA	and	ALT	levels	are	highly	elevated	and	in	patients	with	cirrhosis.	 Interferon	 alpha	 has	 antiviral	 as	 well	 as	 immunomodulatory	 effects	 while	nucleo(s)tide	analogues	 (NUCs)	 inhibit	 the	 reverse	 transcriptase	polymerase.	Because	treatment	does	not	eradicate	the	cccDNA	in	the	nucleus	reactivation	of	HBV	frequently	occurs	 after	 antiviral	 therapy.	 Pegylated	 interferon	 alpha	 has	 to	 be	 administrated	subcutaneously	 once	 a	week	 for	 48	weeks.	 Pegylated	 interferon	 alpha	 therapy	 shows	positive	results	with	a	high	rate	of	HBsAg	seroconversion	but	is	associated	with	severe	side-effects	 such	 as	 flu-like	 symptoms,	 fatigue	 and	 hair	 loss.	 Moreover,	 interferon	therapy	 is	 contraindicated	 in	 patients	 with	 cirrhosis	 or	 liver	 decompensation.		Treatment	 with	 NUCs	 is	 generally	 well	 tolerated	 and	 is	 administrated	 until	 HBeAg	seroconversion	 and/or	 HBsAg	 loss.	 For	 patients	 with	 cirrhosis	 life-long	 treatment	 is	recommended	 to	 prevent	 reactivation	 and	 flares	 of	 infection.	 The	major	 limitation	 of	NUCs	 is	 the	 problem	 of	 antiviral	 drug	 resistance,	 which	 is	 less	 with	 entecavir	 and	tenofovir	 (128-130).	 Currently,	 a	 HBV	 entry	 inhibitor,	 Myrcludex	 B	 is	 examined	 in	clinical	trials.	Myrcludex	B	is	a	synthetic	preS1	peptide	that	irreversibly	binds	to	NTCP	and	 inactivates	 the	HBV	receptor.	 In	addition,	 the	peptide	contains	viral	epitopes	 that	might	 induce	 the	 production	 of	 neutralizing	 antibodies.	 In	 a	 phase	 I	 clinical	 trial,	Myrcludex	B	was	well	tolerated	and	potential	clinical	efficacy	is	suggested	from	a	phase	II	clinical	trial	(140).					
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1.3.2.7	Culture	systems	and	animal	models		Many	 aspects	 of	 the	 HBV	 viral	 life	 cycle	 have	 been	 revealed	 in	 hepatoma	 cell	 lines.	However,	 infection	 of	 hepatoma	 cell	 lines	 was	 mostly	 inefficient	 or	 even	 impossible.	Initially,	HBV	DNA	genomes	and	plasmids	encoding	viral	proteins	were	transfected	or	transduced	 in	 hepatoma	 cell	 lines	 to	 examine	 the	 host	 immune	 response,	 viral	replication,	produce	HBV	inocula	and	to	identify	antiviral	drugs	(127,	141).	The	HepaRG	cell	 line,	obtained	 from	a	tumor	 from	an	HCV-infected	patient,	was	the	 first	hepatoma	cell	 line	 that	 supported	 the	 complete	 HBV	 replication	 cycle,	 including	 entry	 and	production	of	cccDNA.	HepaRG	cells	are	marked	by	bipotency	and	can	differentiate	 to	both	biliary	and	hepatocyte-like	cells	(142).	Entry	in	hepatoma	cell	lines	was	the	main	limiting	factor	for	infection	of	these	cell	 lines.	Since	the	discovery	of	NTCP	as	a	crucial	entry	 receptor,	 cell	 lines	were	made	 that	 stably	 overexpress	NTCP.	 The	HepG2-NTCP	cell	 line	was	shown	to	be	an	efficient	cell	culture	system	that	supported	the	complete	replication	cycle	of	HBV	(126).	This	model	will	further	facilitate	the	in	vitro	study	of	the	hepatitis	B	virus.	Although	hepatoma	cell	lines	are	an	indispensable	in	vitro	HBV	culture	model,	they	remain	transformed,	abnormal	cell	lines	with	deficits	in	host	responses.	The	gold	 standard	 for	 the	 study	 of	 hepatotropic	 viruses	 remains	 human	 primary	hepatocytes,	 which	 are	 readily	 infected.	 Alternatively,	 stem	 cell-derived	 hepatocytes	could	 be	 used	 and	partially	 overcome	 the	 limitations	 of	 primary	 hepatocytes	 scarcity	and	 inter-donor	 variability	 (127,	 141).	 Although	 the	 phenotype	 of	 stem	 cell-derided	hepatocytes	is	still	not	fully	mature,	they	are	susceptible	to	many	hepatotropic	viruses	such	as	HCV,	HBV	and	HEV	and	are	more	physiologically	relevant	to	study	host	factors	and	antiviral	drugs	compared	to	hepatoma	cell	lines	(143-145).		Hepatitis	B	has	a	narrow	host	tropism	and	only	infects	human	and	chimpanzees	which	 impeded	 the	 use	 of	 small	 animal	 models	 for	 in	 vivo	 studies.	 Initially,	 mouse	models	were	used	that	overexpressed	HBV	viral	proteins	or	the	full-length	HBV	genome	to	 screen	antivirals	and	 to	 study	 the	 immune	response	upon	HBV	 infection.	However,	these	mouse	models	have	some	major	limitations.	As	the	HBV	genome	is	integrated,	the	viral	HBV	DNA	cannot	be	completely	eradicated	and	certain	steps	of	the	viral	life	cycle	such	 as	 entry	 are	 lacking.	 Humanized	 mice	 models,	 such	 as	 the	 uPA/SCID	 mice	 are	another	 alternative.	 In	 humanized	mice	 the	 complete	 replication	 cycle	 of	HBV	 can	 be	examined	in	an	in	vivo	setting.	However,	these	mice	are	immunodeficient	which	limits	
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the	 use	 to	 study	 the	 host	 response	 upon	 infection	 (127,	 141).	 Several	 groups	 are	therefore	 trying	 to	 develop	mouse	models	with	 both	 a	 humanized	 liver	 and	 immune	system	by	transplanting	both	human	hepatocytes	and	human	hematopoietic	stem	cells	(146,	147).			
1.3.3	ZIKA	virus		
1.3.3.1	History	and	virology		Zika	virus	(ZIKV)	was	first	isolated	in	1947	in	a	rhesus	monkey	in	Uganda	(148).	Some	years	later,	the	virus	was	isolated	in	humans	and	the	first	outbreaks	of	Zika	virus	were	reported	 in	 regions	of	Africa.	Until	 the	1980s,	 Zika	 virus	 infection	was	believed	 to	be	limited	to	African	and	Asian	countries,	in	which	different	strains	of	the	Zika	virus	occur.	It	 was	 not	 until	 2007	 that	 the	 first	 outbreak	 outside	 of	 Africa/Asia	 was	 reported	 in	Micronesia,	 part	 of	 Oceania	 (149).	 In	 2013,	 there	 was	 another	 endemic	 in	 French	Polynesia,	which	affected	about	11%	of	 the	total	population	(150).	 Initially,	Zika	virus	was	mostly	asymptomatic	or	related	with	mild	symptoms	and	was	not	believed	to	cause	a	 major	 threat	 to	 the	 public	 health.	 However,	 in	 2015,	 the	 first	 cases	 of	 Zika	 virus	infection	in	Brazil	and	neighboring	countries	 in	Latin	America	were	reported	evolving	into	a	new	outbreak	outside	of	Africa	or	Asia,	with	an	estimated	1.5	million	cases	of	Zika	virus	 infection	 (Figure	 8).	 Zika	 virus	 infections	 in	 Latin	 America	 were	 thought	 to	 be	related	 to	 the	 Asian	 strain	 and	were	 associated	 with	 an	 increase	 in	 the	 incidence	 of	microcephaly	in	newborns	causing	severe	birth	defects	(151,	152).					
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Figure	8.	Global	distribution	map	of	the	Zika	virus.	Zika	virus	was	first	reported	in	Africa	
and	Asia	and	 later	 on	 spread	 to	 regions	 of	Oceania	and	 South	America.	 Figure	adapted	
from	(153)	The	Zika	virus	 is	an	arthropod	borne	virus	and	 is	 transmitted	by	Aedes	mosquitos.	 In	addition,	 there	 is	evidence	that	 the	virus	can	be	transmitted	 from	humans	to	humans,	perinataly,	by	sexual	contact	or	by	blood	 transfusion	(154,	155).	The	virus	belongs	 to	the	 family	of	 the	Flaviviridae	and	 is	related	to	the	yellow	fever	and	dengue	virus.	Zika	virus	 is	 an	 encapsulated	 positive	 single-stranded	 RNA	 virus	 with	 a	 genome	 of	approximately	11	kb.	The	viral	RNA	encodes	three	structural	and	seven	non-structural	proteins	and	is	thought	to	replicate	in	a	similar	way	as	other	flaviviruses	(152).			
1.3.3.2	Clinical	manifestations			Zika	 virus	 infection	 is	 often	 asymptomatic	 or	 causes	 flu-like	 symptoms	 such	 as	headache,	fever,	malaise	and	myalgia.	However,	during	the	French	Polynesian	and	Latin	American	outbreak,	 there	was	an	 increase	of	Guilllain-Barré	syndrome	cases.	Guillain-Barré	syndrome	is	an	immune-mediated	peripheral	neuropathy	that	can	be	triggered	by	bacterial	 or	 viral	 infections	 and	 leads	 to	 muscle	 weakness	 (151).	 During	 the	 Latin	American	 outbreak	 Zika	 infection	 was	 for	 the	 first	 time	 linked	 to	 congenital	abnormalities	 and	 microcephaly.	 Newborns	 with	 microcephaly	 have	 decreased	 brain	development	and	abnormally	small	heads.	 In	2015,	during	 the	Brazilian	outbreak,	 the	number	of	newborns	with	microcephaly	increased	20	times.	In	addition,	viral	RNA	has	been	detected	 in	 the	 amniotic	 fluid	 of	 infants	 born	with	microcephaly	 and	 congenital	defects	where	often	documented	when	pregnant	women	underwent	symptomatic	Zika	virus	infection	(151,	156,	157).	Currently,	there	are	no	treatment	options	nor	vaccines	
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available	 for	 Zika	 virus	 infection.	 Prevention	 of	 infection	 and	 control	 of	 the	 Aedes	mosquito	are	therefore	the	only	and	necessary	measurements,	especially	 for	pregnant	women	(151,	152).			
1.3.3.3	Culture	systems	and	in	vivo	models		Until	 the	 large	 endemic	 outbreak	 in	 Latin	 America,	 Zika	 virus	 was	 an	 understudied	pathogen	 due	 to	 the	 mostly	 benign	 nature	 of	 infection.	 However,	 the	 first	 viral	 Zika	strain	was	already	isolated	(MR	766)	in	1947	from	a	rhesus	monkey	in	Uganda	(148).		Later	on,	additional	strains	were	 isolated	from	patients	both	 from	the	African	and	the	Asian	 lineage.	 Vero	 cells	 (African	 green	 kidney	monkey	 cells)	 are	 commonly	 used	 to	propagate	flaviviruses	such	as	dengue	virus	and	were	also	proven	useful	for	Zika	viral	stock	 production.	 However,	 the	 major	 limitation	 is	 the	 interferon	 deficiency	 of	 Vero	cells	 (158).	 Successful	 infection	 of	 human	 keratinocytes	 and	 dendritic	 cells	 already	unraveled	some	of	the	tissue	specificity	of	the	Zika	virus	(159).	Recently,	several	studies	demonstrated	 that	 the	 Zika	 virus	 infects	 hiPSC-derived	 neural	 progenitor	 cells	 and	induces	cytopathogenic	effects	(160-163).		Small	 animal	 models	 have	 also	 provided	 additional	 evidence	 of	 Zika	 virus	replication	in	both	neuroprogenitors	and	neurons.	However,	only	mouse	models	with	a	deficit	 in	 interferon	immunity	were	susceptible	 for	Zika	 infection.	After	 infection,	high	viral	 load	was	detected	 in	many	 tissues,	 including	 the	brain,	blood,	 testes,	 spleen	and	liver.	Wild-type	mice	were	 however	 not	 susceptible	 for	 Zika	 infection	 hampering	 the	study	of	immune-mediated	pathogenesis	(164-166).	Li	et	al.,	further	demonstrated	that	Zika	 virus	 infected	more	 efficiently	 neuroprogenitor	 cells	 than	neurons	 in	 developing	mouse	 embryos,	 which	 supports	 the	 observation	 of	 microcephaly	 and	 neurological	abnormalities	in	human	newborns	(167).	Both	the	in	vitro	cell	culture	models	as	well	as	the	small	animal	models	should	aid	in	the	understanding	of	the	pathology	of	Zika	virus	infection	and	the	production	of	effective	drugs	and	vaccines.							
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The	study	of	the	biology	of	the	replication	of	hepatotropic	viruses	and	inhibition	thereof	is	 hampered	 by	 the	 lack	 of	 cell	 culture	 models	 that	 resemble	 the	 in	 vivo	 cellular	environment	 required	by	 these	viruses.	During	 the	 last	years,	many	groups,	 including	the	Verfaillie	lab,	developed	and	optimized	differentiation	protocols	for	the	production	of	hepatocyte-like	cells	(52,	54,	168,	169).	Despite	 the	major	progress	made,	 the	yield	and	purity,	as	well	as	the	functional	maturity	of	the	stem	cell-derived	hepatocytes	still	need	 to	be	 further	 increased.	The	main	aim	of	 this	 thesis	was	 to	 further	optimize	 the	differentiation	protocol	of	human	hESC/hiPSC,	to	create	a	human	cell	culture	model	that	is	capable	of	propagating	hepatotropic	viruses.		
(1)	Infection	of	stem	cell-derived	hepatocytes	with	the	HEV	The	 objective	 aimed	 to	 determine	 if	 hESC	 –	 and	 hiPSC-derived	 hepatocyte-like	 cells	could	support	the	in	vitro	infection	and	replication	of	the	hepatitis	E	virus.	We	aimed	to	demonstrate	the	susceptibility	of	hPSC	–	hepatocyte-like	cells	to	HEV	by	means	of	RT-qPCR,	 RNA	 fluorescence	 in-situ	 hybridization	 and	 to	 assess	 inhibition	 of	 viral	replication	and	to	test	if	 infected	cells	produced	infectious	virions,	using	a	re-infection	assay.			
	(2)	Determine	if	HEV	infection	is	hepatocyte-specific	As	 knowledge	 about	 HEV	 tissue	 tropism	 is	 limited,	 we	 aimed	 to	 examine	 if	 HEV	infection	and	replication	occurs	in	hepatocytes	only.	The	use	of	PSCs	allows	generation	of	 other	 cell	 types,	 aside	 from	 hepatocyte-like	 cells.	 We	 exploited	 this	 hPSC	characteristic,	 to	 determine	 if	HEV	also	 infects	 and	 replicates	 in	neuroprogenitor	 and	mesodermal	cells.			
(3)	Evaluate	the	effect	of	DMSO	on	hepatic	differentiation/maturation	DMSO	 has	 been	 reported	 to	 enhance	 the	 in	vitro	 differentiation	 of	 stem	 cell-derived	hepatocyte-like	cells	and	to	reduce	dedifferentiation	of	primary	human	hepatocytes.	We	assessed	 the	 effect	 of	 different	 concentrations	 of	 DMSO	 on	 definitive	 endoderm	formation	as	well	as	on	maturation	of	hepatocyte-like	cells	from	hESCs	and	hiPSCs,	and	
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aimed	 to	 determine	 the	 possible	 mechanism(s)	 underlying	 the	 effect	 of	 DMSO	 on	hepatocyte	differentiation	from	PSCs.			
(4)	Infection	of	the	stem	cell-derived	hepatocytes	with	the	HBV	We	hypothesized	that	DMSO	treated	hPSC-hepatocyte-like	cells	might	be	infected	by	the	hepatitis	B	virus	(HBV).	 In	an	 initial	proof	of	principle	experiment,	we	tested	 if	DMSO	treated	 hPSC-HLCs	 could	 be	 infected	with	 the	 HBV	 and	 used	 immunofluorescence	 to	demonstrate	whether	or	not	hPSC-HLCs	were	infected	with	HBV.			
(5)	Infection	of	stem	cell-derived	hepatocytes	with	the	ZIKV	Not	 much	 is	 known	 about	 the	 tissue	 tropism	 of	 Zika	 viral	 (ZIKV)	 replication.	 ZIKV	belongs	to	family	of	the	Flaviviridae,	and	other	members	of	this	virus	family	such	as	the	dengue	virus	and	yellow	 fever	virus	are	known	to	 infect	and	replicate	 in	hepatocytes.	Because	 of	 the	 analogy	 between	 these	 viruses,	 the	 objective	was	 to	 examine	 if	 hPSC-HLCs	 support	 ZIKV	 replication.	 We	 also	 compared	 infection	 of	 hPSC-HLCs	 and	hepatoma	 cells	 to	 determine	 if	 hepatocyte-like	 cells	 would	 be	 superior	 for	 assessing	ZIKV	infection	and	drug	sensitivity.		
	
	
		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
	
	
	
	
	
Chapter	III:	Stem	cell-derived	hepatocytes:	a	novel	model	for	
hepatitis	E	virus	replication	
	
This	chapter	has	been	published	in	the	following	paper:	
	
Helsen	N,	Debing	Y,	Paeshuyse	J,	Dallmeier	K,	Boon	R,	Coll	M,	et	al.	Stem	cell-derived	hepatocytes:	 A	 novel	 model	 for	 hepatitis	 E	 virus	 replication.	 Journal	 of	 hepatology.	2016;64(3):565-73.		
AUTHOR	CONTRIBUTIONS:	N.H.	and	Y.D.	equally	contributed	and	conceived	the	study,	generated	the	data	and	wrote	 the	paper.	 J.P.	contributed	to	 the	 infection	experiments.	K.D	was	involved	in	study	design	and	experimental	set-up.	R.B.,	M.C.,	P.S.B.	contributed	to	 the	 mesoderm	 differentiations.	 C.C.	 contributed	 to	 the	 differentiation	 of	 neural	progenitor	cells.	J.N.	and	C.M.V.	designed	the	study	and	wrote	the	paper.	All	the	authors	have	read	and	edited	the	manuscript.							
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3.1	Introduction	
	In	1978,	 a	novel	non-A,	non-B	hepatitis	 virus	was	discovered	which	was	 identified	 in	1983	as	the	hepatitis	E	virus	(HEV).	HEV	is	an	important	and	emerging	cause	of	acute	self-limiting	 hepatitis	 (170,	 171).	 However,	 fulminant	 cases	 of	 hepatitis	 may	 occur	particular	 in	 pregnant	 women	 with	 mortality	 rates	 up	 to	 20%-30%.	 In	immunocompromised	 solid-organ	 transplant	 recipients	 and	 HIV-infected	 patients	 the	virus	 may	 result	 in	 chronic	 hepatitis,	 which	 evolves,	 in	 some	 patients,	 rapidly	 to	cirrhosis,	graft	loss	and	death	(99,	172-176).	
In	 vitro	 HEV	 culture	 systems	 have	 only	 recently	 been	 established.	 Therefore,	relatively	little	information	is	available	on	the	biology	of	HEV	infection	and	replication,	for	 example	 the	mechanism	 by	which	 HEV	 enters	 the	 host	 cell	 remains	 elusive.	 It	 is	believed	 that	 following	 entry	 in	 the	 cell,	 HEV	 replicates	 in	 the	 cytoplasm	 through	 a	negative	strand	RNA	((-)ssRNA)	intermediate	synthesized	by	the	viral	RNA-dependent	RNA	polymerase	(RdRp)	(82).	Although	HEV	is	a	hepatotropic	virus,	 there	 is	evidence	that	it	may	also	replicate	in	extrahepatic	sites;	for	instance,	HEV	RNA	has	been	detected	in	cerebrospinal	fluid,	possibly	linking	HEV	infection	to	neurological	conditions	that	are	occasionally	observed	in	patients	with	(chronic)	HEV	infections	(100,	101).		In	recent	years,	HEV	strains	have	been	isolated	from	fecal	specimens	of	patients	with	 fulminant	 (JE03-1760F	 strain)	 and	 chronic	 hepatitis	 (Kernow-C1	 strain)	 that	replicated	efficiently	in	cell	culture	(111,	112,	115).	Cell	lines	that	are	used	to	study	the	molecular	 biology	 of	HEV	 are	 the	hepatoma	 cell	 lines	Huh7,	HepG2/C3A,	 PLC/PRF/5,	HepaRG	 and	 surprisingly	 the	 lung-derived	 A549	 adenocarcinoma	 cell	 line	 (111,	 112,	115,	177).	These	 transformed	cell	 lines	are	physiologically	 less	 relevant	 to	 study	HEV	replication	 than	 primary	 hepatocytes,	 the	 latter	 are	 however	 not	 readily	 available.	Hepatoma	 cell	 lines	 in	 general	 poorly	 express	 drug	metabolizing	 enzymes	 and	might	lack	certain	host	factors	that	are	important	to	study	infection	with	hepatotropic	viruses.	For	 instance,	hepatoma	cell	 lines	can	only	be	 infected	with	the	hepatitis	B	virus	when	they	overexpress	the	sodium	taurocholate	co-transporting	polypeptide	(126,	178-180).	Although	human	primary	hepatocytes	would	be	the	best	cell	source	to	study	HEV,	they	are	short	in	supply.			 	
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Human	 embryonic	 (hESC)-	 and	 induced	 pluripotent	 stem	 cell	 (hiPSC)-derived	hepatocytes	 are	 a	 valuable	 alternative	 to	 primary	 hepatocytes.	 Compared	 to	 primary	hepatocytes,	 hESC	 and	 hiPSC	 have	 numerous	 advantages,	 including	 their	 capacity	 to	self-renew	 long-term	 without	 loss	 of	 differentiation	 potential,	 their	 potential	 to	differentiate	to	any	given	cell	type	and	their	ability	to	generate	patient-specific	disease	models	 (181-184).	 Although	 stem	 cell-derived	 hepatocytes	 mimic	 fetal	 but	 not	 adult	hepatocytes	 (56),	 numerous	 studies	 have	 demonstrated	 the	 use	 of	 differentiated	hepatocytes	 to	 study	 drug-induced	 liver	 toxicity	 (25-28).	 Moreover,	 hiPSC-derived	hepatocytes	 make	 it	 possible	 to	 model	 liver	 diseases	 in	 vitro	 and	 to	 assess	 patient-specific	 drug	 responses	 (185-188).	 hESC-	 and	 hiPSC-derived	 hepatocyte-like	 cells	(hPSC-hepatocytes)	may	as	well	be	valuable	cell	culture	models	to	study	the	infection	of	hepatocytes	 with	 hepatotropic	 viruses	 and	 parasites	 (189).	 Others	 and	 we	demonstrated	earlier	that	hESC/hiPSC-	hepatocytes	can	be	infected	with	the	hepatitis	C	virus	 (143,	 190,	 191)	 and	 that	 such	 cultures	 offer	 a	 model	 to	 study	 virus-host	interactions	(192).	Furthermore,	PSC-hepatocytes	have	been	shown	to	be	susceptible	to	infection	with	the	hepatitis	B	virus	(145).		We	 here	 demonstrate	 that	 PSC-hepatocytes	 support	 the	 complete	 HEV	replication	cycle,	infection,	replication	and	generation	of	infectious	virions,	making	this	an	 attractive	 and	 relevant	 in	 vitro	 model	 system	 (in	 non-cancerous	 hepatocytes)	 to	study	 the	 biology	 of	 HEV	 replication	 that	 and	 to	 aid	 in	 the	 design	 of	 therapeutic	strategies	against	the	virus.	Because	PSC	can	not	only	differentiate	into	hepatocytes,	but	also	to	mesodermal	and	neuroprogenitors	(NPCs),	this	PSC	derived	model	also	allowed	to	demonstrate	that	non-endodermal	germ-line	progeny	do	not	allow	HEV	entry,	even	if	they	do	support	HEV	replication	upon	transfection	with	a	subgenomic	HEV	replicon.		
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3.2	Materials	and	methods		
3.2.1	Virus.	Wild-type	and	1634R	infectious	HEV	stocks	(Kernow-C1	p6,	genotype	3,	GenBank	 accession	 number	 JQ679013)	 (112)	 were	 derived	 from	 plasmid	 DNA	 as	described	(193,	194).		
3.2.2	Virus	inoculation.	Day	20	PSC-derived	hepatocyte	progeny	was	infected	with	300	µL	HEV	stock	diluted	to	3	x	107	viral	RNA	copies/mL	per	well	and	incubated	for	24h	at	37°C	 in	 a	5%	CO2	humidified	 incubator.	After	24h,	 the	 inoculum	was	 removed	and	cells	 were	 washed	 5	 times	 with	 500	 µL	 of	 DMEM,	 before	 addition	 of	 500	 µL	 of	hepatocyte	differentiation	medium.	Medium	was	changed	every	other	day	by	collecting	300	μL	and	replacing	it	with	350	μL	fresh	hepatocyte	differentiation	medium.	Infection	of	 mesodermal	 and	 neural	 progenitor	 cell	 differentiations	 was	 performed	 similarly.	Infection	 experiments	 were	 ended	 12	 days	 post	 infection.	 Supernatant	 was	 collected	every	other	day	during	medium	changes	while	cells	were	lysed	with	350	μL	RLT	buffer	(Qiagen,	Hilden)	4,	8,	10	and	12	days	post	infection.	An	identical	protocol	was	used	for	a	clinical	 plasma	 sample	 from	 an	 acutely	 HEV	 genotype	 3-infected	 patient	 (a	 kind	 gift	from	Heiner	Wedemeyer,	Hannover,	Germany).	The	plasma	sample	was	diluted	1:3	 in	hepatocyte	differentiation	medium	and	subsequently	used	for	inoculation.		
3.2.3	 Cell	 cultures.	The	 fibroblast	 cell	 line	BJ1	was	 previously	 reprogrammed	 to	hiPSC	by	lentiviral	transduction	of	OCT4,	c-MYC,	KLF4	and	SOX2	(39).	The	hESC	line	H9	(WA09)	was	purchased	from	WiCell	Research	Institute	(Madison,	WI).	Both	hiPSC	and	hESC	 were	 maintained	 on	 inactivated	 mouse	 embryonic	 fibroblasts	 (iMEF)	 in	 hESC	medium	 (DMEM/F12	 (Invitrogen,	 Carlsbad,	 CA)	 supplemented	 with	 20%	 KnockOut	Serum	Replacement	 (Invitrogen),	 1%	nonessential	 amino	 acids	 (Invitrogen),	 1	mM	L-glutamine	 (Sigma-Aldrich,	 St.	 Louis,	MO),	 0.1	mM	 β-mercaptoethanol	 (Sigma-Aldrich)	and	 4	 ng/mL	 bFGF	 (basic	 fibroblast	 growth	 factor)	 (Peprotech,	 Rocky	 Hill,	 NJ)	 in	 a	humidified	 5%	 CO2	 incubator	 at	 37°C.	 HepG2/C3A	 cells	 (a	 kind	 gift	 from	 Luc	Verschaeve,	 Scientific	 Institute	 of	 Public	Health,	 Brussels,	 Belgium)	 and	Huh7	 cells	 (a	kind	gift	from	Ralf	Bartenschlager,	University	of	Heidelberg,	Germany)	were	cultured	in	
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Dulbecco’s	 modified	 Eagle’s	 medium	 (DMEM)	 (Invitrogen)	 supplemented	 with	 10%	fetal	bovine	serum	(FBS)	(Invitrogen)	in	a	humidified	5%	CO2	incubator	at	37°C.	
	
3.2.4	Hepatocyte	 differentiation.	hESC	and	hiPSC	were	differentiated	 towards	hepatocytes	following	a	previously	described	protocol	with	minor	modifications	(169)	(Figure	9).	Briefly,	cells	were	detached	 from	iMEF	with	0.05%	trypsin	and	plated	at	±	8.75	x	104	cells/cm2	on	matrigel	(BD	Biosciences,	San	Jose,	CA)	coated	wells.	When	cells	reached	70-80%	confluency,	hepatocyte	differentiation	was	 induced	by	 the	sequential	addition	of	different	growth	factors	as	described	(169),	except	that	Activin-A	was	used	at	 50	 ng/mL	 instead	 of	 at	 100	 ng/mL.	 All	 growth	 factors	 were	 purchased	 from	Peprotech.			
	
Figure	9.	Hepatocyte	differentiation	protocol.		
3.2.5	 Mesoderm	 differentiation.	 To	 differentiate	 hESC	 towards	 mesodermal	cells,	 cells	were	 harvested	 from	 iMEF	with	 0.05%	 trypsin	 and	 plated	 at	 ±	 8.75	 x	 104	cells/cm2	 on	 matrigel-coated	 wells.	 Using	 a	 published	 protocol	 (195),	 with	modifications,	 cells	 were	 differentiated	 by	 the	 sequential	 addition	 of	 bone	morphogenetic	 protein	 4	 (BMP4)	 and	 fibroblast	 growth	 factor	 1	 (FGF1).	Mesodermal	cells	were	stained	with	1	μg/mL	PE	mouse	anti-human	platelet-derived	growth	 factor	receptor	 (PDGFRβ)	 antibody	 (BD	 Pharmingen,	 San	 Diego,	 CA)	 or	 1	 μg/mL	 PE	mouse	IgG2a,	 κ	 isotype,	 as	 control	 (BD	 Pharmingen).	 Mesoderm	 differentiated	 cells	 were	defined	as	being	more	than	95%	positive	for	PDGFRβ	by	flow	cytometry	analysis	using	a	FACS-Canto	(BD)	(195).				
3.2.6	Neuroprogenitor	differentiation.	hESC	(H9)	were	harvested	 from	 iMEF	and	 seeded	 at	 a	 density	 of	 5	 x	 105	 cells/cm2	on	 matrigel-coated	 plates	 in	 mTeSR1	
HGFAct-A
Wnt3a
BMP4 FGF1
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medium	(BD)	containing	10	μM	ROCK	inhibitor.	When	they	reached	100%	confluency,	medium	was	changed	to	neural	induction	medium	(NIM)	(Neural	Maintenance	Medium	(Neurobasal	medium,	B27	 supplement,	Glutamax,	N2	 supplement,	2-mercaptoethanol,	MEM	 NEAA,	 sodium	 pyruvate	 (all	 purchased	 from	 Life	 Technologies,	 Waltham,	 MA),	Pen/Strep	and	 Insulin	 (purchased	 from	Sigma-Aldrich)	 (NMM)	supplemented	with	10	μM	SB431542	(Sigma-Aldrich)	and	1	μM	dorsomorphin	(Tocris,	Bristol))	and	replaced	every	day	until	day	12	as	previously	described	(196).	From	day	12	onwards,	cells	were	passaged	with	dispase	and	replated	onto	poly-L-ornithine	and	laminin-coated	plates	in	NIM	 at	 a	 density	 of	 2	 x	 105	 cells/cm2.	 The	 day	 after,	 medium	was	 changed	 to	 NMM	supplemented	with	20	ng/mL	FGF2.	Neural	progenitor	cells	were	passaged	when	they	reached	confluency	and	were	cryopreserved	as	single	cells	between	day	30	and	35	of	differentiation.		
3.2.7	 RNA	 extraction	 and	 quantitative	 reverse-transcription	 PCR	
(qRT-PCR).	 For	 gene	 expression	 analysis,	 RNA	 was	 isolated	 from	 differentiated	progeny	 cells	 by	 the	 GenElute	 Mammalian	 Total	 RNA	 Miniprep	 Kit	 (Sigma-Aldrich)	following	 manufacturer’s	 procedures.	 Genomic	 DNA	 was	 eliminated	 using	 the	 On-Column	DNase	I	Digestion	kit	(Sigma-Aldrich).	The	Superscript	III	First-Strand	synthesis	system	 (Invitrogen)	 was	 used	 for	 subsequent	 cDNA	 synthesis.	 qPCR	 was	 performed	with	 the	 Platinum	 SYBR	 green	 qPCR	 supermix-UDG	 kit	 (Invitrogen)	 in	 a	 ViiA	 7	 Real-Time	 PCR	 instrument	 (Thermo	 Fisher	 Scientific,	 Waltham,	 MA).	 Glyceraldehyde-3-phosphate	 dehydrogenase	 (GAPDH)	 was	 used	 as	 the	 housekeeping	 gene	 for	normalization.	 Sequences	 of	 qRT-PCR	 primers	 are	 listed	 in	 Table	 2.	Viral	 RNA	 was	isolated	 from	 the	 supernatant	 using	 the	 NucleoSpin	 RNA	 virus	 kit	 (Macherey-Nagel,	Düren)	 according	 to	 the	manufacturer’s	 instructions.	 Intracellular	 RNA	 from	 infected	stem	cell	progeny	was	extracted	using	the	RNeasy	Mini	Kit	(Qiagen).	qRT-PCR	for	viral	RNA	was	performed	as	previously	described	(194).	Viral	RNA	detected	 in	 lysates	was	normalized	 to	 total	 RNA	 content	 as	 measured	 by	 spectroscopy	 (Nanodrop	 ND-1000,	Thermo	Fischer	Scientific).		
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Table	2.	Primer	list	used	for	RT-qPCR	experiments			
3.2.8	 Strand-specific	 PCR	 detection	 of	 HEV	 RNA.	 Specific	 amplification	 of	positive-	 and	 negative-sense	 HEV	 RNA	 was	 performed	 as	 described,	 with	 slight	modifications	to	primers	and	procedure	(197).	For	 first-strand	synthesis,	1	µL	of	RNA	extract	was	mixed	with	1	µL	of	10	µM	primer	solution	(ssHEVTagF1	for	negative-strand	assay,	ssHEVTagR1	for	positive-strand	assay)	and	diluted	with	H2O	to	a	final	volume	of	11.75	µL.	Samples	were	heated	at	65°C	for	5	min	and	incubated	on	ice.	To	each	sample,	1.25	µL	of	10	mM	dNTP	mixture,	4	µL	of	5x	first	strand	buffer	(Life	Technologies),	1	µL	of	0.1	M	DTT,	1	µL	of	RNasin	RNase-inhibitor	(equals	40	units,	Promega,	Madison,	WI)	and	 1	 µL	 of	 SuperScript	 III	 reverse	 transcriptase	 (Life	 Technologies)	 was	 added.	Reaction	was	incubated	at	55°C	for	1h	and	consequently	inactivated	at	70°C	for	15	min.	Next,	50	units	of	ExoI	(NEB,	 Ipswich)	were	added	and	reaction	was	 incubated	at	37°C	for	30	min.	DNA	was	purified	with	Qiagen	PCR	purification	kit	 by	 the	manufacturer’s	instructions	with	final	elution	in	30	µL	of	buffer	EB.	Five	µL	of	the	eluate	was	used	in	a	25	µL	PCR	reaction	with	GoTaq	HotStart	MasterMix	(Promega)	and	primer	pairs	Tag	–	ssHEVR1	 for	 negative-strand	 assay	 or	 ssHEVF1	 –	 Tag	 for	 positive-strand	 assay	 with	following	temperature	scheme:	2	min	at	95°C,	40	cycles	of	30s	at	95°C,	30s	at	55°C	and	1	 min	 at	 72°C,	 and	 finally	 5	 min	 at	 72°C.	 DNA	 was	 purified	 with	 the	 Qiagen	 PCR	purification	kit	and	1	µL	was	used	in	a	second	PCR	reaction	with	primer	pair	ssHEVF2	–	ssHEVR2	with	following	temperature	scheme:	2	min	at	95°C,	20	cycles	of	30s	at	95°C,	30s	 at	 55°C	 and	 30s	 at	 72°C,	 and	 finally	 5	 min	 at	 72°C.	 Amplified	 fragments	 were	separated	on	a	2%	agarose	gel	(expected	fragment	length:	415	bp).	For	validation,	RNA	
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extracts	 derived	 from	 culture	 medium	 and	 lysates	 of	 infected	 and	 uninfected	HepG2/C3A	 cells	 were	 used.	 Contrary	 to	 the	 findings	 of	 Chatterjee	 et	 al,	 we	 did	 not	observe	 the	 presence	 of	 negative-strand	 RNA	 in	 viral	 particles	 (i.e.	 in	 the	 culture	medium)	(197).		
3.2.9	 Immunofluorescence.	Cells	 were	 fixed	 with	 4%	 paraformaldehyde	 (PFA)	for	15	min.	at	room	temperature	(RT),	permeabilized	with	0.2%	Triton	X-100,	blocked	with	 5%	 normal	 donkey	 serum	 (Jackson	 Laboratory,	 Bar	 Harbor,	 ME)	 and	 stained	overnight	 at	 4°C	with	 primary	 antibodies	 and	 isotype	 controls	 (Table	 3).	 Afterwards,	cells	 were	 incubated	 with	 appropriate	 secondary	 antibodies	 together	 with	 Hoechst	(Sigma-Aldrich)	 for	 60	 minutes	 at	 RT	 (Images	 were	 taken	 by	 the	 AxioimagerZ.1	fluorescence	microscope.		
	
Table	3.	Antibody	list	used	for	immunofluorescence	staining.			
3.2.10	Albumin	 and	AAT	ELISA.	Enzyme-linked	 immunosorbent	assay	 (ELISA)	for	 albumin	 and	 AAT	 was	 performed	 according	 to	 the	 manufacturer’s	 procedure	(Bethyl,	Montgomery,	TX).	Briefly,	at	day	20	of	the	hepatocyte	differentiation	protocol,	supernatant	was	collected	and	incubated	with	a	primary	albumin	or	AAT	antibody	for	60	min.	at	RT.	Afterwards	an	HRP-detection	antibody	was	added	for	60	min.	followed	by	TMB-peroxidase	solution	for	15	min.	at	RT.	The	reaction	was	stopped	by	a	0.18M	H2SO4	solution	and	the	OD	was	measured	on	a	microplate	reader	at	a	wavelength	of	450	nm.	A	standard	curve	was	used	to	quantify	the	amount	of	albumin	and	AAT	secretion.			
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3.2.11	 Intracellular	 flow	 cytometry.	 For	 intracellular	 AAT	 flow	 cytometry	staining,	 a	 single	 cell	 suspension	 was	 made	 by	 liberase	 treatment	 (Roche,	 Basel,	Switzerland)	 followed	 by	 fixation	 with	 4%	 PFA	 for	 15	 min.	 at	 RT.	 Next,	 cells	 were	permeabilized	with	0.1%	saponin	and	blocked	with	10%	goat	 serum	(Dako,	Glostrup,	Denmark)	 for	45	min.	at	RT.	Afterwards	cells	were	stained	with	0.0625μg/200μL/106	cells	anti-AAT	antibody	(Dako)	or	a	rabbit	IgG	isotype	control	(BD	Pharmingen)	for	1h	at	RT.	After	1h,	a	secondary	Alexa	Fluor	647	antibody	(1:1500)	(Invitrogen)	was	used	for	30	min.	at	RT.	Cells	were	analyzed	by	 flow	cytometry	analysis	using	a	FACS-Canto	(BD).		
3.2.12	 Viral	 infection	 inhibition	 experiments.	 Ribavirin	 (ICN	Pharmaceuticals,	 Quebec)	 and	 interferon	 alpha	 2b	 (Intron-A®,	 Schering-Plough,	Kenilworth,	NJ)	were	used	to	inhibit	viral	replication.	Ribavirin	(100	µM)	and	interferon	(1000	 U/mL)	 were	 added	 to	 the	 differentiation	 medium	 starting	 at	 the	 time	 of	 the	inoculation	until	the	end	of	the	infection	experiment.		
3.2.4	Re-infection	assays.	HepG2/C3A	cells	were	seeded	into	6-well	plates	at	2	x	105	cells	per	well	and	incubated	for	24h	at	37°C.	Day	8,	10	and	day	12	culture	medium	samples	from	HEV-infected	stem	cell-derived	hepatocytes	(a	fixed	volume	of	400	µL	for	each	 sample)	 were	 diluted	 with	 500	 µL	 of	 DMEM	 supplemented	 with	 10%	 FBS	 and	inoculated	 on	HepG2/C3A	 cultures.	 Infection	was	 allowed	 to	 proceed	 for	 4h	 at	 35°C.	Afterwards,	 inoculum	was	removed,	cell	 layers	were	washed	three	times	with	2	mL	of	phosphate-buffered	 saline,	 2.5	 mL	 of	 DMEM	 with	 10%	 FBS	 and	 1%	 pen/strep	 was	added	 and	 cultures	were	 incubated	 at	 35°C	 for	 20	 days	with	 regular	 changing	 of	 the	medium	as	described	(37).	After	20	days,	cellular	lysates	were	prepared	as	described.		
3.2.5	QuantiGene	ViewRNA	fluorescence	 in-situ	hybridization	(FISH).	RNA	FISH	was	performed	using	the	QuantiGene	ViewRNA	protocol.	Briefly,	infected	or	uninfected	 stem	 cell-derived	 hepatocytes	 or	 HepG2/C3A	 cells	 were	 fixed	 with	 4%	formaldehyde	for	30	min	at	room	temperature.	After	fixation,	cells	were	permeabilized	with	 detergent	 solution	 for	 5	 min	 (Affymetrix,	 Santa	 Clara,	 CA)	 and	 treated	 with	proteinase	 K	 (Affymetrix)	 for	 10	 min.	 Cells	 were	 hybridized	 for	 3h	 at	 40°C	 with	 a	
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Quantigene	ViewRNA	designed	probe	covering	the	region	858-1791	of	ORF1	of	the	HEV	clone	Kernow-C1	p6	(Accession	number	HQ389543).	After	hybridization	the	signal	was	amplified	by	sequential	reaction	of	the	PreAmplifier	and	the	Amplifier	mix	(Affymetrix)	followed	by	conjugation	with	 the	 fluorescent	dye-conjugated	 label	probe	(Affymetrix).	Cells	 were	 counterstained	 with	 DAPI	 (Affymetrix).	 Images	 were	 taken	 by	 the	AxioImagerZ.1	fluorescence	microscope.			
3.2.6	 HEV	 replicon	 replication.	 Genotype	 3	 reporter	 replicon	 viral	 RNA	 was	derived	 from	 a	 plasmid	 encoding	 Kernow-C1	 p6/luc,	 (kind	 gift	 from	 Suzanne	 U.	Emerson)	 (13).	 Viral	 RNA	was	 in	vitro	 transcribed	 from	MluI-linearized	 plasmid	DNA	with	the	RiboMAX	Large	Scale	RNA	Production	System-T7	(Promega)	and	capped	with	the	 ScriptCap	m7G	 capping	 system	 (Cellscript,	Madison,	WI).	Huh7	 cells	were	 seeded	into	24-well	plates	at	4	x	104	cells	per	well,	mesoderm	cells	and	neuroprogenitors	were	seeded	at	a	density	of	2	x	105	cells	per	24	well.	Cells	were	transfected	with	capped	RNA	transcripts	 (200	 ng	 per	 well)	 24	 hours	 later	 using	 Lipofectin	 (Life	 Technologies)	according	to	the	manufacturer’s	instructions.	Transfected	cells	were	incubated	at	37°C	and	30	µL	of	cell	culture	medium	was	removed	from	each	well	and	stored	at	-80°C	every	day.	After	3	days,	media	were	thawed	and	Gaussia	 luciferase	activity	was	measured	in	20	 µL	 culture	 medium	 with	 the	 Renilla	 luciferase	 assay	 system	 (Promega).	 For	mesodermal	 cell	 differentiations,	 luminescence	 signal	 was	 normalized	 for	 the	approximate	number	of	seeded	cells	where	necessary.	
	
3.2.7	Statistics.	Data	values	represent	average	±	standard	error	of	the	mean	(SEM)	and	were	analyzed	by	the	two-tailed	Student’s	t	test.	p-values	<	0.05	(*),	p	<	0.01	(**),	p	<	0.001	(***)	and	p	<	0.0001	(****)	were	considered	statistically	significant.						
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3.3	Results	
	
3.3.1	 Stem	 cell-derived	 hepatocyte	 cultures	 support	 the	 full	 HEV	
replication	cycle	
	The	pluripotency	of	hESC	(H9)	and	hiPSC	(BJ1)	lines	was	first	confirmed	(Figure	10).		
	
Figure	 10.	 Characterization	 of	 pluripotent	 hESC	 and	 hiPSC.	 (A)	 hESC	 (H9)	 and	 hiPSC	
(BJ1-iPSC)	were	stained	 for	pluripotency	markers	NANOG,	SSEA4	and	OCT4	(Scale	bar	=	
100	μm).	Images	are	representative	of	three	independent	experiments.	(B)	Flow	cytometry	
analysis	for	TRA-1-60	demonstrated	that	both	hESC	and	hiPSC	lines	were	>80%	for	TRA-1-
60.	Results	represent	the	mean	of	three	independent	experiments	±	SEM	PSCs	were	differentiated	towards	hepatocyte-like	cells	(hPSC-hepatocytes)	during	a	20-day	 differentiation	 protocol.	 Immunofluorescence	 staining,	 flow	 cytometry	 and	 gene	
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expression	analysis	demonstrated	that	PSC-hepatocytes	were	positive	for	AFP,	HNF4α,	AAT	and	albumin,	and	secreted	albumin	and	AAT	(Figure	11).	
		
Figure	 11.	 Characterization	 of	 hPSC-derived	 hepatocytes.	 (A)	 Expression	 of	 hepatocyte	
markers	(AFP,	ALB	and	AAT)	 in	hESC	and	hiPSC	hepatic	progeny	cells.	Results	represent	
the	 mean	 of	 three	 independent	 experiments	 ±	 SEM.	 (B)	 Intracellular	 flow	 cytometry	
analysis	for	AAT	demonstrated	that	approximately	50%	of	the	hESC	and	hiPSC	hepatocyte	
progeny	 were	 positive	 for	 AAT.	 Results	 represent	 the	 mean	 of	 three	 independent	
experiments	±	SEM.	 (C)	 Immunofluorescence	staining	 for	AAT,	HNF4α,	albumin	and	AFP	
showed	abundant	expression	of	the	hepatocyte	proteins	in	both	hESC-	and	hiPSC-derived	
hepatocytes	 (Scale	 bar	 =	 100	 μm).	 Images	 are	 representative	 of	 three	 independent	
experiments.	(D)	ELISA	for	AAT	and	albumin	on	day	20	of	the	hepatocyte	differentiation	
protocol.	Both	hESC-	and	hiPSC-derived	secrete	comparable	amounts	of	AAT	and	albumin	
while	there	was	no	detectable	level	of	AAT	or	albumin	secretion	for	hESC	and	hiPSC	(data	
not	shown).	Results	represent	the	mean	of	four	independent	experiments	±	SEM.		PSC-hepatocytes	 were	 inoculated	 with	 Kernow-C1	 p6	 genotype	 3	 HEV	 that	 carries	 a	G1634R	mutation	in	the	C-terminal	region	of	the	HEV	polymerase.	We	recently	reported	that	 this	mutation	 increases	 the	replication	capacity	of	genotype	3	HEV	 in	vitro	(193).	HEV	 RNA	 was	 detected	 (by	 qRT-PCR)	 in	 the	 culture	 medium	 of	 infected	 hESC-
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hepatocytes	on	day	2	after	infection	and	increased	overtime	from	1.5	±	0.4	x	105	to	5.1	±	1	x	105	viral	RNA	copies	ml-1	on	day	12	after	infection	(Figure	12A).	It	should	be	noted	that	 the	 copy	 numbers	 were	 not	 corrected	 for	 culture	 medium	 replacement.	 Indeed,	every	 other	 day,	 half	 of	 the	 culture	medium	was	 replaced,	which	 accounts	 for	 a	 final	dilution	 factor	 of	 about	 40.	 Viral	RNA	was	 also	detected	 on	day	4,	 8,	 10	 and	12	 after	infection	 in	 lysates	 of	 the	 infected	 hESC-hepatocytes	 and	 the	 viral	 RNA	 copy	 number	remained	constant	during	this	time-span	(Figure	12A).	The	number	of	RNA	copies	in	the	supernatant	 of	 hiPSC-hepatocytes	 increased	 from	6	 ±	 2	 x	 104	 to	 2.9	 ±	 0.5	 x	 105	 RNA	copies	 ml-1	 between	 day	 2	 and	 12	 after	 infection,	 and	 remained	 stable	 at	 the	intracellular	level	(Figure	12A).	Although	the	differentiation	capacity	of	hESC	and	hiPSC	was	comparable	(Figure	11),	intracellular	HEV	RNA	copy	numbers	in	hiPSC-hepatocytes	were	 significantly	 lower	 (Figure	 12A).	 This	 might	 be	 explained	 by	 the	 presence	 of	 a	stronger	 innate	 immune	 response	 in	hiPSC-hepatocytes.	 Indeed,	we	detected	a	higher	level	of	transcripts	for	the	interferon	response	genes,	EIF2AK2,	MX1,	ISG15	and	IFNβ	in	hiPSC-hepatocytes	 compared	with	 hESC-hepatocytes	 (10	 days	 post	 infection)	 (Figure	12B).				
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Figure	 12.	 HEV	 infection	 of	 hESC-	 and	 hiPSC-derived	 hepatocyte	 cultures.	 (A)	 After	
inoculation	 of	 day	 20	 hESC	 (n=6),	 hiPSC	 (n=3)-hepatocytes	 and	HepG2/C3A	 cells	 (n=3),	
HEV	 RNA	 was	 detected	 in	 the	 culture	 supernatant	 on	 the	 indicated	 time	 points	 and	
quantified	by	qRT-PCR.	HEV	RNA	was	quantified	 in	 intracellular	 lysates	4,	 8,	 10	and	12	
days	after	 infection.	Results	were	expressed	as	the	mean	of	six	(hESC),	three	(hiPSC)	and	
three	 (hepG2/C3A)	 independent	 experiments	 ±	 SEM.	 (B)	 qRT-PCR	 results	 10	 days	 after	
infection	for	innate	immune	response	genes	demonstrated	higher	expression	of	interferon	
response	genes	in	hiPSC-hepatocytes	compared	to	hESC-hepatocytes.	Results	represent	the	
mean	of	three	independent	experiments	±	SEM	relative	to	uninfected	control	cells	(UIC).	As	 control,	 hPSC-hepatocytes	 were	 inoculated	 with	 a	 UV-inactivated	 virus	 stock.	 No	HEV	RNA	copies	were	detected	intracellularly	or	in	the	culture	medium	of	the	infected	hPSC-hepatocytes	 (data	 not	 shown).	 The	 characteristics	 of	 the	 infection	 of	 hPSC-hepatocytes	by	HEV	was	directly	compared	with	that	of	 the	established	HEV	model	 in	HepG2/C3A	cells	 (112).	HepG2/C3A	cells	were	 infected	under	 the	same	conditions	as	hPSC-hepatocytes	 (Figure	 12A).	 At	 the	 intracellular	 level	 there	 was	 only	 a	 slight	difference	between	the	viral	RNA	levels	detected	in	infected	hPSC-derived	hepatocytes	and	 the	 infected	HepG2/C3A	cells.	Between	day	2	and	day	6	post	 infection,	HEV	RNA	
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copy	numbers	in	supernatants	of	HepG2/C3A	cells	were	comparable	with	those	in	PSC-hepatocyte	supernatants.	However,	the	number	of	RNA	copies	continued	to	increase	in	supernatants	of	infected	HepG2/C3A	cells	whereas	levels	reached	a	plateau	in	infected	hPSC-hepatocytes	 from	 day	 4-6	 onwards.	 This	 might	 be	 explained	 by	 the	 continued	proliferation	 of	 HepG2/C3A	 cells	 during	 the	 infection	 process	 whereas	 hPSC-hepatocytes	 are	 mostly	 non-dividing.	 Alternatively,	 the	 fact	 that	 the	 Kernow-C1	 p6	strain	 has	 been	 adapted	 to	 the	 specific	 environment	 of	 HepG2/C3A	 cells	 through	 6	consecutive	passages	might	explain	this	difference	(112).		Finally,	 we	 inoculated	 hPSC-hepatocytes	 with	 serum	 from	 an	 acutely	 infected	genotype	3	HEV	patient.	However,	no	robust	HEV	replication	was	observed,	which	is	not	unexpected,	 since	 in	 vitro	 culturing	 of	 clinical	 isolates	 of	 HEV	 has	 proven	 to	 be	extremely	difficult,	even	in	primary	hepatocytes	(198,	199).		
3.3.2	Both	(+)ss	and	(-)ss	HEV	RNA	is	detected	in	the	infected	hepatic		
progeny		Next	RNA	in-situ	hybridization	was	used	to	localize	(+)ss	viral	RNA	in	hPSC-hepatocytes.	This	technique	specifically	detects	the	presence	of	HEV	RNA	by	hybridization	of	an	RNA	probe	to	the	positive-sense	viral	RNA.	Small	clusters	of	positive	cells	were	detected	10	days	post	infection	in	infected	hPSC-hepatocytes,	but	not	in	mock-infected	control	cells	or	infected	cultures	that	had	been	stained	without	the	HEV	probe	(Figure	13A).	Because	 HEV	 replicates,	 akin	 to	 other	 (+)ssRNA	 viruses,	 through	 a	 (-)ssRNA	intermediate,	 presence	 of	 negative-strand	 RNA	 is	 the	 ultimate	 proof	 of	 active	 viral	replication	(47).	To	this	end,	we	used	a	strand-specific	RT-PCR	protocol.	No	(+)ssRNA	or	(-)ssRNA	 was	 detected	 in	 non-infected	 lysates	 and	 culture	 medium	 collected	 from	mock-infected	 cells	 (Figure	 13B).	 (+)ssRNA	 was	 detected	 in	 the	 lysates	 and	 the	supernatant	of	HEV-infected	hESC-	and	hiPSC-hepatocytes	whereas			(-)ssRNA	was	only	detected	 in	 the	 lysates,	 but	 not	 in	 the	 supernatant	 of	 infected	 hESC-	 and	 hiPSC-hepatocytes.	This	confirms	that	the	hPSC-hepatocytes	support	HEV	replication	(Figure	13B.)		
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Figure	13.	Detection	of	both	(+)ss	and	(-)ss	HEV	RNA	in	hepatocyte	progeny.	(A)	Ten	days	
after	 infecting	ESC-derived	hepatocytes,	 cells	were	 fixed	and	stained	 for	HEV	RNA	by	 in-
situ	RNA	hybridization.	Mock-infected	and	infected	cells	stained	without	HEV	RNA	probe	
were	 used	 as	 negative	 controls.	 Images	 are	 representative	 of	 three	 independent	
experiments	(Scale	bar	=	50	μm).	(B)	Strand-specific	RT-PCR	demonstrated	that	negative-
strand	HEV	RNA	was	 detected	 in	 the	 intracellular	 lysates	 of	 ESC-	 and	 iPSC-hepatocytes	
while	positive-sense	RNA	was	detected	 in	all	 inoculated	cultures	 in	both	culture	medium	
samples	and	lysates.	Images	are	representative	of	three	independent	experiments.	Ex,	RNA	
extracted	 from	culture	medium	samples;	 In,	RNA	extracted	 from	lysates;	L,	100	basepair	
DNA	ladder	(Promega).		
3.3.3	Inhibition	of	HEV	replication		To	further	corroborate	the	observation	that	HEV	replicates	in	hPSC-derived	hepatocyte	progeny,	 the	 effect	 of	 the	 replication	 inhibitors	 ribavirin	 (RBV)	 and	 interferon	 alpha	(IFN)	was	studied	(194).	Treatment	of	HEV-infected	hepatocyte	progeny	with	100	μM	ribavirin	 or	 1000	 U/mL	 IFN	 markedly	 and	 significantly	 reduced	 HEV	 RNA	 copies	number	 both	 intra-	 and	 extracellularly	 in	 infected	 hESC-	 (Figure	 14A)	 and	 hiPSC-hepatocytes	(Figure	14B).	The	observed	lag	time	in	the	antiviral	effects	of	IFN	and	RBV	in	 hPSC-hepatocytes	 at	 day	 4	 post	 infection	 could	be	 due	 to	 the	 detection	 of	 residual	viral	RNA	remaining	from	the	inoculum	that	has	attached	to	the	cell,	but	has	not	been	
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internalized.	By	day	8	post	infection,	these	remnants	are	probably	degraded	or	released,	explaining	the	strong	antiviral	effect	observed	at	this	point.		
	
Figure	 14.	 Inhibition	 of	 HEV	 replication.	 (A)	 HEV	 replication	 was	 inhibited	 hESC-
hepatocytes	cells	by	100	μM	ribavirin	(RBV)	and	1000	U/mL	interferon	alpha	(IFN)	added	
from	 the	 inoculation	 until	 the	 end	 of	 the	 infection	 experiment.	 (B)	 Similarly,	 infected	 h	
hiPSC-hepatocytes	 treated	 with	 100	 μM	 RBV	 and	 1000	 U/mL	 IFN	 displayed	 strongly	
inhibited	 HEV	 replication	 as	 analyzed	 by	 qRT-PCR.	 The	 percentage	 HEV	 replication	
represents	the	number	of	RNA	copies	in	the	treated	condition	relative	to	the	number	in	the	
untreated	condition.	Results	represent	the	mean	of	three	independent	experiments	±	SEM.		
3.3.4	Comparison	of	the	replication	efficiency	of	wild-type	and	1634R	
mutant	HEV	in	hESC-derived	hepatocyte	progeny		We	 recently	 demonstrated	 that	 a	 G1634R	mutation	 in	 the	HEV	 polymerase	 enhances	the	 in	 vitro	 HEV	 replication	 in	 HepG2/C3A	 and	 Huh7	 cells	 (193).	 Because	 of	 this	replication	advantage,	 initial	studies	were	performed	with	HEV	genotype	3	containing	
4 6 8 10 12
0
20
40
60
80
100
Days post infection
%
 H
E
V
 R
N
A
 re
pl
ica
tio
n 
*** *** ******** ****
**
**** **** ********
4 8 10 12
0
20
40
60
80
100
Days post infection
%
 H
E
V
 R
N
A
 re
pl
ica
tio
n 
RBV (100 µM)
IFN (1000 U/ml)
**
**
*
** ** **
4 8 10 12
0
50
100
150
Days post infection
%
 H
E
V
 R
N
A
 re
pl
ica
tio
n 
RBV (100 µM)
IFN (1000 U/ml)
*
* ****
*
***
4 6 8 10 12
0
20
40
60
80
100
Days post infection
%
 H
E
V
 R
N
A
 re
pl
ica
tio
n 
** **
** ***
******** ******* ********
Culture medium Intracellular
A
B
hESC hepatocyte progeny
hiPSC hepatocyte progeny
Culture medium Intracellular
Chapter	III																																																																																																																												Results:	HEV	
	 47	
the	 1634R	mutation.	 In	 line	 with	 these	 results,	 the	 HEV	 RNA	 copy	 number	 in	 hPSC-hepatocytes	 or	 supernatant	 following	 infection	 with	 wild-type	 HEV	 was	 consistently	lower	than	in	cultures	infected	with	mutant	HEV,	although	this	did	not	reach	statistical	significance	(Figure	15).	
		
Figure	15.	Wild-type	versus	mutant	HEV	replication.	Hepatocyte	differentiated	cells	were	
infected	with	either	wild-type	(G1634)	or	mutant	(1634R)	HEV.	Mutant	HEV	has	a	slight	
replication	advantage	compared	to	wild-type	as	quantified	by	qRT-PCR.	Results	represent	
the	mean	of	three	independent	experiments	±	SEM.	
3.3.5	 hESC-derived	 hepatocyte	 progeny	 infected	with	 1634R	mutant	
HEV	produces	infectious	virus	capable	of	re-infecting	hepatoma	cells	
	Detection	 of	 infectious	 virus	 in	 culture	 supernatant	 of	 infected	 hPSC-hepatocytes	provides	evidence	that	these	cells	support	the	full	replication	cycle	of	HEV.	Additional	confirmation	 was	 obtained	 by	 assessing	 whether	 HEV	 infected	 PSC-hepatocyte	supernatant	contained	infectious	virions.	When	day	8,	10	or	12	culture	medium	of	wild-type	 HEV-infected	 hESC-hepatocytes	 (3	 independent	 experiments)	 was	 used	 for	reinfection	of	HepG2/C3A,	in	only	one	of	the	9	samples	detectable	levels	of	intracellular	HEV	RNA	were	measured.	By	 contrast,	 culture	 supernatant	 collected	 from	medium	of	hESC-hepatocytes	that	had	been	infected	with	mutant	R1634	HEV,	resulted	in	infection	in	4	of	9	HepG2/C3A	cultures	(data	not	shown).	The	moderate	number	of	successful	re-infections	 may	 be	 explained	 by	 the	 rather	 low	 viral	 titer	 in	 the	 culture	 medium	combined	 with	 the	 relatively	 low	 efficiency	 of	 infection	 of	 HepG2/C3A	 cells.	Nevertheless,	the	infectivity	of	the	culture	medium	collected	from	mutant	1634R	HEV-
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infected	 hESC-hepatocytes	 provides	 further	 evidence	 that	 these	 cells	 support	 the	complete	HEV	replication	cycle,	including	the	production	of	infectious	viral	particles.	
	
3.3.6	 hPSC-derived	 mesoderm	 and	 neuroprogenitor	 cells	 do	 not	
support	complete	HEV	replication		To	 assess	 whether	 HEV	 infection	 and	 replication	 occurs	 specifically	 in	 hPSC-derived	hepatocytes	 and	 not	 in	 other	 cell	 types,	 hESC-derived	 mesodermal	 cells	 (hESC-mesoderm)	 and	 differentiating	 NPCs	 (hESC-NPCs)	 were	 generated.	 Flow	 cytometry	analysis	 of	 the	 hESC-mesoderm	demonstrated	 that	 >95%	of	 cells	 stained	 positive	 for	PDGFRβ,	 a	marker	expressed	by	mesenchymal	 cells	 (Figure	16A).	qRT-PCR	analysis	 a	10-100	 fold	 increase	 in	 levels	of	mesoderm	specific	 transcripts	 (alpha	smooth	muscle	actin	(αSMA),	leech	homeobox	1	(LOX1)	and	collagen	type	1	alpha	1	(COL1A1)	(Figure	16B).	 Immunofluorescence	 staining	 confirmed	 the	presence	of	 αSMA	while	 there	was	no	 detectable	 expression	 of	 AAT,	 HNF4α,	 albumin	 or	 AFP	 (Figure	 16C).	 qRT-PCR	analysis	of	the	hESC-NPCs	demonstrated	a	10-1000	fold	increase	in	transcripts	for	NPC-specific	 transcripts	 (distal-less	 homeobox	 2	 (DLX2),	 PAX6	 (paired	 box	 6)	 and	 brain	lipid-binding	protein	(BLBP))	(Figure	16D).	In	addition,	hESC-NPCs	stained	positive	for	nestin	and	PAX6	but	negative	for	AAT,	HNF4α,	albumin	or	AFP	(Figure	16E).	
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Figure	 16.	Characterization	of	mesoderm	and	neuroprogenitor	cels.	 (A)	Mesoderm	cells	
were	 >90%	 positive	 for	 PDGFRβ	 as	 analyzed	 by	 flow	 cytometry.	 Results	 represent	 the	
mean	 of	 three	 independent	 experiments	 ±	 SEM.	 (B)	 The	 expression	 of	 mesoderm	 genes	
(LOX1,	COL1A1,	αSMA)	was	determined	by	RT-qPCR.	Results	represent	the	mean	of	three	
independent	 experiments	 ±	 SEM.	 (C)	 The	 expression	 of	 αSMA	was	 further	 confirmed	 by	
immunofluorescence	 staining	 while	 mesoderm	 cells	 stained	 negative	 for	 hepatocyte	
markers	(AAT/HNF4α,	ALBUMIN,	AFP)	(Scale	bar	=	100	μm).	Images	are	representative	of	
three	independent	experiments.	(D)	The	expression	of	neuroprogenitor	genes	(DLX2,	PAX6,	
BLBP)	 was	 determined	 by	 RT-qPCR.	 Results	 represent	 the	 mean	 of	 three	 independent	
experiments	 ±	 SEM.	 (E)	 Neuroprogenitors	 stained	 positive	 for	 NESTIN	 and	 PAX6	 but	
negative	for	AAT/HNF4α,	ALBUMIN,	AFP	(Scale	bar	=	100	μm).	Images	are	representative	
of	three	independent	experiments.	hESC-mesoderm	and	-NPCs	were	infected	under	the	same	conditions	that	were	used	to	infect	hPSC-hepatocytes.	On	day	2	post	 infection,	viral	HEV	RNA	was	detectable	 in	the	culture	 supernatant	 of	 hESC-mesoderm	 and	 -NPCs,	 however	 from	day	 4	 onwards	 the	number	of	RNA	copies	in	both	cultures	decreased	significantly,	which	was	in	contrast	to	the	 situation	 in	 culture	medium	of	hESC-hepatocytes	 (Figure	17).	 Similarly,	HEV	RNA	
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copy	 numbers	 in	 cell	 extracts	 of	 hESC-mesoderm	 and	 -NPCs	 decreased	 progressively	(Figure	17).		
	
Figure	 17.	HEV	 specifically	 infects	 stem	cell-derived	hepatocytes.	 (A&B)	Viral	HEV	RNA	
was	detected	in	the	culture	medium	and	intracellular	lysates	hPSC-mesoderm	and	NPCs	on	
the	 indicated	 time	 points	 by	 qRT-PCR.	 Results	 were	 expressed	 as	 the	 mean	 of	 two	
(mesoderm)	and	three	(NPC)	independent	experiments	±	SEM.	Also	shown	(line	above	the	
bar	graphs),	is	the	level	of	HEV	RNA	copies	in	the	supernatant	of	hPSC-hepatocytes	and	in	
the	cellular	lysate	of	hPSC-hepatocytes,	as	reference.			Neither	RBV	nor	IFN	had	a	significant	effect	on	the	viral	RNA	levels,	suggesting	that	the	viral	RNA	detected	was	not	 the	 result	 of	HEV	 replication	but	 rather	 a	 remnant	of	 the	inoculum	(Figure	18A).	Moreover,	no	negative	strand	RNA	was	detected	in	the	lysates	of	infected	hESC-mesoderm	and	-NPCs,	confirming	that	these	non-endodermal	lineages	do	not	support	replication	of	the	HEV	(Figure	18B).	
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Figure	 18.	 Mesoderm	 and	 neuroprogenitors	 cells	 do	 not	 support	 HEV	 replication.	 (A)	
Neither	ribavirin	(RBV)	nor	interferon	alpha	(IFN)	had	an	effect	on	the	detected	viral	HEV	
viral	 RNA	 levels	 in	 hPSC-mesoderm	 and	 NPCs.	 Results	 represent	 the	 mean	 of	 three	
independent	experiments	±	SEM.	(B)	No	negative	strand	RNA	was	detected	in	the	lysates	of	
hPSC-mesoderm	and	NPCs.	Positive	 strand	RNA	was	however	detected	 in	 lysates	of	both	
cell	types.	Images	are	representative	of	three	independent	experiments.	Ex,	RNA	extracted	
from	culture	medium	samples;	In,	RNA	extracted	from	lysates;	L,	100	basepair	DNA	ladder	
(Promega).	
3.3.7	The	entry	of	HEV	is	restricted	to	hPSC-derived	hepatocytes	
	To	examine	whether	the	apparent	failure	to	infect	hESC-mesoderm	and	-NPCs	with	HEV	occurs	at	 the	 level	of	RNA	replication	or	 rather	at	 an	early	 step	of	 the	viral	 life	 cycle,	both	 cell	 populations	 were	 transfected	 with	 the	 genotype	 3	 subgenomic	 p6/luc	 HEV	replicon	to	examine	whether	these	non-endodermal	progeny	cells	support	intracellular	HEV	replication.	 Interestingly,	we	demonstrated	 that	both	hESC-mesoderm	and	 -NPCs	do	support	replication	of	the	HEV	replicon,	which	for	the	hESC-NPCs,	approached	levels	also	 observed	 in	 the	Huh7	 hepatoma	 control	 cell	 line	 (Figure	 19).	 Furthermore,	 HEV	
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replicon	 replication	was	 in	 all	 three	 cell	 lines	 efficiently	 inhibited	 by	 RBV	 treatment.	This	 provides	 compelling	 evidence	 that	 the	 inability	 of	 HEV	 to	 enter	 into	 hESC-mesoderm	 and	 -NPCs	 is	 the	 main	 reason	 why	 these	 cells	 are	 not	 supporting	 the	complete	replication	cycle	of	the	HEV.	
	
Figure	 19.	 Mesoderm	 and	 neuroprogenitors	 cells	 do	 support	 HEV	 replication	 upon	
transfection.	 Huh7	 hepatoma,	 hPSC-mesoderm	 and	 NPCs	 were	 transfected	 with	 capped	
HEV	 p6/luc	 replicon	 RNA	 and	 Gaussia	 luciferase	 activity	 was	 measured	 in	 the	 culture	
medium	at	1,	2	or	3	days	post	transfection	in	the	presence	or	absence	of	ribavirin	(RBV).	
Solid	 intracellular	 replication	 can	 be	 observed	 in	 all	 3	 cell	 types.	 Results	 represent	 the	
mean	 of	 three	 independent	 experiments	 ±	 SEM.	 VC,	 virus	 control;	 RBV,	 ribavirin;	 RLU,	
relative	light	units.	
	
3.4	Discussion	
	Hepatitis	 E	 is	 an	 emerging	 disease	 in	 developing	 and	 industrialized	 countries,	 that	typically	 results	 in	 acute	 self-limiting	 hepatitis,	 but	 severe	 cases	 of	 both	 chronic	 and	acute	 hepatitis	 have	 been	 reported	 (200).	 We	 here	 demonstrate	 that	 differentiated	hepatocyte	 progeny	 from	 pluripotent	 stem	 cells	 support	 the	 complete	 replication	 of	
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HEV	and	thus	forms	a	physiologically	relevant	model	system	to	study	the	biology	of	HEV	replication	and	strategies	to	 inhibit	viral	replication.	Moreover,	 the	pluripotent	nature	of	 these	stem	cells,	allowed	us	to	generate	mesodermal	and	ectodermal	cell	 types.	We	demonstrate	 that	 these	 cannot	 be	 infected	 although	 they	 support	 intracellular	replication	 of	 the	 virus.	 This	 cell	 cultures	model(s)	 thus	 provide	 an	 elegant	model	 to	study	the	mechanism	underlying	the	hepatotropism	of	HEV.		Interest	in	HEV	research	is	growing	due	to	the	increasing	medical	importance	of	HEV	 infections,	 yet	 currently	 available	 cell	 culture	 models	 rely	 mostly	 on	 the	 use	 of	hepatoma	 cells.	 	 These	 are	 however	 transformed	 cell	 lines	 that	 may	 not	 completely	recapitulate	the	biology	of	HEV	replication	in	the	infected	hepatocyte.	Therefore,	other	cell	sources	are	being	explored	for	their	ability	to	support	HEV	infection	and	replication.	In	2012,	a	porcine	ESC	line	was	differentiated	into	hepatocytes	and	successfully	infected	with	swine	fecal	samples	containing	HEV	of	genotype	3	(177).	Viral	HEV	RNA	was	 detected	 until	 35	 days	 after	 infection	 in	 the	 supernatant	 and	 started	 to	 increase	from	day	8	onwards.	Similarly	 to	our	 findings,	 intracellular	viral	RNA	 levels	remained	constant	 in	 the	swine	ESC-derived	hepatocytes,	but	were	 lower	compared	to	what	we	observed	 in	 hPSC-hepatocytes.	 Negative	 strand	 RNA	 was	 also	 detected	 in	 porcine-derived	hepatocytes,	but	because	the	low	viral	titer	in	the	culture	medium,	reinfection	experiments	 failed.	 By	 contrast,	 we	 detected	 in	 the	 supernatant	 of	 almost	 half	 of	infected	hESC-hepatocytes	 infectious	viral	progeny	capable	of	re-infecting	HepG2/C3A	cells.	Thus	human	PSC-hepatocytes	 support	 the	 entire	HEV	 replication	 cycle	 and	 thus	allow	 the	 study	 of	 the	 complete	 biology	 of	 HEV	 infection	 and	 replication	 in	 a	physiologically	relevant	context.		The	 number	 of	 HEV	 RNA	 copies	 in	 the	 culture	medium	was	 lower	 in	 primary	HEV	 infected	hPSC-hepatocytes	 compared	 to	HepG2/C3A	 cells	 that	 had	 been	 infected	under	 the	same	conditions.	Noteworthy,	 intracellularly	and	during	 the	 initial	4-6	days	after	infection	RNA	copy	levels	were	comparable	in	both	systems.	We	hypothesize	that	the	 difference	 in	 viral	 kinetics	 may	 in	 part	 be	 due	 to	 the	 fact	 that	 hepatoma	 cells	continue	 to	proliferate	 in	culture,	whereas	hPSC-hepatocytes	are	chiefly	quiescent.	An	alternative	explanation	might	be	that	that	the	Kernow-C1	p6	strain,	used	in	this	study,	was	 passaged	 6	 times	 in	 HepG2/C3A	 cells	 and	 may	 thus	 have	 been	 adapted	 to	 the	HepG2/C3A	cellular	environment	(112).	The	advantage	of	using	pluripotent	stem	cells	is	 that	 they	can	easily	be	obtained	 from	different	donors	whereas	hepatoma	cell	 lines	
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are	derived	from	a	single	donor.	Availability	of	multiple	donor	hPSC-hepatocytes	should	allow	 further	 examination	 of	 specific	 virus-host	 interactions.	 Indeed,	 we	 found	 that	there	were	differences	in	innate	immune	response	following	HEV	infection	of	two	PSC-derived	hepatocyte	progeny.	Use	of	additional	patient-specific	iPSC	lines	should	permit	to	 further	 elaborate	 on	 this	 observation	 to	 fully	 understand	 virus-host	 interactions.	Unfortunately,	we	were	unable	 to	 cultivate	HEV	 from	a	 clinical	 plasma	 sample	 in	 our	system,	which	confirms	the	challenging	nature	of	HEV	propagation	in	tissue	culture.	In	 the	 hPSC-hepatocytes,	 HEV	 replication	was	 efficiently	 inhibited	 by	RBV	 and	IFN,	 the	 only	 drugs	 currently	 available	 to	 treat	HEV	 infections.	 Both	 drugs	 decreased	(both	 intra-	and	extracellular)	 levels	of	viral	RNA	but	did	not	 fully	eliminate	 the	virus	from	the	hPSC-hepatocytes.	Complete	eradication	may	require	either	longer	treatment,	more	potent	drugs,	or	may	only	be	possible	in	the	context	of	an	intact	immune	response	in	the	infected	host.		Initially,	 infection	 studies	 were	 performed	 with	 genotype	 3	 HEV	 carrying	 an	additional	 G1634R	 mutation.	 Comparison	 of	 the	 replication	 efficiency	 between	 wild	type	and	mutant	HEV	in	hESC-hepatocytes	revealed	the	1634R	mutant	might	have	some	replication	 advantage	 in	 these	 cells	 as	 well,	 although	 the	 differences	 were	 not	statistically	 significant.	 However,	 only	 supernatant	 collected	 from	 hESC-hepatocytes	that	 had	 been	 infected	 with	 the	 mutant	 HEV	 was	 able	 to	 re-infect	 HepG2/C3A	 cells,	which	 is	 consistent	 with	 the	 notion	 that	 1634R	mutant	 results	 in	 an	 increased	 viral	fitness.	 hESC-hepatocytes	 might	 therefore	 also	 serve	 as	 a	 valuable	 tool	 to	 study	 the	importance	 of	 mutations	 identified	 in	 HEV-infected	 patients	 that	 became	 non-responsive	to	ribavirin	treatment.		In	 hPSC-mesoderm	 and	 NPCs,	 (-)ssRNA	 was	 not	 detectable	 and	 levels	 of	(+)ssRNA	decreased	over	time,	suggesting	that	these	cells	do	not	support	in	vitro	the	full	cycle	of	HEV	infection	and	replication,	which	would	be	consistent	with	the	tropism	seen	
in	vivo.	However,	as	successful	 infection	of	a	culture	system	depends	not	only	on	viral	replication	 but	 also	 on	 the	 ability	 of	 the	 virus	 to	 enter	 the	 cell,	 i.e.	 infect	 the	 cell,	we	explored	 whether	 hPSC-mesoderm	 and	 NPCs	 support	 HEV	 subgenomic	 replication	following	transfection	of	the	replicon	in	the	host	cells.	hPSC-mesoderm	and	NPCs	could	support	 intracellular	HEV	replication,	 and	 therefore	 strongly	 suggest	 that	entry	 is	 the	limiting	 factor	 to	allow	 the	complete	 replication	cycle	of	 the	HEV	and	may	be	 the	key	determinant	of	HEV	tissue	tropism.	Although	some	studies	have	demonstrated	that	HEV	
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infection	 can	 be	 associated	 with	 neurological	 symptoms	 such	 as	 Guillain-Barré	syndrome	(201-203),	it	is	not	clear	whether	such	neurological	symptoms	are	a	direct	or	indirect	 consequence	 of	 HEV	 infection.	 In	 one	 study,	 HEV	 viral	 RNA	was	 detected	 in	cerebrospinal	 fluid	 of	 some	 patients	 and	 viral	 sequences	 found	 in	 the	 cerebrospinal	fluid	were	 different	 from	 those	 detected	 in	 serum	 (204).	 This	may	 suggest	 that	 HEV	variants	with	neurotropic	capacity	may	 indeed	exist.	 	The	HEV	infection	model	 in	PSC	(from	 which	 we	 can	 generate	 many	 different	 mature	 cell	 types)	 will	 allow	 studying	cell/tissue	tropisms	of	HEV	as	well	as	the	underlying	mechanism.	In	 conclusion,	 pluripotent	 stem	 cells	 have	 the	 unique	 capacity	 to	 differentiate	into	 any	 given	 cell	 type,	 which	 allows	 to	 study	 HEV	 infection	 not	 only	 in	 hPSC-hepatocytes	 but	 also	 to	 discover	 possible	 extrahepatic	 sites	 of	 HEV	 infection	 and	replication.	 We	 here	 demonstrate	 that	 hPSC-mesoderm	 and	 NPCs	 support	 HEV	replication,	but	only	upon	transfection	of	viral	(replicon)	RNA	suggesting	that	the	in	vivo	hepatotropism	seen	 is	 likely	due	 to	 the	 inability	of	HEV	to	enter	non-hepatic	cells.	On	the	contrary,	hepatocyte-like	cells	generated	from	hPSCs	are	a	valuable	alternative	for	hepatoma	cell	lines	and	human	primary	hepatocytes	in	the	study	of	the	viral	biology	of	the	HEV.				
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4.1	Introduction			Dimethyl	 sulfoxide	 (DMSO)	 is	 widely	 used	 as	 an	 amphiphilic	 solvent	 and	 a	cryoprotectant.	 DMSO	 also	 functions	 as	 a	 free	 radical	 scavenger	 and	 influences	 the	physiological	properties	of	 the	 lipid	membrane.	 In	addition,	 it	was	demonstrated	 that	DMSO	 induces	 cell	 differentiation	 and	 retards	 dedifferentiation	 of	 cultured	 primary	human	hepatocytes	(205,	206).	DMSO	is	added	in	a	concentration	of	2%	to	the	human	hepatoma	cell	 line,	HepaRG,	to	 induce	differentiation	and	polarization	(27).	Therefore,	DMSO	has	been	included	in	varying	concentrations	ranging	from	0.5	to	1%	to	numerous	pluripotent	stem	cell	 (PSC)	hepatocyte	differentiation	protocols	(50,	186,	207).	Chetty	
et	al.	previously	demonstrated	that	the	addition	of	DMSO	to	PSCs	prior	to	differentiation	increased	the	number	of	cells	in	early	G1	phase	and	induced	the	differentiation	of	PSCs	to	all	three	germ	layers,	 including	endoderm	(208).	Another	study	confirmed	that	0.5-0.6%	DMSO	downregulated	the	expression	of	pluripotency	genes	in	human	embryonic	stem	cells	(hESCs)	and	improved	endodermal	differentiation	(209).	The	mechanism	of	action	whereby	 DMSO	 induces	 (endodermal)	 differentiation	 and	 prevents	 hepatocyte	dedifferentiation	remains	however	to	be	elucidated.			 The	hepatitis	B	virus	has	a	remarkable	host	specificity	and	hepatotropism.	HBV	research	was	until	 recently	hindered	by	 the	 lack	of	 a	 robust	 and	 efficient	 cell	 culture	models.	The	HepaRG	cell	 line	was	the	first	hepatoma	cell	 line	reported	that	supported	the	complete	HBV	replication	cycle	but	only	upon	differentiation	with	2%	DMSO	(142).	In	 addition,	 it	 was	 shown	 that	 DMSO	 enhances	 the	 infection	 of	 primary	 human	hepatocytes	 with	 HBV	 (210).	 Microarray	 analysis	 of	 undifferentiated	 HepaRG	 cells,	DMSO-differentiated	 HepaRG	 cells	 and	 non-susceptible	 HuH7/	 HepG2	 cells	 identified	NTCP	 as	 a	 candidate	 receptor	 for	 the	 HBV	 and	 overexpression	 of	 human	 NTCP	 in	HuH7/HepG2	cells	rendered	these	cells	susceptible	to	HBV	infection.	Remarkably,	2.5%	DMSO	also	increased	the	efficiency	of	HBV	infection	in	NTCP	overexpressing	HuH7	and	HepG2	 cells.	 The	 exact	 role	 of	 DMSO	 during	 HBV	 infection	 remains	 unclear	 but	 it	 is	thought	 that	DMSO	enhances	 the	adsorption	and	cell	association	of	HBV	(210).	DMSO	induces	 the	expression	of	NTCP	and	overall	 differentiation	of	HepaRG	cells	but	might	also	enhance	or	maintain	certain	 liver-enriched	transcription	 factors	 that	control	HBV	transcription	(180).		
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	 Based	on	previous	 reports,	we	added	0.6%	DMSO	during	 the	differentiation	of	PSCs	 towards	 endoderm	 and	 demonstrated	 an	 improvement	 in	 endodermal	differentiation.	 However,	 DMSO	 is	 used	 at	 higher	 concentrations,	 ranging	 between	 2	and	 2.5%,	 in	 HepaRG	 and	 primary	 human	 hepatocytes	 cultures.	 Therefore,	 we	hypothesized	that	addition	of	2%	might	also	enhance	maturation	of	hepatoblasts	from	day	 12	 of	 differentiation	 onwards.	 We	 demonstrated	 that	 a	 more	 homogenous	population	of	hepatocyte-like	cells	was	generated	using	this	protocol,	yielding	cells	that	were	more	susceptible	 to	HEV	 infection.	Moreover,	 the	addition	of	DMSO	significantly	increased	 NTCP	 expression	 and	 preliminary	 studies	 suggest	 that	 this	 may	 render	hepatocyte-like	 cells	 from	PSCs	 susceptible	 to	HBV	 infection.	 Finally,	we	performed	 a	number	 of	 studies	 to	 determine	 how	 addition	 of	 DMSO	 enhances	 endoderm	 and	hepatocyte-like	cells	differentiation	from	PSCs,	but	these	studies	were	not	conclusive.			
4.2	Materials	and	methods		
4.2.1	 Cells	 and	 compounds.	 The	 fibroblast	 cell	 line	 BJ1	 was	 previously	reprogrammed	to	hiPSC	by	lentiviral	transduction	of	OCT4,	c-MYC,	KLF4	and	SOX2	(39).	The	hESC	line	H9	(WA09)	was	purchased	from	WiCell	Research	Institute	(Madison,	WI).	Both	 hiPSC	 and	 hESC	 were	 maintained	 either	 on	 inactivated	 mouse	 embryonic	fibroblasts	 (iMEF)	 in	 hESC	 medium	 (DMEM/F12	 (Invitrogen,	 Carlsbad,	 CA)	supplemented	with	20%	KnockOut	Serum	Replacement	 (Invitrogen),	1%	nonessential	amino	acids	(Invitrogen),	1	mM	L-glutamine	(Sigma-Aldrich,	St.	Louis,	MO),	0.1	mM	β-mercaptoethanol	 (Sigma-Aldrich)	 and	 4	 ng/mL	 bFGF	 (basic	 fibroblast	 growth	 factor)	(Peprotech,	 Rocky	 Hill,	 NJ)	 or	 on	 human	 matrigel	 (BD)	 coated	 plates	 in	 Essential	 8	medium	 (Life	 Technologies)	 in	 a	 humidified	 5%	 CO2	 incubator	 at	 37°C.	 HepG2-NTCP	cells	(a	kind	gift	 from	Prof.	Stephan	Urban,	University	of	Heidelberg)	were	cultured	in	DMEM	 (Gibco,	 Gaithersburg,	 MD)	 supplemented	 with	 10%	 FBS,	 1%	 penicillin-streptomycine	 (Gibco),	 1%	 L-glutamine	 200nM	 (Gibco)	 and	 1%	 non-essential	 amino	acids	 (Gibco))	 in	 a	 humidified	 5%	 CO2	 incubator	 at	 37°C.	 Myrcludex	 B	 (MyrB),	 GFP-labeled	MyrB	and	a	mutated	GFP-labeled	MyrB	were	kindly	provided	by	Prof.		Stephan	Urban.	 N-acetylcysteine	 was	 purchased	 from	 Sigma-Aldrich.	 Janus	 kinase	 (JAK)	inhibitor	was	purchased	from	Millipore	(Billerica,	Massachusetts).			
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4.2.2	 Optimization	 of	 the	 hepatocyte	 differentiation	 protocol	 by	
DMSO.	 hESC	 and	 hiPSC	 were	 differentiated	 towards	 hepatocytes	 following	 a	previously	 described	 protocol	 with	 minor	 modifications	 (169)	 (Figure	 9).	 During	differentiation	 DMSO	 (Sigma-Aldrich)	 was	 added	 in	 various	 concentrations	 ranging	from	0.6%	-	2%	(Figure	22).		
4.2.3	RNA	extraction	and	quantitative	reverse-transcription	PCR	(RT-
qPCR).	For	 gene	 expression	 analysis,	 RNA	was	 isolated	 from	 differentiated	 progeny	cells	 by	 the	 GenElute	 Mammalian	 Total	 RNA	 Miniprep	 Kit	 (Sigma-Aldrich)	 following	manufacturer’s	procedures.	Genomic	DNA	was	removed	using	the	On-Column	DNase	I	Digestion	 kit	 (Sigma-Aldrich).	 The	 Superscript	 III	 First-Strand	 synthesis	 system	(Invitrogen)	was	 used	 for	 subsequent	 cDNA	 synthesis.	 qPCR	was	 performed	with	 the	Platinum	SYBR	green	qPCR	 supermix-UDG	kit	 (Invitrogen)	 in	 a	ViiA	7	Real-Time	PCR	instrument	 (Thermo	 Fisher	 Scientific,	 Waltham,	 MA).	 Glyceraldehyde-3-phosphate	dehydrogenase	 (GAPDH)	 was	 used	 as	 the	 housekeeping	 gene	 for	 normalization.	Sequences	 of	 qRT-PCR	 primers	 are	 listed	 in	 (	Table	4).	Viral	RNA	was	isolated	from	the	supernatant	using	the	NucleoSpin	RNA	virus	kit	(Macherey-Nagel,	Düren)	according	to	the	manufacturer’s	instructions.	Intracellular	RNA	from	infected	stem	cell	progeny	was	extracted	using	the	RNeasy	Mini	Kit	(Qiagen,	Hilden,	Germany).	qRT-PCR	for	viral	RNA	was	performed	as	previously	described	(194)	(Table	 2).	 Viral	 RNA	 detected	 in	 lysates	 was	 normalized	 to	 total	 RNA	 content	 as	measured	by	spectroscopy	(Nanodrop	ND-1000,	Thermo	Fischer	Scientific).												
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Gene Forward Reverse 
GAPDH TCAAGAAGGTGGTGAAGCAGG ACCAGGAAATGAGCTTGACAAA 
AFP TGAGCACTGTTGCAGAGGAG GTGGTCAGTTTGCAGCATTC 
ALB ATGCTGAGGCAAAGGATGTC AGCAGCAGCACGACAGAGTA 
AAT AGGGCCTGAAGCTAGTGGAT TCCTCGGTGTCCTTGACTTC 
HNF4a ACTACGGTGCCTCGAGCTGT GGCACTGGTTCCTCTTGTCT     
NTCP ATCGTCCTCAAATCCAAACG CCACATTGATGGCAGAGAGA 
G6PD endo ACAGCGTCATGGCAGAGC TCTTCTTCTTGGCCAGGTCAC 
G6PD exo GTGACCTGGCCAAGAAGAAG AGGTGGAGGGCATTCATGT 
OCT4 TCGAGAAGGATGTGGTCCGA  GCCTCAAAATCCTCTCGTTG  
SOX2 TGGCGAACCATCTCTGTGGT CCAACGGTGTCAACCTGCAT 
NANOG CCTGTGATTTGTGGGCCTG GACAGTCTCCGTGTGAGGCAT 
CXCR4 CACCGCATCTGGAGAACCA GCCCATTTCCTCGGTGTAGTT 
FOXA2 AGGAGGAAAACGGGAAAGAA GGTGCTTGAAGAAGCAGGAG 
EOMES AACAACACCCAGATGATAGTC TCATAGTTGTCTCTGAAGCCT 
MIXL1 GGATCCAGGTATGGTTCCAG CATGAGTCCAGCTTTGAACC 
	
Table	4.	RT-qPCR	primer	list.			
4.2.4	 Flow	 cytometry.	 On	 day	 4,	 cells	 were	 detached	 with	 trypsin	 0.05%	 and	stained	with	1	µg/mL	anti-CXCR4-PE	(BD	Biosciences,	San	Jose,	CA)	and	2	µg/mL	anti-cKIT-APC	antibody	(BD	Biosciences)	 for	15	minutes	at	 room	temperature.	Afterwards	cells	were	washed	and	analyzed	by	 flow	cytometry	analysis	using	a	FACS-Canto	 (BD).		For	 intracellular	 AAT	 flow	 cytometry	 staining,	 a	 single	 cell	 suspension	 was	made	 by	liberase	treatment	(Roche,	Basel,	Switzerland)	followed	by	fixation	with	4%	PFA	for	15	min.	 at	RT.	Next,	 cells	were	 permeabilized	with	 0.1%	 saponin	 and	blocked	with	 10%	goat	serum	(Dako,	Glostrup,	Denmark)	for	45	min.	at	RT.	Afterwards	cells	were	stained	with	 0.0625μg/200μL/106	 cells	 anti-AAT	 antibody	 (Dako)	 or	 a	 rabbit	 IgG	 isotype	control	(BD	Pharmingen)	for	1h	at	RT.	After	1h,	a	secondary	Alexa	Fluor	647	antibody	(1:1500)	 (Invitrogen)	 was	 used	 for	 30	 min.	 at	 RT.	 Cells	 were	 analyzed	 by	 flow	cytometry	analysis	using	a	FACS-Canto	(BD).		
4.2.5	 Immunofluorescence.	Cells	 were	 fixed	 with	 4%	 paraformaldehyde	 (PFA)	for	15	min.	at	room	temperature	(RT),	permeabilized	with	0.2%	Triton	X-100,	blocked	with	 5%	 normal	 donkey	 serum	 (Jackson	 Laboratory,	 Bar	 Harbor,	 ME)	 and	 stained	overnight	 at	 4°C	 with	 primary	 antibodies	 and	 isotype	 controls		Table	 5).	 Afterwards,	 cells	 were	 incubated	 with	 appropriate	 secondary	 antibodies	together	with	Hoechst	(Sigma-Aldrich)	for	60	minutes	at	RT).	Images	were	taken	by	the	AxioimagerZ.1	fluorescence	microscope.		
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Antibody Catalog number Company Dilution 
SOX17 AF1924 R&D 1:200 
HNF4α Ab41898 Abcam 1:200 
NTCP HPA042727 Sigma 1:500 
	
Table	5.	Antibody	list	used	for	immunofluorescence	assays.			
4.2.6	Recombinant	mediated	cassette	exchange	(RMCE).	A	master	cell	line	containing	 an	 FRT-flanked	 CAGGS-GFP-hygromycin/Thymidine	 Kinase	 (TK)	 cassette	introduced	 in	 the	 AAVS1	 locus,	 using	 homologous	 recombination,	 was	 previously	generated	in	the	lab	by	Dr.	Ordovas	(211).	Two	million	cells	were	nucleofected	with	6μg	of	 the	 donor	 plasmid	 containing	 an	 FRT-flanked	 inducible	 G6PD-puromycine	 cassette	together	with	3μg	of	the	Flippase	expression	vector	using	the	Nucleofector	solution	kit	2	(Amaxa)(Figure	24).	Nucleofected	cells	were	plated	on	puromycin	resistant	iMEFs	and	2	days	after	nucleofection	puromycin	selection	was	started	with	increasing	concentration	of	puromycin	ranging	from	100-200ng/mL	for	6	days.	As	negative	selection,	four	days	after	 the	 start	 of	 puromycin	 selection	 0.5	 μM	 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodouracil	 (FIAU)	 was	 used	 for	 7	 days.	 After	 selection,	puromycin/FIAU	resistant	colonies	were	picked,	expanded	and	characterized.			
4.2.7	Albumin	and	AAT	ELISA.	Enzyme-linked	immunosorbent	assay	(ELISA)	for	albumin	 and	AAT	was	 performed	 according	 to	 the	manufacturer’s	 procedure	 (Bethyl,	Montgomery,	 TX).	 Briefly,	 on	 day	 20	 of	 the	 hepatocyte	 differentiation	 protocol,	supernatants	were	collected	and	incubated	with	a	primary	albumin	or	AAT	antibody	for	60	min.	at	RT.	Afterwards	an	HRP-detection	antibody	was	added	for	60	min.	followed	by	TMB-peroxidase	solution	for	15	min.	at	RT.	The	reaction	was	stopped	by	a	0.18M	H2SO4	solution	and	the	OD	was	measured	on	a	microplate	reader	at	a	wavelength	of	450	nm.	A	standard	curve	was	used	to	quantify	the	amount	of	albumin	and	AAT	secretion.			
4.2.8	 Cell	 cycle	 analysis.	 Day	 20	 PSC-progeny	 were	 harvested	 with	 liberase	(Roche,	Basel,	Switzerland),	washed	with	1X	PBS,	suspended	in	1X	PBS	+	0.1%	glucose	and	 immediately	 fixed	with	 ice	cold	70%	ethanol	 for	1	hour.	After	 fixation,	 cells	were	spun	down,	washed	with	1X	PBS	and	 resuspended	 in	 the	 staining	 solution	containing	
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propidium	 iodide	 and	 pyronin	 Y	 for	 30-45	 minutes	 at	 37°C,	 and	 cells	 subsequently	analyzed	by	flow	cytometry	analysis	using	a	FACS-Canto	(BD).		
4.2.9	HEV	viral	inoculation.	Day	20	PSC-derived	hepatocyte	progeny	was	infected	with	300	µL	HEV	stock	diluted	to	3	x	10^7	viral	RNA	copies/mL	per	well	and	incubated	for	24h	at	37°C	in	a	5%	CO2	humidified	incubator.	After	24h,	the	inoculum	was	removed	and	 cells	 were	 washed	 5	 times	 with	 500	 µL	 of	 DMEM,	 before	 addition	 of	 500	 µL	 of	hepatocyte	differentiation	medium.	Medium	was	changed	every	other	day	by	collecting	300	μL	and	replacing	it	with	350	μL	fresh	hepatocyte	differentiation	medium		
4.2.10	 Myrcludex	 B	 staining.	 Stem	 cell-derived	 hepatocytes	 and	 HepG2-NTCP	cells	were	cultured	on	cover	slips	and	at	incubated	with	400nM	GFP-labeled	Myrcludex	B	for	30	minutes	at	37°C.	After	incubation,	cells	were	washed	3x	with	PBS/2%	bovine	serum	albumin	and	fixed	with	4%	PFA	for	15	minutes	at	room	temperature.	Afterwards	cells	 were	 washed	 3x	 with	 PBS,	 stained	 with	 Hoechst	 (Sigma-Aldrich)	 and	mounted.	Images	were	taken	by	an	AxioimagerZ.1	fluorescence	microscope.		
4.2.11	HBV	viral	inoculation.	HepG2-NTCP	cells	(kindly	provided	by	Professor	S.	Urban)	were	seeded,	one	day	prior	to	infection,	at	a	density	20.000	cells	per	well	of	a	96	well	plate.	Both	HepG2-NTCP	and	day	16	stem	cell-derived	hepatocytes	were	 infected	with	 a	 1:100	 (»	 8	 x	 109	genome	 equivalents)	 and	 1:10	 dilution	 (»	 8	 x	 1010	genome	equivalents)	 of	 the	 HBV	 stock	 (produced	 by	 the	 laboratory	 of	 Professor	 S.	 Urban),	respectively.	 The	 viral	 inoculum	 was	 supplemented	 with	 2.5%	 DMSO	 and	 8%	polyethylene	 glycol	 (PEG).	 Cells	 were	 incubated	 for	 24	 hours	 at	 37°C.	 After	 viral	inoculation,	medium	was	 replaced	by	HepG2	medium	or	 liver	differentiation	medium	(169).	 Medium	 was	 changed	 every	 other	 day	 until	 6	 days	 post	 infection.	 Cells	 were	treated	from	the	inoculation	until	the	end	of	the	experiment	with	200nM	of	Myrcludex	B	(kindly	 provided	 by	 Professor	 S.	 Urban)	 or	 with	 1µM	 Janus	 Kinase	 (JAK)	 inhibitor	(Millipore).			
4.2.12	HBcAg	staining.	On	day	6	post	infection,	cells	were	fixed	with	4%	PFA	for	15	 minutes	 at	 room	 temperature.	 Afterwards,	 cells	 were	 blocked	 and	 permeabilized	
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overnight	at	4°C	with	3%	Bovine	Serum	Albumin,	2%	Fetal	Calf	Serum	and	0.2%	Tween-20.	 The	 next	 day,	 cells	 were	 stained	 for	 90	 minutes	 at	 room	 temperature	 with	 a	hepatitis	 B	 core	 antigen	 (HBcAg)	 antibody	 (Dako)	 in	 a	 dilution	 of	 1:750.	 After	incubation	with	the	primary	antibody,	cells	were	washed	3X	with	PBS	and	stained	for	1	hour	 at	 room	 temperature	 with	 a	 complementary	 secondary	 antibody	 and	 Hoechst.	Images	were	taken	either	using	an	InCellAnalyzer	(GE	Healthcare	Life	Sciences,	Diegem,	Belgium).			
4.3	Results		
4.3.1	DMSO	improves	definitive	endoderm	formation	from	hPSCs		DMSO	was	added	at	a	concentration	of	0.6%	to	the	differentiation	protocol	from	day	0	onwards	 (Figure	 20A).	 The	 effect	 of	 DMSO	 on	 definitive	 endoderm	 formation	 was	evaluated	 by	RT-qPCR,	 flow	 cytometry	 and	 immunofluorescence	 staining.	 Addition	 of	DMSO	significantly	enhanced	downregulation	of	pluripotency	genes	such	as	OCT4,	and	significantly	 increased	a	number	of	endodermal	markers	transcripts	 in	both	hESC	and	hiPSC-derived	endodermal	cells	(Figure	20B).	In	addition,	the	frequency	of	CXCR4/cKIT	double	 positive	 cells	 increased	 to	 approximately	 70-80%	 (Figure	 21A).	 The	improvement	 of	 definitive	 endoderm	 by	 DMSO	 was	 further	 confirmed	 by	 SOX17	immunofluorescence	staining	(Figure	21B).	The	effect	of	DMSO	was	more	pronounced	when	evaluating	endodermal	protein	expression	compared	with	gene	transcript	levels.		
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Figure	 20.	 DMSO	 improved	 endoderm	 formation.	 Differentiation	 of	 hPSCs	 to	 definitive	
endoderm	 was	 performed	 with	 or	 without	 addition	 of	 0.6%	 DMSO	 (A)	 Differentiation	
protocol.	(B)	RT-qPCR	analysis	of	pluripotency	genes	and	definitive	endoderm	genes	(n=3;	
*:	p=0.05%)).	
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Figure	21.		DMSO	improved	the	generation	of	definitive	endoderm	cells.	Differentiation	of	
hPSCs	to	definitive	endoderm	was	performed	with	or	without	addition	of	0.6%	DMSO.	(A)	
FACS	 analysis	 with	 antibodies	 against	 CXR4	 and	 cKIT	 on	 day	 4	 hPSC	 progeny	 (n=3;	
*p=0.5%).	 (B)	 Immunofluorescence	 staining	 with	 antibodies	 against	 SOX17:	 left	 panel	
representative	example;	right	panel:	quantification	of	SOX17	positive	cells	(n=3;	*p=0.5%).			
4.3.2	Effect	of	DMSO	on	the	differentiation	of	hepatocytes	from	hPSCs		We	next	examined	the	effect	of	DMSO	on	hepatocyte	differentiation	by	day	20.	The	first	protocol	was	the	standard	protocol	without	DMSO	(0%	DMSO),	published	by	our	group	(144,	169);		the	second	protocol	contained	0.6%	DMSO	from	day	0	until	the	end	of	the	differentiation	(0.6%	DMSO);	while	 in	 the	 third	protocol	0.6%	DMSO	was	added	 from	
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day	0	until	day	12	and	then	further	increased	to	a	concentration	of	2%	until	day	20.	In	the	last	and	fourth	protocol,	2%	DMSO	was	only	administrated	only	from	day	12	until	the	 end	 of	 differentiation	 (2%	 DMSO)	 (Figure	 22A).	 The	 rationale	 for	 increasing	 in	DMSO	 concentration	 to	 data	 2%	 from	 day	 12	 (hepatoblasts	 stage)	was	 based	 on	 the	published	 studies	 demonstrating	 that	maturation	 of	HepaRG	 cells	 is	 accomplished	 by	addition	 of	 2%	 DMSO,	 and	 the	 ability	 of	 2%	 DMSO	 to	 prevent	 too	 some	 extent	 the	dedifferentiation	of	primary	human	hepatocytes	(27,	206).		
	
	
Figure	 22.	 Late-term	 effect	 of	 DMSO	 on	 PSC-hepatocyte	 differentiation.	 (A)	 Various	
concentrations	 of	 DMSO	were	 added	 during	 the	 hepatocyte	 differentiation	 protocol.	 (B)	
RT-qPCR	 analysis	 for	 AFP,	 HNF4a,	 AAT,	 ALB,	 CYP3A4	 and	 NTCP	 (n=3;	 *:p=0.05%).	 (C)	
Flow	cytometry	analysis	for	AAT	(representative	example	of	n=3;	mean	±	SEM	of	the	three	
studies).	 (D)	 Immunofluoresence	 staining	 for	 HNF4a	 (representative	 example	 of	 n=3;	
quantification	 of	 the	 three	 studies,	 *:p=0.05%).	 (E)	 Cell	 cylce	 analysis	 on	 day	 20	 using	
propidium	iodide	and	pyronin	Y	to	define	the	frequency	of	cells	 in	G0,	G1,	S	and	G2/M	of	
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the	 cell	 cycle	 (n=2).	 (F)	ELISA	on	 supernatant	 of	 day	20	hPSC	progeny	 for	 albumin	and	
AAT	(n=3).		RT-qPCR	 analysis	 for	 hepatocyte	 markers	 demonstrated	 that	 AFP,	 AAT,	 HNF4a	 and	
NTCP	were	 all	 upregulated	by	 the	 addition	of	DMSO.	The	gene	expression	of	 albumin	remained	similar	when	0.6%	DMSO	was	added	to	the	differentiation	medium	compared	to	cultures	without	DMSO.	However,	ALB	transcripts	were	significantly	decreased	when	the	concentration	was	increased	to	2%	DMSO.	Expression	of	CYP3A4	was	the	highest	in	the	0.6%	DMSO	protocol	 but	 decreased	 as	well	with	when	2%	DMSO	was	used,	 even	though	these	differences	were	not	statistically	significant.	(Figure	22B).	In	line	with	the	RT-qPCR	studies,	ELISA	demonstrated,	although	not	significant,	a	decrease	 in	albumin	secretion	when	2%	DMSO	protocols	were	used,	while	AAT	secretion	was	increased	in	all	DMSO	protocols	(Figure	22F).	In	addition,	immunostaining		demonstrated	a	significant	increase	 in	 the	 frequency	 of	HNF4a	 positive	 cells	 in	 the	DMSO	protocols	 rendering	 a	more	 homogenous	 population	 of	 hepatocytes	 (Figure	 22D).	 The	 improvement	 of	homogeneity	of	the	differentiation	was	further	demonstrated	by	AAT	flow	cytometry.	In	accordance	 with	 the	 gene	 expression	 and	 ELISA	 data,	 the	 frequency	 of	 AAT	 +	 cells	increased,	altough	not	signifciant,	by	the	addition	of	DMSO	with	the	highest	of	frequency	of	AAT	+	 cells	 (approximately	85%)	 	 in	 the	0.6-2%	DMSO	protocol	 (Figure	22C).	 Cell	cycle	analysis	of	day	20	hPSC	progeny,	demonstrated	that	more	cells	 treated	with	2%	DMSO	were	 in	G0	phase	 of	 the	 cell	 cycle	 compared	with	 cultures	 treated	with	0%	or	0.6%	DMSO.			
3.3.6	 N-acetylcysteine	 and	 induction	 of	 glutathione	 have	 a	 similar	
effect	on	definitive	endoderm	formation	as	DMSO		DMSO	can	act	both	as	an	oxidant	of	free	thiol	groups	in	proteins	or	as	a	reducing	agent,	scavenging	 free	 hydroxyl	 and	 peroxy	 radicals.	 The	 overall	 effect	 of	DMSO	 is	 however	highly	 cell	 type	and	concentration	dependent	 (212)(213).	 	Because	of	 the	 free	 radical	scavenger	and	antioxidant	properties,	we	tested	if	another	well-established	antioxidant,	N-acetylcysteine	 (NAC),	 would	 phenocopy	 the	 effect	 of	 DMSO	 on	 PSC-hepatocyte	differentiation	(205).	 	NAC	is	a	precursor	of	L-cysteine	and	glutathione,	and	scavenges	free	 radicals	 (214,	 215).	 NAC	 was	 added	 to	 the	 medium	 from	 day	 0	 to	 4	 at	 a	
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concentration	of	2.5mM	(Figure	23A).	The	addition	of	NAC	significantly	 improved	 the	generation	of	definitive	endoderm	to	a	similar	extent	as	DMSO.	The	frequency	of	both	CXCR4/cKIT	double	positive	cells	and	SOX17	positive	cells	was	significantly	 increased	as	well	the	expression	of	transcripts	for	the	endodermal	markers	such	as	CXCR4,	EOMES	and	MIXL1,	while	pluripotency	markers	were	significantly	more	downregulated	(Figure	23).	However,	 improved	generation	of	definitive	endoderm	by	NAC	did	not	 lead	 to	an	improved	differentiation	of	day	20	hepatocyte-like	cells.	Neither	 the	administration	of	NAC	from	day	0	until	day	4	or	from	day	0	until	day	20	influenced	the	later	time-points	of	the	hepatocyte	differentiation	as	was	demonstrated	by	RT-qPCR	(Figure	23E).		
	
Figure	23.	Effect	of	NAC	on	definitive	endoderm	formation.	(A)	2.5mM	NAC	was	added	to	
differentiation	from	day	0	until	day	4.	(B)	RT-qPCR	for	pluripotency	genes	and	definitive	
endoderm	 markers	 (n:6;	 *:	 p=0.05%).	 (C)	 FACS	 analysis	 for	 CXCR4	 and	 CKIT	 double	
positive	cells	in	cultures	supplemented	with	or	without	0.6%	DMSO	or	2.5mM	NAC	(n=3;	*:	
p=0.05%).	 (D)	 Immunostaining	 for	 SOX17	 and	 quantification	 (n=3;	 left	 panels	
representative	image;	right	panel	quantification;	*:	p=0.05%).	
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Given	rationale	 first,	we	examined	 the	effect	of	glucose-6-phosphatase	dehydrogenase	(G6PD)	overexpression.	We	created	a	doxycycline	 inducible	G6PD	overexpression	cell	line	 by	 recombinant	 mediated	 cassette	 exchange	 (RMCE)	 in	 the	 H9	 hESC	 line	engineered	with	an	FRT	 flanked	cassette	 in	 the	AAVS1	 locus	(211).	Overexpression	of	G6PD	 increased	reduced	glutathione	 (GSH)	content	 in	 the	cell.	Reduced	glutathione	 is	the	main	antioxidant	produced	in	cells	and	neutralizes	reactive	oxygen	species	and	free	radicals	 (Figure	 24).	 However,	 additional	 experiments	 are	 required	 to	 measure	 the	balance	between	reduced	and	oxidized	glutathione	content	in	the	cell.			
	
Figure	24.	Overexpression	of	G6PD.	A	G6PD	doxycycline	inducible	cell	line	was	created	by	
using	flippase	recombinant	mediated	cassette	exchange	in	the	AAVS1	locus	of	H9	hESC.		Overexpression	of	G6PD	from	day	0	until	day	4	was	confirmed	by	RT-qPCR	and	western	blot	 (Figure	 25	 A&B).	 Although	 not	 significantly,	 upon	 doxycycline	 treatment	 the	frequency	of	CXCR4/cKIT	double	positive	cells	was	 increased	as	was	 the	 frequency	of	SOX17	positive	cells	(Figure	25	C&E).	Additionally,	transcripts	for	definitive	endoderm	makers	were	significantly	higher	in	response	to	G6PD	overexpression	(Figure	25D).	The	effect	of	overexpression	of	G6PD	on	day	20	hepatic	progeny	has	not	yet	been	assessed.		
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Figure	 25.	 Effect	 of	G6PD	overexpression	 on	definitive	 endoderm	 formation.	 (A&B)	RT-
qPCR	 and	western	 blot	 for	 G6PD	 in	 cells	 treated	with	 or	without	 doxycycline.	 (C)	 FACS	
analysis	for	CXCR4/cKIT	double	positive	cells	(n=3;	*:	p=0.05%).	(D)	RT-qPCR	analysis	for	
definitive	endoderm	genes	on	day	4	of	ESC	progeny	 treated	with	or	without	doxycycline	
(DOXY)	 during	 endoderm	 differentiation	 (n=3;	 *:	 p=0.05%).	 (E)	 Immunostaining	 for	
SOX17	and	quantification	(n=3,	representative	image).											
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4.3.4	Infection	of	DMSO-treated	hepatocytes	with	the	hepatitis	E	virus		As	 addition	of	DMSO	 improves	 the	homogeneity	of	hPSC	hepatocyte-like	 cells	 (Figure	22),	we	re-examined	the	susceptibility	of	hPSC	progeny	differentiated	without	DMSO	or	with	0.6%	DMSO	from	day	0	until	day	12	following	the	addition	of	2%	DMSO	from	day	12	until	day	20	(Figure	22)	to	HEV	infection.	Intracellular	and	secreted	HEV	RNA	levels,	quantified	by	RT-qPCR	were	significantly	increased	over	the	course	of	12	days	following	infection	 in	cells	 treated	with	DMSO	(Figure	26).	The	 improved	homogeneity	of	hPSC-hepatocyte-like	cell	progeny	in	the	presence	of	DMSO	is	therefore	beneficial	for	the	HEV	infection	efficiency	of	hPSC	hepatocyte-like	cells.		
		
Figure	 26.	 DMSO	 enhances	 the	 susceptibility	 of	 stem	 cell-derived	 hepatocytes	 with	 the	
HEV.	RT-qPCR	for	viral	RNA	levels	in	the	supernatant	and	in	the	cell	lysates	over	a	period	
of	12	days	(n=3;	*:	p=0.05%).			
4.3.5	Effect	of	DMSO	on	NTCP	expression		NTCP	was	 recently	 identified	 as	 the	 key	 receptor	 for	HBV	entry	 and	 its	 expression	 is	required	for	successful	HBV	infection	in	hepatoma	cells	or	primary	human	hepatocytes	
in	 vitro	 (126,	 180).	 We	 demonstrated	 that	 the	 addition	 of	 DMSO	 significantly	upregulated	 transcripts	 for	NTCP,	 which	 was	 most	 pronounced	 in	 the	 0.6-2%	 DMSO	protocol	 (Figure	 22B).	 Immunofluorescence	 staining	 also	 demonstrated	 that	approximately	 70.1%	 (±5.47)	 of	 the	 cells	 were	 NTCP	 positive	 following	 treatment	 of	hPSC	 hepatocyte-like	 cell	 progeny	 using	 0.6-2%	 DMSO	 protocol,	 whereas	 only	 4.7%	(±3.81)	 hepatocyte-like	 cells	 from	 cultures	 without	 DMSO	 stained	 positive	 for	 NTCP.	
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NTCP	 was	 as	 well	 detected	 by	 western	 blot,	 both	 in	 hESC	 and	 hiPSC	 –	 derived	hepatocytes	on	day	16	of	 the	differentiation	 in	 the	presence	of	0.6-2%	DMSO	 (Figure	27A&B),	even	if	levels	remained	significantly	lower	than	those	in	NTCP	overexpressing	HepG2	cells	(HepG2-NTCP).	This	 is	however	not	surprising	as	HepG2-NTCP	cells	were	generated	by	lentiviral	vector–mediated	overexpression	of	NTCP.	Time-course	analysis	of	PSCs	differentiated	in	the	presence	of	0.6-2%	demonstrated	that	NTCP	is	significantly	upregulated	from	day	8	onwards	with	the	highest	expression	of	NTCP	on	day	16	of	the	differentiation	(Figure	27C).		
			
Figure	 27.	 Effect	 of	 DMSO	 on	 NTCP	 expression.	 (A)	 Immunofluorescence	 staining	 for	
NTCP	 of	 day	 20	 cells	 treated	 with	 or	 without	 DMSO	 treatment	 (n=3;	 *:	 p=0.05%).	 (B)	
Western	 blot	 analysis	 for	 NTCP	 protein	 in	 hESC	 and	 hiPSC	 derived	 progeny	 on	 day	 16.	
HepG2	 cells	 (HepG2-NTCP)	 were	 used	 as	 a	 positive	 control	 (n=3,	 lower	 graph	 shows	
quantification;	NS=	non-significant:	p>0.05%).	(C)	RT-qPCR	time-course	analysis	for	NTCP	
transcripts	 in	 hESC	 and	 hiPSC	 progeny	 in	 comparison	 with	 HepG2-NTCP	 cells	 (n=3;	 *	
relative	to	day	0	(D0):	p=0.05%;	#	relative	to	HepG2-NTCP:	p=0.05%).			
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4.3.6	 Infection	 of	 stem	 cell-derived	 hepatocytes	with	 the	 hepatitis	 B	
virus		Initially,	we	examined	 the	binding	of	GFP-labeled	Myrcludex	B	(MyrB-GFP)	 to	HepG2-NTCP	 cells	 and	 day	 16	 PSC-hepatocyte-like	 cells.	 Myrcludex	 B	 is	 a	 peptide	 that	corresponds	 to	 the	 pre-S1	 domain	 of	 the	 large	 envelop	 protein	 of	 HBV	 which	 was	demonstrated	to	reversibly	bind	to	the	NTCP	receptor	and	to	block	entry	of	HBV	(126,	180).	 As	 a	 control,	 cells	 were	 incubated	 with	 a	 GFP-labeled	 mutated	 form	 of	 MyrB	(MyrB-mut-GFP)	that	is	not	capable	of	binding	to	the	NTCP	receptor.	As	demonstrated	by	 immunofluorescence	 staining,	 NTCP	 was	 abundantly	 expressed	 by	 both,	 HepG2-NTCP	 cells	 and	 0.6-2%	DMSO	 treated	 day	 16	 hPSC-HLCs.	MyrB	 stained	 both	 HepG2-NTCP	 cells	 and	 hPSC-HLCs.	 However,	 staining	 of	 hPSC-HLCs	 with	 MyrB	 was	 lower	compared	 to	HepG2-NTCP	 cells	 (Figure	 28).	MyrB	 +	 cells	were	 not	 quantified	 due	 to	technical	issues.			
	
	
Figure	28.	Immunofluorescence	with	an	antibody	against	NTCP	and	GFP-labeled	MyrB	of	
HepG2-NTCP	cells	and	day	16	hPSC-derived	HLCs	(n=3;	representative	example	shown).			As	MyrB	was	shown	to	bind	DMSO	differentiated	hPSC-derived	HLCs,	we	 investigated	their	susceptibility	to	HBV	infection.	Overexpression	of	NTCP	in	the	HepG2-NTCP	cells	was	 previously	 shown	 to	 allow	 highly	 efficient	 HBV	 infection,	 and	 these	 cells	 were	
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therefore	used	a	positive	control	(180).	Both	HepG2-NTCP	cells	and	hPSC-derived	HLCs	(differentiated	with	 the	 0.6-2%	DMSO	protocol)	were	 inoculated	with	 a	 concentrated	HBV	 stock	 for	 24	 hours	 in	 the	 presence	 of	 2.5%	DMSO	 and	 8%	PEG.	 Presence	 of	 the	hepatitis	 B	 core	 antigen	 (HBcAg)	 was	 assessed	 6	 days	 after	 infection	 by	immunofluorescence	 staining.	 HepG2-NTCP	 cells	 and	 PSC-derived	 HLCs	 were	susceptible	to	HBV	infection.	 In	addition,	 infection	of	PSC-derived	HLCs	with	HBV	was	reduced	by	treatment	with	200nM	of	the	entry	blocker	MyrB	(Figure	29).		
		
Figure	 29.	 Infection	 of	 HepG2-NTCP	 and	 hPSC-derived	 HLCs	 with	 HBV.	 (A)	
Immunostaining	demonstrated	 the	presence	of	HBcAg	 in	both	 infected	(IC)	HepG2-NTCP	
and	 hPSC-HLCs.	 HBV	 infection	 of	 hPSC-HLCs	 was	 inhibited	 by	 treatment	 with	 200nM	
MyrB.	Uninfected	cells	(UIC)	were	used	as	negative	control	(n=3)	(representative	image).	
(B)	Percentage	of	HBV	inhibition	by	MyrB	treatment	was	quantified	by	the	InCell	Analyzer	
Software	(n=3;	*:	p=0.05%).						
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4.4	Discussion		The	 role	 of	 dimethyl	 sulfoxide	 (DMSO)	 in	 cell	 differentiation	 was	 established	 many	years	ago.	 In	1975,	DMSO	was	shown	to	 induce	the	differentiation	of	erythroleukemia	cells,	 and	 later	 on	 also	 to	 further	 induce	 the	 differentiation	 of	 neuroblastoma	 cells	among	others	 (216,	217).	 In	addition,	 Isom	et	al.,	demonstrated	 for	 the	 first	 time	 that	the	addition	of	2%	DMSO	could	delay	the	dedifferentiation	of	primary	rat	hepatocytes	in	
vitro	 (218).	 More	 recently,	 DMSO	 was	 found	 to	 be	 required	 to	 differentiate	 the	bipotential	 hepatocarcinoma	 cell	 line,	 HepaRG,	 and	 several	 studies	 were	 published	demonstrating	 a	 beneficial	 effect	 of	 DMSO	 on	 the	 differentiation	 of	 pluripotent	 stem	cells	toward	hepatocyte-like	cells	(27,	50,	168,	186,	207,	209,	219).		We	 here	 demonstrated	 that	 the	 addition	 of	 0.6%	 DMSO	 during	 endoderm	differentiation	generated	a	more	homogenous	population	of	definitive	endoderm	cells.	DMSO	is	involved	in	different	cellular	processes	and	until	now,	the	mechanism	of	action	whereby	 DMSO	 affects	 differentiation	 of	 hepatocytes	 from	 hPSCs	 has	 not	 been	unraveled.	One	possible	mechanism	might	be	that	DMSO	affects	the	permeability	of	the	membrane	 lipid	 bilayer,	which	might	 enable	 transport	 of	media	 components	 into	 the	cell.	In	line	with	this	hypothesis	is	the	notion	that	DMSO	might	function	as	a	carrier	of	nutrients	and	supplements	(205).	Another	property	of	DMSO	is	its	scavenger	function	of	free	 radicals	 (205).	 We	 replaced	 DMSO	 by	 N-acetylcysteine	 (NAC),	 a	 well-studied	antioxidant,	 and	examined	whether	possible	 scavenging	of	DMSO	was	 involved	 in	 the	improvement	of	definitive	endoderm	differentiation.	Addition	of	NAC	indeed	improved	the	formation	of	definitive	endoderm	cells	to	the	same	extent	as	DMSO.	Moreover,	the	overexpression	of	G6PD,	 the	rate-limiting	enzyme	 for	glutathione	synthesis,	 improved	as	well	the	differentiation	of	hPSCs	towards	endoderm.	We	could	however	not	detect	a	difference	in	reactive	oxygen	species	(ROS)	in	non-treated	versus	DMSO	or	NAC	treated	cells	(data	not	shown).	Additional	experiments	will	be	required	to	further	elucidate	the	involvement	of	the	antioxidant	response	PSC-endoderm	differentiation.	As	 DMSO	 is	 added	 at	 a	 concentration	 of	 2%	 to	 prevent	 de-differentiation	 of	primary	 hepatocyte	 cultures	 and	 to	 induce	 hepatocyte	 differentiation	 from	 HepaRG	cells,	 we	 also	 examined	 the	 effect	 of	 0.6	 and	 2%	 DMSO	 during	 the	 hepatocyte	maturation	from	hepatoblasts	between	day	12	and	20	of	the	differentiation	assay.	When	either	0.6	or	2%	DMSO	was	present,	the	number	of	AAT	and	HNF4a	positive	cells	was	
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significantly	increased,	with	in	addition	an	increase	in	AAT	secretion.	In	contrast,	upon	addition	 of	 2%	 DMSO,	 the	 expression	 of	 CYP3A4	 and	 albumin	 were	 downregulated	compared	with	 cultures	 supplemented	with	 0.6%	DMSO.	 The	 addition	 of	NAC	 during	only	 the	endodermal	stage	or	during	 the	complete	hepatocyte	differentiation	protocol	did,	however,	not	improve	the	generation	of	hepatocyte-like	cells.	The	redox	state	of	the	cell	 can	 therefore	 not	 explain	 the	 effect	 of	 DMSO	 on	 hepatocyte	 maturation.	 In	conclusion,	addition	of	DMSO	during	the	hepatocyte	differentiation	protocol	generated	a	more	homogenous	population	of	hepatocyte-like	cells	but	did	not	 induce	completely	mature	hepatocytes.		We	previously	demonstrated	that	PSC-derived	hepatocyte-like	cells	support	the	complete	 replication	 of	 HEV.	 As	 DMSO	 addition	 improved	 the	 homogeneity	 of	hepatocyte-like	cells	on	day	20	of	differentiation,	we	tested	if	DMSO	also	rendered	the	stem	PSC-derived	hepatocyte-like	 cells	more	 susceptible	 for	HEV	 infection.	More	HEV	viral	 copies	 were	 detected,	 both	 in	 the	 supernatant	 as	 well	 as	 intracellularly	 when	hPSCs	were	differentiated	using	the	0.6-2%	DMSO	protocol,	consistent	with	the	greater	homogeneity	of	 the	differentiated	hepatocyte-like	cells.	 If	possible	effects	of	DMSO	on	the	cell	membrane,	and	hence	binding	of	HEV,	may	play	a	role	in	the	increased	infection	efficiency	of	hepatocyte-like	cells	will	still	need	to	be	determined.	Strikingly,	but	not	unexpectedly,	2%	DMSO	also	increased	NTCP	expression	both	transcript	 and	protein	 level.	NTCP	was	 recently	 identified	 as	 the	key	 receptor	 for	 the	entry	of	the	hepatitis	B	virus	into	cells	(126).	In	the	absence	of	DMSO,	only	3	±	3.4	%	of	hepatocyte-like	cells	expressed	NTCP,	while	treatment	with	DMSO	increased	this	to	70	±	5.4	 %	 of	 hepatocyte-like	 cells,	 which	 was	 most	 pronounced	 in	 the	 0.6-2%	 DMSO	protocol.	Moreover,	Myrcludex	B,	 a	 peptide	 corresponding	 the	pre-S1	domain	of	HBV	was	shown	to	bind	to	the	differentiated	hPSC-hepatocyte-like	cells	(140).	Shlomai	et	al.	previously	 demonstrated	 the	 presence	 of	 HBV	 pregenomic	 RNA,	 cccDNA	 and	 HBsAg	upon	HBV	infection	of	hPSC-HLCs	(145).	Our	preliminary	studies	confirm	these	findings	and	suggest	also	that	PSC-hepatocyte-like	cells	from	DMSO	containing	cultures	might	be	susceptible	 to	 HBV	 infection,	 but,	 additional	 experiments	 are	 necessary	 to	 further	evaluate	the	infection	of	PSC-hepatocyte-like	cells	with	HBV	to	use	this	 in	vitro	system	as	a	model	to	evaluate	HBV	infection.				
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5.1	Introduction		Zika	 virus	 (ZIKV)	 is	 a	 single	 stranded,	 positive	 sense	 RNA	 virus,	 belonging	 to	 the	
Flaviviridae.	 The	 virus	 is	 an	 arthropod	 borne	 virus	 mostly	 transmitted	 by	 Aedes	mosquitos.	 However,	 cases	 of	 sexual	 transmission	 and	 transmission	 via	 blood	transfusion	have	 as	well	 been	described	 (155,	 220,	 221).	Most	 ZIKV	 infected	patients	are	asymptomatic	or	present	only	mild	clinical	symptoms	similar	to	dengue-like	illness	(222,	223).	A	major	public	health	concern	 is	however	the	 link	between	ZIKV	infection	and	 abnormalities	 during	 fetal	 brain	 development.	 ZIKV	 viral	 particles	 have	 been	detected	in	the	amniotic	fluid	of	pregnant	women	and	in	the	brain	tissue	of	fetuses	with	microcephaly	(156,	157).	Furthermore,	the	African	ZIKV	MR766	strain	was	reported	to	infect	human	induced	pluripotent	stem	cell	(hiPSC)-derived	cortical	neural	progenitors	(NPCs),	which	resulted	in	an	attenuated	growth	of	the	cortical	NPCs,	due	to	an	increase	in	apoptosis	 in	 the	NPC	population	(160,	162,	163).	 	Recently,	mouse	models	 that	are	susceptible	 to	 ZIKV	were	 established.	 ZIKV	 infected	 interferon	 deficient	 Ifnar1-/-	 and	AG129	mice	contained	a	high	viral	load	in	not	only	the	brain	but	also	in	the	spinal	cord,	kidney,	spleen,	liver	and	testes	(164,	166).	Interestingly,	a	case	report	published	in	1954	described	 the	 occurrence	 of	 liver	 damage	 and	 jaundice	 in	 two	 patients	with	 elevated	ZIKV	 viral	 antibodies	 (224).	 However,	 to	 the	 best	 of	 our	 knowledge,	 there	 is	 no	additional	 evidence	 that	 ZIKV	 infects	 hepatocytes	 and	 can	 be	 a	 causative	 agent	 of	hepatitis	and/or	liver	damage.			 Dengue	virus	(DENV)	and	Yellow	Fever	virus	(YFV),	both	members	of	the	family	of	Flavivirdae	are	closely	related	to	ZIKV	(225).	Both	DENV	and	YFV	are	known	to	infect	hepatocytes,	causing	liver	damage	and	jaundice	(226-228).	Therefore,	and	based	on	the	finding	 of	 high	 ZIKV	 load	 in	 the	 liver	 of	murine	models,	 the	 question	 arises	whether	ZIKV	may	 as	well	 be	 able	 to	 infect	 hepatocytes.	 However,	 the	 availability	 of	 primary	human	hepatocytes	(PHHs)	is	limited	and	they	are	known	to	rapidly	dedifferentiate	in	culture	 (24,	 229).	 There	 has	 been	 a	 major	 interest	 in	 the	 development	 of	 functional	mature	hepatocytes	 from	human	pluripotent	 stem	cell	 (hPSC)	 to	 study	viral	hepatitis,	liver	disease	and	liver	toxicity	in	vitro.	Others	and	we	have	previously	shown	that	hPSC-derived	hepatocyte-like	cells	(HLCs)	are	susceptible	to	hepatotropic	viruses	such	as	the	hepatitis	 E	 virus	 (HEV)	 (144),	 hepatitis	 B	 virus	 (HBV)	 (145),	 hepatitis	 C	 virus	 (HCV)		
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and	 dengue	 virus	 infection	 (143,	 190,	 192,	 230).	 hPSC-derived	 hepatocytes	 are	 a	valuable	and	physiologically	relevant	model	to	study	the	tissue	tropism	of	viruses	and	to	examine	the	host	response	induced	upon	infection.		We	 here	 demonstrate	 that	 both	 human	 embryonic	 (hESC)-	 and	 hiPSC-derived	hepatocyte-like	 cells	 (HLCs)	 support	 the	 complete	 replication	 cycle	 of	 ZIKV	 including	entry,	replication	and	the	production	of	infectious	virions,	while	infection	was	inhibited	by	7-deaza-2’-C-methyladenosine	 (7DMA)	 treatment.	 In	addition,	ZIKV	 induced	a	host	response	in	PSC-HLCs,	which	was	absent	in	an	infected	hepatoma	cell	line.	These	results	indicate	 that	ZIKV	can	target	hepatocytes	and	might	 like	other	Flaviviridae	 cause	 liver	damage.			
5.2	Materials	and	methods		
5.2.1	Cell	cultures.	The	hESC	line	H9	was	purchased	from	WiCell	Research	Institute	(Madison,	 US).	 	 The	 fibroblast	 cell	 line	 BJ1	 was	 previously	 reprogrammed	 to	 hiPSCs	using	 lentiviral	 transduction	 of	 OCT4,	 SOX2,	 KLF4	 and	 c-MYC	 and	 was	 fully	characterized	as	described	(21).	A	second	hiPSC	line	was	obtained	from	Sigma-Aldrich	(Saint	Louis,	MO).	hPSCs	were	maintained	on	human	matrigel	(BD	Biosciences,	San	Jose,	CA)	coated	plates	in	E8	Flex	medium	(Gibco)	in	a	humidified	5%	CO2	incubator	at	37°C.	hPSC	 were	 differentiated	 towards	 HLCs	 following	 a	 previously	 published	 20-day	differentiation	protocol	with	minor	adjustments	(21,26).	Dimethylsulfoxide	(DMSO)	in	a	concentration	 of	 0.6%	was	 added	 during	 differentiation	 from	day	 0	 until	 day	 12	 and	increased	 to	2%	 from	day	12	until	 the	 end	of	 the	hepatocyte	differentiation	protocol.	The	 human	 hepatoma	 cell	 line	 HuH7	 (kindly	 provided	 by	 Ralf	 Bartenschlager,	University	 of	 Heidelberg,	 Germany)	 was	 maintained	 in	 Dulbecco’s	 modified	 Eagle’s	medium	(DMEM)	(Gibco)	supplemented	with	10%	fetal	bovine	serum	(FBS)	(Gibco),	1%	non-essential	amino	acids	(Gibco)	and	1%	penicillin-streptomycine	in	a	humidified	5%	CO2	incubator	at	37°C.		
5.2.2	 Virus.	 Infections	 were	 performed	 using	 the	 ZIKV	 strain	 MR766	(Rhesus/1947/Uganda)	 and	 the	 NR-50240	 strain	 (clinical	 isolate)	 (PRVABC59)	(Human/2015/Puerto	Rico).	Viral	stocks	were	generated	as	previously	described	(13).		
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5.2.3	 Virus	 inoculation.	On	 day	 16	 of	 differentiation,	 hPSC-derived	 HLCs	 were	inoculated	with	2%	ZIKV	stock	(viral	titer:	1x103	PFU/ml)	in	hepatocyte	differentiation	medium	and	incubated	during	6h	at	37°C	in	a	5%	CO2	humidified	incubator.	Following	the	 6h	 incubation,	 the	 cells	 were	washed	 extensively	 with	 PBS	 and	 fresh	 hepatocyte	differentiation	medium	was	 added.	Half	 of	 the	medium	was	 replaced	every	other	day	and	 supernatant	was	 collected	 2,	 4	 and	 6	 days	 after	 infection.	 	 Cells	were	 lysed	with	350ul	RLT	buffer	4	and	6	days	after	infection	(Qiagen,	Hilden).		Infection	of	Huh7	cells	was	performed	similarly.		
5.2.4	 Inhibition	experiments.	7-deaza-2'-C-methyl-D-adenosine	(7DMA)	and	2’-C-methylcytidine	 (2’CMC)	were	purchased	 from	Carbosynth	(Berkshire,	UK).	T705	(6-fluoro-3-hydroxy-2-pyrazinecarboxamide;	 Favipiravir)	 was	 obtained	 as	 custom	synthesis	 product	 from	 abcr	 GmbH	 (Karlsruhe,	 Germany).	 ZIKV	 infected	 cells	 were	treated	with	 3	 different	 concentrations	 of	 each	 compound	 (7DMA:	 10,	 30	 and	 90µM;	2’CMC:	5,	15	and	45µM	;	T705:	25,	75	and	225µM	)	based	on	the	EC50		using	Vero	cells	(African	Green	monkey	kidney	 cells;	ECACC)	as	previously	published	 (13).	7DMA	and	2’CMC	were	added	to	the	medium	at	the	time	of	the	viral	inoculation	until	the	end	of	the	infection	experiment,	while	T705	was	added	1h	before	inoculation	with	ZIKV.		
5.2.5	 RNA	 isolation	 and	 quantitative	 RT-qPCR.	 	 Viral	 RNA	 was	 extracted	from	150ul	 supernatant	 using	 the	Nucleospin	RNA	 cirus	 kit	 (Macherey-Nagel,	Düren)	following	the	manufacturer’s	protocol.	 Intracellular	RNA	was	 isolated	by	means	of	 the	RNeasy	 Mini	 kit	 (Qiagen).	 	 RT-qPCR	 was	 performed	 to	 analyze	 viral	 RNA	 levels	 as	previously	described	(13).	Detected	viral	RNA	levels	in	the	lysates	were	normalized	for	total	RNA	content.	Total	RNA	content	was	measured	by	spectrometry	 (Nanodrop	ND-1000,	 Thermo	 Fischer	 Scientific).	 For	 gene	 expression	 analysis,	 cDNA	 synthesis	 was	performed	 using	 the	 Superscript	 III	 First-Strand	 synthesis	 kit	 (Invitrogen).	 Following	cDNA	 synthesis,	 RT-qPCR	 was	 performed	 with	 the	 Platinum	 SYBR	 green	 qPCR	supermix-UDG	 kit	 (Invitrogen)	 using	 the	 ViiA7	 Real-Time	 PCR	 instrument	 (Thermo	Fischer	 Scientific,	Waltham,	 US).	 The	 housekeeping	 gene	 glyceraldehyde-3-phosphate	
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dehydrogenase	 (GAPDH)	was	used	 for	normalization.	All	qRT-qPCR	primer	sequences	are	listed	in	(Table	6).		
Gene	 Forward	 Reverse	
GAPDH	 TCAAGAAGGTGGTGAAGCAGG	 ACCAGGAAATGAGCTTGACAAA	
AFP	 TGAGCACTGTTGCAGAGGAG	 GTGGTCAGTTTGCAGCATTC	
ALB	 ATGCTGAGGCAAAGGATGTC	 AGCAGCAGCACGACAGAGTA	
AAT	 AGGGCCTGAAGCTAGTGGAT	 TCCTCGGTGTCCTTGACTTC	
HNF4a	 ACTACGGTGCCTCGAGCTGT	 GGCACTGGTTCCTCTTGTCT					
NTCP	 ATCGTCCTCAAATCCAAACG	 CCACATTGATGGCAGAGAGA	
EIF2AK2	 GAGAATTTCCAGAAGGTGAAGGT	 ATTCCCCATGGATAATCCTTCT	
MX1	 TGCTTATCCGTTAGCCGTGG	 CGCCAGCTCATGTGCATCT	
ISG15	 GAGAGGCAGCGAACTCATCT	 CTTCAGCTCTGACACCGACA	
IFNβ	 AAACTCATGAGCAGTCTGCA	 AGGAGATCTTCAGTTTCGGAGG	
CXCL2	 CCACACTCAAGAATGGGCA	 CAATAAGCTTCCTCCTTCCTTCTG	
CXCL3	 TAGCCACACTCAAGAATGGGAA	 TCTCTCCTGTCAGTTGGTGC	
NFkB	 CAGAGAGTGAGGATGAGGAGAG	 TCATCATAGGGCAGCTCGT	
	
Table	6.	Primers	used	for	RT-qPCR.	
5.2.6	Immunofluorescence.	Cells	were	fixed	with	4%	paraformaldehyde	(PFA)	4	days	after	infection	and	washed	with	PBS.	Cells	were	permeabilized	with	0,2%	Triton-X	in	PBS	and	blocked	with	5	%	donkey	serum	in	PBS.		The	cells	were	stained	overnight	at	4°C	 with	 1:2000	 rabbit	 anti-HNF4a	 (Ab41898,	 Abcam),	 1:500	 mouse	 anti-Flavivirus	Group	Antigen	(clone	D1-4G2-4-1,	Millipore)	and/or	1:200	rabbit	anti-caspase	3	(active,	cleaved	 form)	(AB3623,	Millipore)	antibody.	 	Afterwards,	 the	cells	were	 incubated	 for	1h	 at	 room	 temperature	 with	 the	 appropriate	 secondary	 antibodies	 and	 Hoechst	(Sigma-Aldrich).	Appropiate	isotye	control	antibodies	were	used	for	all	images.	Images	were	taken	using	the	AxioimagerZ.1	fluorescence	microscope.			
5.2.7	Re-infection	assays.	hESC-HLCs	were	inoculated	with	6	days	post	infection	supernatant	of	ZIKV	infected	hESC-HLCs	(1:10	dilution).	After	incubation	for	6h	at	37°C	in	 a	 5%	 CO2	 humidified	 incubator,	 the	 inoculum	 was	 removed	 and	 the	 cells	 were	washed	extensively	with	PBS.	Supernatant	was	collected	2	and	4	after	post	infection.	At	day	4	after	infection,	cells	were	lysed	with	350	µl	RLT	buffer	(Qiagen).				
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5.2.8	MTS	assay.	Cells	were	seeded	and	differentiated	in	a	96-well	format	plates.		On	6	days	after	infection,	the	medium	was	removed	from	the	ZIKV	infected	cells	and	100	µL	3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium/phenazinemethosulfate	 (MTS/PMS;	 Promega,	 Leiden,	 Netherlands) was	added.	 After	 1.5h	 incubation	 at	 37°C	 in	 a	 5%	 CO2	 humidified	 incubator,	 the	 optical	density	(OD)	was	determined	at	498	nm	using	the	Tecan	Safire2	TM.	The	%	cell	survival	was	calculated	using	the	following	formula:	%	survival	=	100	x	(ODIC/ODUIC).	
	
5.2.9	Statistics.		Data	is	represented	as	mean	±	SEM	and	analyzed	by	the	two-tailed	Student’s	 t	 test.	 p-values	 <	 0.05	 (*)(+)(#),	 p	 <	 0.01	 (**)(++)(##),	 p	 <	 0.001	(***)(+++)(###)	 and	 p	 <	 0.0001	 (****)(++++)(####)	 were	 considered	 statistically	significant.		
5.3	Results		
5.3.1	Hepatocyte-like	cells	and	hepatoma	cells	are	susceptible	to	ZIKV		hESCs	and	hiPSCs	were	differentiated	toward	hepatocyte-like	cells	(HLCs).	Both,	day	16	differentiated	 HLCs	 and	 the	 HuH7	 hepatoma	 cell	 line	 were	 infected	with	 the	 African	MR766	 ZIKV	 strain.	 Zika	 viral	 RNA	 levels	 were	 quantified	 by	 RT-qPCR	 on	 the	supernatant	 on	 day	 2,	 4	 and	 6	 after	 infection	 (days	 post	 infection,	 dpi)	 and	 in	 the	cellular	 lysates	 (intracellular)	 4	 and	 6	 days	 after	 infection.	 Infection	 efficiency	 was	comparable	 between	 ZIKV	 infected	 hPSCs-derived	 HLCs	 and	 HuH7	 cells	 with	approximately	 1	 x	 108	viral	 RNA	 copies	 mL-1	 or	 µg-1	 in	 the	 supernatant	 or	 cellular	lysates,	 respectively	 (Figure	 30A).	 Four	 days	 after	 infection,	 ZIKV	 infection	 of	 hPSC-HLCs	and	HuH7	cells	was	confirmed	by	immunofluorescence	staining	demonstrating	10	
±	 2.1%	 and	 12.4	 ±	 2.0%	 ZIKV	 infected	 hPSC-HLCs	 and	 HuH7	 cells,	 respectively.	 In	addition,	ZIKV	infected	hPSC-HLCs	and	HuH7	cells	were	positive	for	the	liver-enriched	transcription	factor	HNF4a	(Figure	30B).			
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Figure	30.	Infection	of	hPSC-HLCs	and	HuH7	with	MR766	zika	viral	strain.	(A)	RT-qPCR	
was	 used	 to	 quantify	 the	 viral	RNA	 levels	 in	 the	 supernatant	 and	 intracellularly	 (d	 pi	 =	
days	post	infection)	(n=3).	(B)	Left;	Immunofluorescence	staining	for	HNF4a	and		ZIKV	in	
infected	 	 hPSC-HLCs	 and	 HuH7	 cells	 4	 days	 after	 infection.	 Right;	 quantification	 of	
immunofluorescence	 staining.	 Images	 are	 representative	 of	 three	 independent	
experiments	(Scale	bar	=	100µM).		
5.3.2	Differences	 in	 inhibition	of	ZIKV	replication	 in	HLCs	and	HuH7	
cells			Zmurko	et	al.,	recently	demonstrated	the	antiviral	activity	of	three	viral	RNA-dependent	RNA	 polymerase	 inhibitors:	 2’-C-methylcytidine,	 7-deaza-2'-C-methyladenosine	(7DMA),	2’-C-methylcytidine	 (2’	CMC)	and	6-fluoro-3-hydroxy-2-pyrazinecarboxamide	(Favipiravir;	 T705),	 on	 ZIKV	 infected	 Vero	 cells	 (164).	 The	 administration	 of	 7DMA	(10µM	-	90µM)	significantly	inhibited	ZIKV	replication	in	a	dose-dependent	manner	in	the	cellular	lysates	and	supernatants	of	both,	ZIKV	infected	hPSC-HLCs	and	HuH7	cells	(Figure	31).	However,	even	at	 the	highest	concentration	used,	7DMA	did	however	not	completely	abolish	ZIKV	replication	as	ZIKV	RNA	levels	continued	to	increase	over	time	(Figure	31).	2’CMC	and	T705	treatment	significantly	inhibited	viral	replication	in	HuH7	infected	cells	but	failed	to	inhibit	ZIKV	replication	in	hPSC-HLCs	(Figure	32).			
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Figure	 31.	 Inhibition	 of	 ZIKV	 replication	 by	 7DMA.	 (A)	 RT-qPCR	 analysis	 of	 the	
supernatant	of	ZIKV	infected	hESC-HLCs,	hiPSC-HLCs	and	HuH7	cells.	ZIKV	replication	was	
inhibited	by	increasing	concentrations	of	7DMA	(10µM	-	90µM)	(IC	=	infected	cell)	(n=3;	*:	
p=0.05).	 (B)	RT-qPCR	analysis	 of	 the	 cellular	 lysates	 of	 ZIKV	 infected	hESC-HLCs,	 hiPSC-
HLCs	and	HuH7	cells.	ZIKV	replication	was	inhibited	by	increasing	concentrations	of	7DMA	
(10µM	-	90µM)	(n=3;	*:	p=0.05).	
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Figure	32.	Inhibition	of	ZIKV	replication	by	2’CMC	and	T705.	(A)	RT-qPCR	analysis	of	the	
supernatant	 of	 ZIKV	 infected	 hESC-HLCs,	 hiPSC-HLCs	 and	HuH7	 cells.	 Infected	 cells	 (IC)	
were	 treated	 with	 increasing	 concentrations	 of	 2’CMC	 (5µM	 -	 45µM)	 or	 T705	 (25µM	 -	
225µM)	 (n=3;	 *:	 p=0.05).	 (B)	 RT-qPCR	 analysis	 of	 the	 cellular	 lysates	 of	 ZIKV	 infected	
hESC-HLCs,	 hiPSC-HLCs	 and	 HuH7	 cells.	 Infected	 cells	 were	 treated	 with	 increasing	
concentrations	of	2’CMC	(5µM	-	45µM)	or	T705	(25µM	-	225µM)	(n=3;	*:	p=0.05).		
5.3.3	ZIKV	infected	hPSC-HLCs	produce	infectious	virions		The	 supernatant	 collected	 from	ZIKV	 infected	hPSC-HLCs	was	used	 to	 re-infect	 hPSC-HLCs.	 Infection	was	quantified	by	RT-qPCR	and	viral	RNA	was	detected	2	 and	4	days	after	infection	in	the	supernatant	and	as	well	4	days	after	infection	in	the	cellular	lysates	of	 re-infected	 hPSC-HLCs.	 To	 examine	 the	 efficiency	 of	 7DMA	 treatment,	 we	 also	
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collected	the	supernatants	(SN)	of	7DMA	treated	primary-infected	hPSC-HLCs	and	used	this	 for	 re-infection	 experiments.	 Although	 7DMA	 significantly	 inhibited	 ZIKV	replication	 (Figure	 31),	 ZIKV	 persisted	 in	 sufficient	 levels	 to	 allow	 re-infection	 of	secondary	 PSC-HLCs.	 Although	 re-infection	 of	 hPSC-HLCs	 with	 supernatant	 collected	from	cells	treated	with	either		30µM		or	90µM	7DMA	was	significantly	lower	on	day	2	compared	 to	 cells	 re-infected	with	 supernatant	 from	 initial	 cultures	 not	 treated	with	7DMA,	 viral	 RNA	 levels	 on	 day	 4	 either	 in	 the	 supernatant	 or	 cellular	 lysates	 of	secondarily	 infected	hPSC-HLcs	was	not	 significant	 different	when	 supernatants	 from	7DMA	treated	or	untreated	(IC)	primary	infected	hPSC-HLCs	were	used	(Figure	33).		
		
Figure	33.	ZIKV	infected	hPSC-HLCs	produce	infectious	virions.	hPSC-HLCs	were	infected	
with	supernatant	(SN)	of	ZIKV	infected	but	untreated	hPSC-HLCs	(IC)	or	with	supernatant	
(SN)	of	ZIKV	 infected	but	7DMA	treated	hPSC-HLCs.	RT-qPCR	was	used	 to	quantify	ZIKV	
RNA	(n=3;	*:	p=0.05).		 	
5.3.3	ZIKV	induces	a	cytopathic	effect	
	ZIKV	infection	of	hPSC-HLCs	and	HuH7	cells	induced	a	cytopathic	effect	(CPE).	CPE	was	assessed	6	after	post	infection	by	microscopic	evaluation,	MTS	readout	assay	and	active	Caspase-3	 staining.	 The	 survival	 rate	 of	 ZIKV	 infected	 hPSC-HLCs	was	 approximately	80%.	Although	the	infection	efficiency	of	hPSC-HLCs	and	HuH7	was	comparable	(Figure	30),	ZIKV	infected	HuH7	had	a	survival	rate	of	only	31.6	±	4.09%.	CPE	was	significantly	reduced	 in	ZIKV	 infected	hPSC-HLCs	that	were	 treated	with	 increasing	concentrations	of	 7DMA.	Treatment	 of	 ZIKV	 infected	 hPSC-HLCs	with	 2’CMC	or	T705	did	 not	 reduce	CPE,	in	line	with	our	observation	that	2’CMC	or	T705	did	not	reduce	ZIKV	RNA	levels	in	
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infected	hPSC-HLCs.	By	contrast,	7DMA,	2’CMC	and	T705	significantly	 reduced	CPE	 in	ZIKV	 infected	 HuH7	 cells,	 consistent	 with	 the	 viral	 RT-qPCR	 data.	 In	 addition,	 ZIKV	infected	hPSC-HLCs	stained	positive	for	activated	Caspase-3	(Figure	34B).		
	
Figure	 34.	 ZIKV	 induces	CPE.	 (A)	CPE	was	quantified	by	MTS	readout	assay.	Cells	were	
either	 untreated	 (IC	 =	 infected	 cell)	 or	 treated	 with	 7DMA,	 2’CMC	 or	 T705	 (n=3;	
*p=0.05%).	 (B)	 Immunofluorescence	 staining	 for	 activated	 Caspase-3.	 Images	 are	
representative	of	three	independent	experiments	(Scale	bar	=	50µM).			
5.3.4	ZIKV	 induces	a	host	 immune	response	 in	hPSC-HLCs	but	not	 in	
HuH7	cells		Upon	viral	 infection,	 the	 innate	 immune	system	of	 cells	 is	 triggered	 to	 clear	 the	virus	from	 the	 infected	 cells.	 Therefore,	 we	 quantified	 transcript	 levels	 of	 the	 interferon	stimulated	 genes	 (ISGs)	 EIF2AK2,	MX1,	 IFNb	 and	 ISG15	 by	 RT-qPCR	 in	 ZIKV	 infected	
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cells.	 All	 ISGs	 were	 significantly	 more	 upregulated	 in	 both	 ZIKV	 infected	 hESC-	 and	hiPSC-HLCs	 compared	 to	 ZIKV	 infected	 HuH7	 cells.	 The	 expression	 of	 all	 ISGs	 was	significantly	 and	 dose-dependently	 downregulated	 upon	 7DMA	 treatment	 of	 ZIKV	infected	hPSC-HLCs.	There	was	no	effect	on	the	expression	of	ISGs	when	infected	hPSC-HLCs	 were	 treated	 with	 either	 2’CMC	 or	 T705	 consistent	 with	 our	 observation	 that	these	 two	 antivirals	 failed	 to	 inhibit	 ZIKV	 replication	 in	 hPSC-HLCs.	 Although	 7DMA,	2’CMC	 and	 T705	 all	 inhibited	 viral	 replication	 in	 HuH7	 cells,	 treatment	 with	 these	compounds	had	no	significant	effect	on	the	expression	of	ISGs	(Figure	35).			
	
Figure	35.	ZIKV	induces	an	innate	immune	response	only	in	infected	hPSC-HLCs.	RT-qPCR	
analysis	for	different	ISGs.	(IC	=	infected	cell)	(n=3;	*	significance	of	treated	cells	to	IC;	+	
significance	of	IC	HuH7	to	IC	hESC-HLCs;	#	significance	of	IC	HuH7	to	hiPSC-HLCs).		As	 ZIKV	 induced	 an	 interferon	 immune	 response	 and	 ZIKV	 infected	 cells	 rapidly	underwent	 apoptosis,	 we	 examined	 the	 induction	 of	 the	 NFkB	 stress	 response	 upon	infection.	 Similar	 to	 the	 induction	 of	 ISGs,	 transcripts	 for	NFkB	 and	 its	 target	 genes	
CXCL2	 and	 CXLC3,	 were	 significantly	 more	 induced	 in	 ZIKV	 infected	 hPSC-HLCs	compared	 to	 ZIKV	 infected	 HuH7	 cells,	 even	 if	 the	 latter	 were	 more	 prone	 to	 ZIKV	mediated	 CPE.	 	 Inhibition	 of	 ZIKV	 replication	 by	 7DMA	 in	 infected	HLCs	 significantly	
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decreased	 the	 transcript	 levels	 of	NFkB	 and	 its	 target	 genes.	 In	HuH7	 cells,	 the	NFkB	host	response	was	not	influenced	by	the	antiviral	compounds.	(Figure	36).		
		
Figure	36.	ZIKV	 induces	an	NFkB	response	only	in	infected	hPSC-HLCs.	RT-qPCR	analysis	
for	NFkB,	CXLC2	and	CXCL3.	(IC	=	infected	cell)	(n=3;	*	significance	of	treated	cells	to	IC;	+	
significance	of	IC	HuH7	to	IC	hESC-HLCs;	#	significance	of	IC	HuH7	to	hiPSC-HLCs).		
5.3.5	Infection	of	hPSC-HLCs	with	the	Asian	ZIKV	lineage		We	 demonstrated	 that	 hPSC-HLCs	 were	 as	 well	 susceptible	 to	 infection	 with	 a	 ZIKV	clinical	isolate	from	the	Asian	lineage.	hPSC-HLCs	were	infected	with	the	same	viral	titer	as	the	MR766	African	strain.	The	Asian	strain	induced	significantly	more	CPE	compared	to	the	African	strain	(40.9%	vs.	81.0%	survival).	Presence	of	the	Asian	lineage	of	ZIKV	in	infected	 hPSC-HLCs	 was	 further	 demonstrated	 by	 immunofluorescence,	 even	 if	quantification	of	the	percentage	ZIKV	infected	HLCs	was	difficult	due	to	the	high	levels	of	 apoptotic	 cells.	 7DMA	 also	 inhibited	 replication	 of	 the	 Asian	 strain	 of	 ZIKV	demonstrated	by	a	significant	CPE	reduction.			 	
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Figure	37.	Infection	of	hPSC-HLCs	with	the	Asian	ZIKV	strain.	(A)	MTS	assay	was	used	to	
quantify	 the	%	survival	upon	ZIKV	 infection.	 Infected	cells	were	either	untreated	 (IC)	or	
treated	with	increasing	concentration	of	7DMA	(n=3;	*p=0.05%).	(B)	The	presence	of	ZIKV	
was	as	well	confirmed	by	immunofluorescence	staining.	Images	are	representative	of	three	
independent	experiments	(Scale	bar	=	100µM).		
5.4	Discussion		The	fact	that	hPSCs	can	be	differentiated	in	all	cells	of	the	human	body,	make	them	an	interesting	tool	to	study	the	tissue	tropism	of	viruses.	Currently,	knowledge	regarding	the	 tissue	 tropism	 of	 ZIKV	 is	 very	 limited.	 Recent	 studies	 demonstrated	 that	 hPSC-derived	neuroprogenitors	are	susceptible	to	ZIKV	 in	vitro	 (160,	162,	163).	 In	addition,	studies	 wherein	 interferon-deficient	 mouse	 models	 were	 infected	 with	 ZIKV	 have	suggested	that	high	viral	titers	of	ZIKV	can	be	detected	not	only	in	the	brain	but	also	in	the	 testes,	 spleen,	 kidney	 and	 liver	 (164,	 165).	 ZIKV	 belongs	 to	 the	 virus	 family	 of	
Flaviviridae,	which	also	includes	dengue,	yellow	fever	and	hepatitis	C	virus,	all	known	to	infect	hepatocytes	and	cause	acute	hepatitis	(152,	227).	A	case	report	published	in	1954	suggested	that	tow	patients	with	ZIKV	antibodies	also	had	signs	of	hepatitis,	 including	jaundice	(224).	However,	aside	from	the	mouse	model	and	these	case	reports,	there	are	to	 the	 best	 of	 our	 knowledge,	 no	 cases	 of	 liver	 damage	 reported	 following	 ZIKV	infection.	 Nevertheless,	 in	 view	 of	 the	 data	 from	 the	mouse	models	 and	 the	 fact	 that	ZIKV	belongs	to	a	strain	of	viruses	known	to	have	hepatocyte	tropism	and	cause	acute	hepatocyte	damage,	we	here	examined	if	human	hepatocytes	can	be	infected	by	ZIKV.		Therefore,	we	infected	hPSC-HLCs	and	HuH7	cells	with	the	ZIKV	MR766	African	strain.	Both,	hESC	and	hiPSC-HLCs	as	well	as	HuH7	cells	could	be	infected	with	ZIKV	as	was	 demonstrated	 by	 quantification	 of	 ZIKV	RNA,	 ZIKV	 immunofluorescence	 staining	and	 the	 fact	 that	of	 infectious	virions	were	produced,	 that	could	re-infect	other	hPSC-HLCs.	 We	 also	 demonstrated	 that	 hPSC-HLCs	 were	 susceptible	 to	 infection	 with	 a	
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clinical	isolate	of	the	Asian	type	ZIKV.	The	Asian	type	ZIKV	is	responsible	for	the	recent	outbreaks	of	ZIKV	in	Latin-America	and	is	believed	to	be	associated	with	an	increased	risk	for	microcephaly	in	newborns	(156,	231).	Our	studies	suggest	that	the	Asian	type	ZIKV	 strain	 may	 also	 be	 more	 efficacious	 in	 infecting	 hPSC-HLCs,	 as	 hPSC-HLC	 CPE	caused	 by	 the	 Asian	 strain	 ZIKV	 at	 the	 same	MOI	 as	 used	 for	 the	 African	 strain	was	significantly	higher.		A	recent	study	has	demonstrated	that	7DMA	can	delay	the	disease	progression	in	a	 ZIKV	 infected	mice	 (164).	 	We	 here	 demonstrated	 that	 7DMA	 could	 as	well	 inhibit	viral	replication	of	both,	the	African	and	Asian	ZIKV	strain	in	a	dose-dependent	way	in	infected	HuH7	cells	and	hPSC-HLCs.	By	contrast,	2’CMC	and	T705,	previously	shown	to	inhibit	ZIKV	in	Vero	cells	(164),	inhibited	ZIKV	replication	only	in	HuH7	cells.	However,	even	 the	 highest	 concentration	 of	 7DMA	 used	 could	 not	 completely	 clear	 ZIKV	 from	infected	hPSC-HLCs,	as	supernatants	from	7DMA	treated	ZIKV	infected	hPSC-HLCs	still	contained	infectious	virions	that	could	re-infect	secondary	hPSC-HLCs	cultures.		As	 is	 also	 seen	 for	 other	 Flavivirdae,	 ZIKV	 infection	 caused	 CPE	 in	 both,	 ZIKV	infected	HuH7	cells	and	hPSC-HLCs.	Although	the	percentage	of	ZIKV	infected	cells	was	comparable	between	HuH7	cells	and	hPSC-HLCs,	CPE	was	more	pronounced	in	infected	HuH7	cells.	Consistent	with	the	viral	transcript	studies,	CPE	was	completely	abolished	in	 HuH7	 cells	 and	 hPSC-HLCs	 by	 7DMA,	while	 2’CMC	 and	 T705	 only	 reduced	 CPE	 in	ZIKV	infected	HuH7	cells.	Although	autophagy	usually	kills	pathogens,	flaviviruses	such	as	 dengue	 virus	 were	 shown	 to	 modulate	 autophagy-dependent	 processing	 of	 lipid	droplets	 to	benefit	 their	replication.	Liang	et	al.	 recently	demonstrated	that	ZIKV	non-structural	proteins	NS4A	and	NS4B	also	 induced	autophagy	to	promote	 its	replication	which	 eventually	 leads	 to	 cellular	 dysregulation,	 attenuated	 growth	 and	 cell	 death	(232).		Hamel	et	al.,	demonstrated	the	induction	of	interferon	stimulated	genes	(ISGs)	is	triggered	upon	ZIKV	infection	of	human	dermal	fibroblasts	and	epidermal	keratinocytes	(159).	Moreover,	 only	 interferon	 deficient	mice	were	 found	 to	 be	 permissive	 to	 ZIKV	and	 the	 virus	was	 recently	demonstrated	 to	 evoke	 a	human	 innate	 immune	 response	through	 degradation	 of	 STAT2,	 which	 is	 a	 transcriptional	 activator	 of	 interferon	stimulated	 genes	 (ISGs)	 (164,	 165,	 233).	 Consistent	 with	 these	 in	 vitro	 and	 in	 vivo	published	results,	we	demonstrated	that	ZIKV	induced	ISGs	significantly	in	hPSC-HLCs.	Interestingly,	this	was	not	the	case	in	ZIKV	infected	HuH7	cells.	Consistently,	we	found	
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induction	of	NFkB	and	target	genes	only	in	hPSC-HLCs	and	not	HuH7	cells,	even	if	the	latter	displayed	more	extensive	CPE	following	ZIKV	infection.		In	 conclusion,	 hepatoma	 cells	 as	 well	 as	 hPSC-HLCs	 are	 susceptible	 to	 ZIKV	infection.	The	antiviral	effect	of	three	viral	polymerase	inhibitors	and	the	host	response	upon	infection	were	however	significantly	different	between	ZIKV	infected	HuH7	cells	and	 hiPSC-HLCs.	 We	 believe	 that	 hPSC-HLCs	 more	 closely	 resemble	 primary	 human	hepatocytes	(PHH)	and	better	recapitulate	the	in	vivo	situation.	However,	ZIKV	infection	studies	 with	 PHH	 are	 necessary	 to	 confirm	 our	 findings.	 As	 hPSC-HLCs	 mimic	 fetal	rather	than	mature	hepatocytes	(56,	57),	we	hypothesize	that	ZIKV	might	infect	as	well	fetal	 liver	but	 additional	 studies	 are	 required.	We	 further	demonstrated	 that	 the	host	response	 and	 the	 effect	 of	 antiviral	 compounds	 are	 highly	 cell	 type-	 and	 cell	 line-dependent.	It	is	crucial	to	validate	the	effect	of	antiviral	drugs	not	only	in	cancerous	(e.g.	hepatoma	 cell	 lines)	 and	 immortalized	 (e.g.	 Vero	 cells)	 cell	 lines	 but	 also	 in	 more	physiologically	 relevant	 systems	 such	 as	 differentiated	 hPSC	 and	 primary	 human	cultures.								
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6.1	Conclusion			The	 study	 of	 hepatotropic	 viruses	 is	 hampered	 by	 to	 the	 lack	 of	 efficient	 and	physiologically	 relevant	 cell	 culture	 and	 animal	 models.	 Primary	 human	 hepatocytes	(PHH)	 are	 the	 gold	 standard	 to	 examine	 the	 replication	 of	 hepatotropic	 viruses	 and	inhibition	 thereof.	 However,	 PHH	 are	 scarce	 and	 highly	 variable	 among	 different	donors.	 Moreover,	 cultured	 PHH	 dedifferentiate	 in	 less	 than	 24	 hours	 and	 lose	 their	phenotypic	characteristics,	including	their	main	drug	metabolizing	enzymes.		hPSC-derived	 hepatocyte-like	 cells	 are	 a	 valuable	 alternative	 to	 PHH	 as	 hPSCs	have	 the	ability	 to	 indefinitely	self-renew	and	 to	differentiate	 into	all	 cell	 types	of	 the	human	body.	 In	addition,	 the	 iPSC	 technology	allows	 to	create	patient-specific	models	and	overcomes	the	limitation	of	donor	variability	and	shortage.	However,	to	date	and	to	the	 best	 of	 our	 knowledge,	 no	 research	 group	 succeeded	 in	 the	 generation	 of	 fully	mature	hepatocytes.	Compared	to	PHH,	hPSC-derived	hepatocyte-like	cells	(hPSC-HLCs)	are	 immature	and	characterized	by	persistent	alpha-fetoprotein	 (AFP)	expression	and	low	 metabolizing	 enzyme	 expression	 and	 function	 (56,	 57).	 In	 accordance,	 the	hepatocyte	 differentiation	 protocol	 published	 by	 the	 Verfaillie	 lab	 is	 robust	 but	generates	HLCs	that	are	unfortunately	not	completely	mature	yet	(169).	Nevertheless,	Roelandt	et	al.,	among	others,	published	in	2012	that	hPSC-derived	HLCs	are	susceptible	to	HCV	infection	(143).		In	this	thesis,	I	demonstrated	that	hPSC-derived	HLCs	also	support	the	complete	replication	cycle	of	the	hepatitis	E	virus	(HEV).	HEV	infection	was	demonstrated	by	the	presence	of	 (+)	and	 (-)	 ssRNA	as	quantified	by	RT-qPCR.	 In	addition,	 viral	 replication	was	inhibited	by	ribavirin	and	interferon-alpha	2b	treatment.	Interestingly,	we	showed	that	neuroprogenitors	and	mesodermal	cells,	both	derived	from	hESCs,	did	only	support	HEV	replication	when	the	virus	was	transfected	in	the	cells.	We	therefore	hypothesize	the	 presence	 of	 a	 hepatocyte-specific	 receptor,	 which	 is	 absent	 on	 hPSC-derived	neuroprogenitor	and	mesodermal	cells	and	is	required	for	entry	of	HEV	in	hepatocytes,	the	 nature	 of	 which	 is	 yet	 to	 be	 discovered.	 hPSC-HLCs	 are	 therefore	 a	 valuable	alternative	to	hepatoma	cell	lines	and	PHH	to	study	the	biology	of	HEV	and	might	aid	in	the	identification	of	the	HEV	receptor(s)	(144).		
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Secondly,	 this	 thesis	 assessed	means	 to	 improve	 the	hepatocyte	differentiation	from	hPSCs	by	the	addition	of	dimethyl	sulfoxide	(DMSO).	DMSO	was	previously	shown	to	 prevent	 too	 some	 extent	 the	 dedifferentiation	 of	 cultured	 PHH	 and	 to	 induce	differentiation	of	the	bipotential	hepatoma	cell	line,	HepaRG	(27,	206).	The	addition	of	0.6%	DMSO	significantly	 improved	endoderm	 formation	which	was	 confirmed	by	RT-qPCR,	SOX17	staining	and	CXCR4/cKIT	flow	cytometry,	resulting	in	a	more	homogenous	population	of	hPSC-derived	endodermal	cells.	By	comparing	different	concentrations	of	DMSO,	we	 concluded	 that	 a	 concentration	 of	 0.6%	DMSO	 between	 day	 0	 and	 day	 12	followed	by	an	increased	concentration	of	2%	from	day	12	onwards	generated	a	more	homogenous	 population	 of	 hPSC-HLCs	 that	 expressed	 significantly	more	AAT,	HNF4a	and	NTCP	transcripts	and	proteins.	I	hypothesized	that	the	effect	of	DMSO	could	be	due	to	 its	antioxidant	and	 free	radical	scavenging	properties.	To	confirm	this	hypothesis,	 I	examined	the	effect	of	a	well-known	antioxidant,	N-acetylcysteine	(NAC),	on	endoderm	and	 subsequent	 hepatocyte	 differentiation.	 	 Addition	 of	 NAC	 significantly	 improved	definitive	 endoderm	 formation	 but	 did,	 however,	 not	 improve	 hepatocyte	differentiation/maturation.	The	mechanism	of	action	of	DMSO	and	NAC	might	therefore	be	different	and	not	be	regulated	by	the	induction	or	reduction	of	ROS.	In	addition,	ROS	assays	failed	to	detect	increased	or	reduced	ROS	levels	in	DMSO	or	NAC	–	treated	cells.	Moreover,	DMSO	 is	also	known	to	have	oxidizing	properties	and	 increased	ROS	 levels	are	 believed	 to	 induce	 stem	 cell	 differentiation	 (234).	 Our	 results	 are	 therefore	conflicting	and	additional	experiments	will	be	needed	to	elucidate	the	role	of	DMSO	and	NAC	during	stem	cell	differentiation.	What	was	however	striking	was	 the	 tremendous	upregulation	of	NTCP	in	DMSO	treated	hPSC-HLCs.	As	NTCP	was	recently	identified	as	the	 key	 receptor	 for	 HBV	 entry	 (180),	 I	 examined	 whether	 hPSC-derived	 HLCs	 also	supported	the	replication	of	HBV.	I	first	demonstrated	binding	of	Myrcludex	B,	a	peptide	corresponding	the	pre-S1	domain	of	HBV	to	hPSC-derived	HLCs.	 In	addition,	I	showed	the	 presence	 of	 HBcAg	 by	 immunofluorescence	 staining.	 However,	 these	 results	 are	preliminary	and	should	be	further	confirmed	by	additional	assays.		Finally,	 I	 demonstrated	 that	 hPSC-HLCs	 are	 also	 susceptible	 to	 ZIKV	 infection.	ZIKV	recently	gained	ample	attention	due	to	major	outbreaks	in	Latin-America,	and	the	possible	 link	 between	 ZIKV	 infection	 and	 microcephaly	 in	 newborns	 during	 this	outbreak	(156,	157).	ZIKV	infected	mouse	models	have	been	established	that	sustained	high	viral	 load	not	only	in	the	brain	but	also	in	the	liver	(164,	165).	As	ZIKV	is	closely	
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related	 to	 dengue	 and	 yellow	 fever	 virus,	 both	 known	 to	 infect	 and	 replicate	 in	hepatocytes	 (226,	 228),	 I	 tested	 if	 ZIKV	 would	 also	 infect	 hPSC-HLCs.	 I	 first	demonstrated	 by	 RT-qPCR	 and	 immunofluorescence	 that	 the	 African	 MR766	 ZIKV	strain	 infected	both	hPSC-HLCs	and	the	hepatoma	cell	 line,	HuH7.	 Infection	was	dose-dependently	 inhibited	 in	 both	 cell	 types	 by	 treatment	 with	 the	 viral	 polymerase	inhibitor	7DMA.	Two	other	viral	polymerase	inhibitors,	2’CMC	and	T705	inhibited	ZIKV	infection	in	HuH7	cells	but	not	in	ZIKV	infected	hPSC-HLCs.	A	host	innate	immune	and	NFkB	response	were	induced	in	ZIKV	infected	hPSC-HLCs	but	not	in	infected	HuH7	cells.	Finally,	a	clinical	isolate	from	the	ZIKV	Asian	strain,	which	caused	the	recent	outbreak	in	Latin-America,	was	also	shown	to	infect	hPSC-HLCs	and	HuH7	cells.	Although	there	are,	to	 the	 best	 of	 our	 knowledge,	 no	 clinical	 data	 about	 ZIKV	 induced	 liver	 damage	 or	hepatitis,	 hPSC-HLCs	 may	 be	 a	 good	 model	 to	 study	 ZIKV	 infection,	 including	 the	assessment	of	the	host	response,	which	was	only	induced	upon	infection	of	hPSC-HLCs	but	 not	 upon	 infection	 HuH7	 cells.	 Moreover,	 the	 antiviral	 drug	 activity	 was	 highly	dependent	on	the	cell	type	used.	In	 conclusion,	 I	 demonstrated	 that	 hPSC-HLCs	 are	 a	 valuable	 alternative	 to	hepatoma	cell	lines	and	PHH	to	study	the	biology	of	replication	of	hepatotropic	viruses.	In	addition,	 the	differentiation	 capacity	of	hPSCs	allows	 to	generate	 from	a	 single	 cell	population	all	cell	types	of	the	human	body	representing	an	interesting	tool	to	study	the	host	and	tissue	tropism	of	different	viruses.			
6.2	Future	perspectives		Our	 studies	 demonstrated	 the	 susceptibility	 of	 hPSC-derived	 HLCs	 to	 different	hepatotropic	 viruses.	 hPSC-derived	HLCs	 are	 susceptible	 to	HCV,	HEV,	HBV	 and	 ZIKV	and	provide	 a	 tool	 to	 study	 the	biology	of	 replication	of	 these	 viruses	 and	 to	 test	 the	efficiency	 of	 antiviral	 drugs.	 Future	 studies	 should	 however	 still	 be	 performed	 to:	 (i)	improve	 the	 maturation	 of	 hPSC-HLCs,	 (ii)	 identify	 the	 hepatocyte-specific	 HEV	receptor,	 (iii)	 study	 the	 infection	 of	 hPSC-HLCs	 with	 HBV	 and	 (iv)	 study	 in	 vivo	 the	biology	 of	 replication	 of	 hepatotropic	 viruses	 in	 hPSC-derived	 humanized	 mouse	models.			
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(i)	Maturation	of	hPSC-HLCs	Many	research	groups	have	succeeded	in	the	differentiation	of	PSCs	toward	HLCs	(47,	50,	168,	169,	207).	However,	all	 studies	demonstrate	 that	only	 immature	hepatocytes	can	be	generated	that	resemble	fetal	hepatocytes	and	also	display	some	of	the	features	of	de-differentiated	PHHs	(56,	57).	As	some	important	drug	metabolizing	enzymes,	such	as	CYP3A4,	are	only	poorly	expressed	in	the	differentiated	PSC	progeny,	the	use	of	PSC-HLCs	 to	 test	 antivirals	 remains	 limited.	 In	 addition,	 hepatocytes	 are	 not	 only	responsible	 for	 drug	 inactivation	 but	 also	 for	 drug	 activation.	 Many	 antivirals	 are	synthetized	 as	 prodrugs	 and	 a	 physiological	 relevant	 drug	metabolizing	machinery	 is	therefore	 inevitable	 to	 assess	 their	 efficacy.	 The	 process	 of	 hepatocyte	 maturation	remains	 to	 be	 elucidated.	 Recent	 advances	 using	 fir	 instance	 overexpression	 of	 key	hepatocyte	TFs	and	 improved	cell	culture	 techniques	are	promising,	but	still	have	not	yet	 allowed	 generation	 of	 mature	 hPSC-hepatocytes.	 As	 transcription	 factors	 and	microRNAs	(miRNAs)	are	known	to	be	key	regulators	of	gene	expression,	activation	and	inactivation	of	 transcription	factors	and	miRNAs	that	are	not	sufficiently	expressed	or	are	 miss-expressed,	 respectively,	 (57)	 by	 novel	 genome	 editing	 techniques	 such	 as	CRISP/Cas9	 might	 induce	 hepatocyte	 maturation.	 In	 addition,	 using	 culture	 systems	reflecting	 the	 physical	 properties	 of	 liver,	 most	 importantly	 the	 low	 stiffness	 (4	 Kilo	Pascal)	 as	well	 as	 liver	 sinusoid	 specific	 extracellular	matrix	 components,	 and	3D	 co-culture	 systems	 of	 hepatocyte	 with	 ideally	 stem	 cell-derived	 non-parenchymal	 cells	such	as	LSECs	will	be	necessary	to	better	recapitulate	the	liver	niche	in	a	dish.			
(ii)	Identify	HEV	receptor(s)	One	 of	 the	 advantages	 of	 hPSCs	 is	 their	 multi-lineage	 differentiation	 potential.	 We	demonstrated	 that	 hPSCs	 can	 be	 differentiated	 to	 hepatocytes,	mesodermal	 cells	 and	neuroprogenitors,	 among	 others.	 Only	 hPSC-derived	 hepatocytes	 were	 susceptible	 to	HEV	 infection.	 However,	 mesodermal	 cells	 and	 neuroprogenitors	 do	 support	 HEV	replication	when	HEV	was	transfected	in	the	cells.	We	therefore	hypothesize	that	hPSC-derived	 mesodermal	 and	 neuroprogenitor	 cells	 lack	 a	 hepatocyte-specific	 receptor	(144).	Membrane	proteomics,	microarray	and/or	RNA-sequencing	studies	may	uncover	the	 identity	 of	 differentially	 expressed	 proteins	 and	 genes	 between	 these	 three	 cell	populations	 and	 aid	 in	 the	 identification	 of	 one	 or	 more	 HEV	 candidate	 receptor(s).	
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Identification	of	the	HEV	receptor	might	be	a	potential	candidate	to	 inhibit	viral	entry	and	subsequent	HEV	infection,	as	has	been	recently	shown	for	HBV.		
(iii)	Study	the	infection	of	hPSC-HLCs	with	HBV	As	 proof	 of	 principle,	 we	 demonstrated	 by	 HBcAg	 staining	 that	 hPSC-HLCs	 are	susceptible	 to	 HBV	 infection.	 Additional	 experiments	 need	 to	 be	 performed	 to	demonstrate	 the	 suitability	 of	 this	model	 to	 study	 the	biology	of	HBV	 replication	 and	inhibition	thereof.	HBV	infection	should	be	monitored	by	means	of	measuring	secreted	HBcAg	by	ELISA.	Detection	of	pregenomic	RNA,	which	is	not	present	in	the	particle	and	thus	 not	 in	 the	 inocula,	 should	 be	 quantified	 by	 RT-qPCR	 to	 detect	 active	 viral	replication.	 Scaled	up	differentiations	 should	 then	be	used	 to	 study	 the	production	of	HBV	cccDNA	and	pregenomic	RNA	synthesis	by	Southern	and	Northern	hybridization,	respectively.	In	addition,	the	antiviral	effect	of	HBV	inhibitors	such	as	Myrcludex	B	and	tenofovir	could	then	be	evaluated	using	the	aforementioned	methods.	If	hPSC-HLCs	are	susceptible	 to	 HBV	 infection	 and	 the	 deposition	 of	 cccDNA,	 I	 hypothesize	 that	 as	PSc0HLCs	can	be	maintained	for	at	least	another	10	days	following	differentiation	to	the	HLC	as	described	 in	 this	 thesis,	 the	model	 could	be	used	 to	perform	high	 throughput	antiviral	 drug	 screens	 to	 eliminate	 cccDNA,	 and	 to	 study	 the	 host	 response	 following	HBV	infection.			
(iv)	Humanized	mouse	models		To	recapitulate	and	predict	the	complex	process	of	absorption,	distribution,	metabolism	and	 excretion	 (ADME),	 relevant	 in	 vivo	 models	 are	 necessary.	 Two	 frequently	 used	humanized	liver	mouse	models	are	the	urokinase	plasminogen	activator	(uPA)	and	the	fumaryl	 acetoacetate	 hydrolase	 (FAH)	 mouse	 model.	 In	 these	 mouse	 models,	 liver	damage	 is	 caused	 by	 hepatocyte	 specific	 overexpression	 of	 uPA	 or	 by	 loss	 of	 FAH,	respectively.	Both	mouse	models	can	be	back-crossed	to	mice	with	an	immunodeficient	phenotype,	 permitting	 robust	 engraftment	 of	 PHH	 (118,	 147).	 Humanized	 mouse	models	 can	 more	 closely	 predict	 the	 pharmacokinetics,	 pharmacodynamics	 and	metabolism	of	drugs	than	in	vitro	models.	Humanized	mouse	models	are	also	useful	to	model	 infectious	diseases	caused	by	hepatotropic	viruses	such	as	HBV,	HCV	and	HEV,	which	 display	 a	 unique	 human	 hepatocyte	 tropism,	 and	 other	 infections	 such	 as	 by	
Plasmodium	 parasites	 (117,	 118,	 235).	 hPSC-derived	 hepatocytes	 would	 be	 an	 ideal	
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alternative	 source	of	hepatocytes,	 because	 they	 are	unlimited	 in	 supply,	 and	 could	be	created	from	a	diverse	panel	of	donors	with	different	susceptibility	to	drug	toxicity	and	viral	 infections.	 Unfortunately,	 engraftment	 of	 the	 immature	 hPSC-HLCs	 is	 not	 robust	(236).	 Increased	maturation	 of	 hPSC-HLCs	will	 be	 crucial	 to	 allow	 them	 to	 efficiently	repopulate	 damaged	 mouse	 livers.	 Another	 drawback	 is	 that	 the	 immune	 responses	cannot	be	 studied	 in	 these	 immunodeficient	mouse	models.	 Theoretically,	 it	might	be	possible	to	create	mouse	models	that	harbor	aside	from	human	hepatocytes	as	well	as	an	 HLA-identical	 humanized	 immune	 system	 (146),	 both	 derived	 from	 PSCs,	 which	would	provide	an	 ideal	model	 to	study	hepatitis	virus	pathology	and	 identify	efficient	antiviral	approaches	for	hepatotropic	pathogens.																										
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